U.S. patent application number 13/945925 was filed with the patent office on 2015-02-19 for substituted pyrazolone compounds and methods of use.
This patent application is currently assigned to Calitor Sciences, LLC. The applicant listed for this patent is Yanming Feng, Min Liao, Yanjun Wu, Ning Xi. Invention is credited to Yanming Feng, Min Liao, Yanjun Wu, Ning Xi.
Application Number | 20150050239 13/945925 |
Document ID | / |
Family ID | 50028432 |
Filed Date | 2015-02-19 |
United States Patent
Application |
20150050239 |
Kind Code |
A1 |
Xi; Ning ; et al. |
February 19, 2015 |
SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE
Abstract
The present invention provides novel substituted pyrazolone
compounds, pharmaceutical acceptable salts and formulations thereof
useful in modulating the protein tyrosine kinase activity, and in
modulating cellular activities such as proliferation,
differentiation, apoptosis, migration and invasion. The invention
also provides pharmaceutically acceptable compositions comprising
such compounds and methods of using the compositions in the
treatment of hyperproliferative disorders in mammals, especially
humans.
Inventors: |
Xi; Ning; (Newbury Park,
CA) ; Wu; Yanjun; (Dongguan, CN) ; Liao;
Min; (Dongguan, CN) ; Feng; Yanming;
(Dongguan, CN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Xi; Ning
Wu; Yanjun
Liao; Min
Feng; Yanming |
Newbury Park
Dongguan
Dongguan
Dongguan |
CA |
US
CN
CN
CN |
|
|
Assignee: |
Calitor Sciences, LLC
Newbury Park
CA
Sunshine Lake Pharma Co., Ltd.
Dongguan
|
Family ID: |
50028432 |
Appl. No.: |
13/945925 |
Filed: |
July 19, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61676944 |
Jul 28, 2012 |
|
|
|
61679416 |
Aug 3, 2012 |
|
|
|
Current U.S.
Class: |
424/85.4 ;
435/184; 514/110; 514/171; 514/215; 514/234.5; 514/235.2;
514/236.5; 514/243; 514/252.16; 514/252.18; 514/252.19; 514/253.06;
514/253.07; 514/254.06; 514/262.1; 514/266.2; 514/266.22;
514/266.24; 514/266.4; 514/274; 514/275; 514/291; 514/313; 514/318;
514/333; 514/338; 514/34; 514/341; 514/49; 544/131; 546/256;
546/276.1 |
Current CPC
Class: |
A61P 1/04 20180101; A61P
5/00 20180101; A61P 11/00 20180101; A61P 43/00 20180101; A61P 17/00
20180101; C07D 401/14 20130101; A61P 19/00 20180101; A61P 13/12
20180101; A61K 31/444 20130101; A61P 13/08 20180101; A61P 35/04
20180101; A61P 1/18 20180101; A61P 25/00 20180101; A61P 13/10
20180101; A61K 31/4439 20130101; C07D 401/12 20130101; A61K 31/5377
20130101; A61K 45/06 20130101; A61K 31/4439 20130101; A61K 2300/00
20130101; A61K 31/5377 20130101; A61P 35/00 20180101; A61P 9/10
20180101; C07D 413/14 20130101; A61K 2300/00 20130101; A61P 1/16
20180101 |
Class at
Publication: |
424/85.4 ;
514/34; 514/49; 514/110; 514/171; 514/215; 514/234.5; 514/235.2;
514/236.5; 514/243; 514/252.18; 514/252.19; 514/253.07; 514/253.06;
514/254.06; 514/262.1; 514/266.22; 514/266.2; 514/266.24;
514/266.4; 514/252.16; 514/275; 514/274; 514/291; 514/313; 514/318;
514/333; 514/338; 514/341; 544/131; 546/256; 546/276.1;
435/184 |
International
Class: |
C07D 401/12 20060101
C07D401/12; C07D 413/14 20060101 C07D413/14; A61K 45/06 20060101
A61K045/06; A61K 31/444 20060101 A61K031/444; A61K 31/5377 20060101
A61K031/5377; C07D 401/14 20060101 C07D401/14; A61K 31/4439
20060101 A61K031/4439 |
Claims
1. A compound of Formula (I): ##STR00091## or a stereoisomer, a
geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a
metabolite, a pharmaceutically acceptable salt or a prodrug
thereof, wherein: Q is H, NR.sup.aR.sup.b, OR.sup.a,
--N(R.sup.c)C(.dbd.O)R.sup.d or --N(R.sup.c)C(.dbd.O)OR.sup.a; W is
CR.sup.7 or N; each of X, Y and Z is independently H, D,
(C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl comprising 1, 2, 3
or 4 heteroatoms independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl and
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3, 4 or 5 substituents
independently selected from D, F, Cl, Br, CN,
(C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, OR.sup.a,
NR.sup.aR.sup.b, --(C.sub.1-C.sub.4)alkylene-OR.sup.a and
--(C.sub.1-C.sub.4)alkylene-NR.sup.aR.sup.b; each of R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is
independently H, D, F, Cl, Br, CN, N.sub.3, OR.sup.a,
(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.2-C.sub.6)alkenyl or (C.sub.2-C.sub.6)alkynyl; each of
R.sup.a, R.sup.b and R.sup.c is independently H,
(C.sub.1-C.sub.6)aliphatic, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl comprising 1, 2, 3
or 4 heteroatoms independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), with the
proviso wherein R.sup.a and R.sup.b are bonded to the same nitrogen
atom, R.sup.a and R.sup.b, together with the nitrogen atom they are
attached to, optionally form a substituted or unsubstituted 3-8
membered heterocyclic ring, wherein each of the
(C.sub.1-C.sub.6)aliphatic, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl,
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) and 3-8
membered heterocyclic ring is optionally substituted with 1, 2, 3
or 4 substitutents independently selected from D, F, Cl, CN,
N.sub.3, OH, NH.sub.2, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.1-C.sub.6)alkoxy and (C.sub.1-C.sub.6)alkylamino; and
R.sup.d is H, (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl or
(C.sub.6-C.sub.10)aryl, with the proviso where each R.sup.1,
R.sup.2, R.sup.3, R.sup.5 (or R.sup.4), R.sup.6 and R.sup.7 is H,
R.sup.4 (or R.sup.5) is F, R.sup.d is not
(C.sub.3-C.sub.7)heterocyclyl, wherein each of the
(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl and
(C.sub.6-C.sub.10)aryl is optionally substituted with 1, 2, 3 or 4
substitutents independently selected from D, F, Cl, Br, CN,
OR.sup.a, NR.sup.aR.sup.b, (C.sub.1-C.sub.6)alkyl,
(C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl,
--(C.sub.1-C.sub.4)alkylene-OR.sup.a and
--(C.sub.1-C.sub.4)alkylene-NR.sup.aR.sup.b.
2. The compound according to claim 1, wherein Q is NR.sup.aR.sup.b,
--N(R.sup.c)C(.dbd.O)R.sup.d or --N(R.sup.c)C(.dbd.O)OR.sup.a.
3. The compound according to claim 1, wherein each of X, Y and Z is
independently H, D, (C.sub.1-C.sub.4)alkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, phenyl,
5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms
independently selected from O, S and N,
--(C.sub.1-C.sub.2)alkylene-phenyl or
--(C.sub.1-C.sub.2)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, phenyl,
5-10 membered heteroaryl, --(C.sub.1-C.sub.2)alkylene-phenyl and
--(C.sub.1-C.sub.2)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3, 4 or 5 substituents
independently selected from D, F, Cl, Br, CN,
(C.sub.2-C.sub.4)alkenyl, (C.sub.2-C.sub.4)alkynyl, OR.sup.a,
NR.sup.aR.sup.b, --(C.sub.1-C.sub.2)alkylene-OR.sup.a and
--(C.sub.1-C.sub.2)alkylene-NR.sup.aR.sup.b.
4. The compound according to claim 1, wherein each of R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is
independently H, D, F or Cl.
5. The compound according to claim 1, wherein each of R.sup.a,
R.sup.b and R.sup.c is independently H, (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)haloalkyl, (C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl or
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, with the
proviso where R.sup.a and R.sup.b are bonded to the same nitrogen
atom, R.sup.a and R.sup.b, together with the nitrogen atom they are
attached to, optionally form a substituted or unsubstituted 3-8
membered heterocyclic ring, wherein each of the
(C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)haloalkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl and 3-8
membered heterocyclic ring is optionally substituted with 1, 2, 3
or 4 substituents independently selected from D, F, Cl, CN,
N.sub.3, OH, NH.sub.2, (C.sub.1-C.sub.3)haloalkyl,
(C.sub.1-C.sub.3)alkoxy and (C.sub.1-C.sub.3)alkylamino.
6. The compound according to claim 1, wherein R.sup.d is
independently H, D, (C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl or
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, with the
proviso where each R.sup.1, R.sup.2, R.sup.3, R.sup.5 (or R.sup.4),
R.sup.6 and R.sup.7 is H, R.sup.4 (or R.sup.5) is F, R.sup.d is not
(C.sub.3-C.sub.6)heterocyclyl, wherein each of the
(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl and
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl is
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from D, F, CN, OR.sup.a, NR.sup.aR.sup.b,
(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.4)alkenyl,
(C.sub.2-C.sub.4)alkynyl, --(C.sub.1-C.sub.2)alkylene-OR.sup.a and
--(C.sub.1-C.sub.2)alkylene-NR.sup.aR.sup.b.
7. The compound according to claim 1, wherein Q is NH.sub.2 or
--N(R.sup.c)C(.dbd.O)R.sup.d.
8. The compound according to claim 1, wherein each of X, Y and Z is
independently H, D, methyl, ethyl, phenyl or phenyl group
substituted with 1, 2, 3, 4 or 5 substituents independently
selected from D, F and Cl.
9. The compound according to claim 1, wherein Q is: ##STR00092##
##STR00093##
10. The compound according to claim 1 having Formula (II):
##STR00094## wherein: Q is NR.sup.aR.sup.b,
--N(R.sup.c)C(.dbd.O)R.sup.d or --N(R.sup.c)C(.dbd.O)OR.sup.a; each
of X, Y and Z is independently H, D, (C.sub.1-C.sub.6)alkyl,
(C.sub.3-C.sub.8)cycloalkyl, (C.sub.3-C.sub.7)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl comprising 1, 2, 3
or 4 heteroatoms independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl, (C.sub.6-C.sub.10)aryl, 5-10
membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl and
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3, 4 or 5 substituents
independently selected from D, F, Cl, Br, CN,
(C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, OR.sup.a,
NR.sup.aR.sup.b, --(C.sub.1-C.sub.4)alkylene-OR.sup.a and
--(C.sub.1-C.sub.4)alkylene-NR.sup.aR.sup.b; each of R.sup.a,
R.sup.b and R.sup.c is independently H, (C.sub.1-C.sub.6)alkyl,
(C.sub.3-C.sub.6)cycloalkyl, (C.sub.3-C.sub.6)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl comprising 1, 2, 3
or 4 heteroatoms independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl, (C.sub.6-C.sub.10)aryl, 5-10
membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl and
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from D, F, Cl, CN, N.sub.3, OH, NH.sub.2,
(C.sub.1-C.sub.6)haloalkyl, (C.sub.1-C.sub.6)alkoxy and
(C.sub.1-C.sub.6)alkylamino; and R.sup.d is (C.sub.1-C.sub.6)alkyl,
wherein the (C.sub.1-C.sub.6)alkyl is optionally substituted with
1, 2, 3 or 4 substituents independently selected from D, F, Cl, OH,
NH.sub.2, (C.sub.1-C.sub.6)alkoxy and
(C.sub.1-C.sub.6)alkylamino.
11. The compound according to claim 10, wherein Q is
NR.sup.aR.sup.b or --N(R.sup.c)C(.dbd.O)R.sup.d.
12. The compound according to claim 10, wherein each of X, Y and Z
is independently H, D, (C.sub.1-C.sub.4)alkyl or phenyl, wherein
each of the (C.sub.1-C.sub.4)alkyl and phenyl is optionally
substituted with 1, 2, 3, 4 or 5 substituents independently
selected from D, F and Cl.
13. The compound according to claim 10, wherein each of R.sup.a,
R.sup.b and R.sup.c is independently H, (C.sub.1-C.sub.4)alkyl,
(C.sub.3-C.sub.6)cycloalkyl, (C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl or
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, wherein
each of the (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl and
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl is
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from D, F, Cl, CN, N.sub.3, OH, NH.sub.2,
(C.sub.1-C.sub.6)haloalkyl, (C.sub.1-C.sub.6)alkoxy and
(C.sub.1-C.sub.6)alkylamino.
14. The compound according to claim 10, wherein R.sup.d is Me, Et,
n-Pr or i-Pr.
15. The compound according to claim 10, wherein Q is NH.sub.2 or
--N(R.sup.c)C(.dbd.O)R.sup.d.
16. The compound according to claim 10, wherein each of X, Y and Z
is independently H, D, Me, CH.sub.2D, CHD.sub.2, CD.sub.3, ethyl,
propyl, isopropyl, phenyl or phenyl optionally substituted with 1,
2, 3, 4 or 5 substituents independently selected from D, F and
Cl.
17. The compound according to claim 10, wherein Q is:
##STR00095##
18. The compound of claim 1 having one of the following structures:
##STR00096## ##STR00097## ##STR00098## ##STR00099## ##STR00100##
##STR00101## ##STR00102## ##STR00103##
19. A pharmaceutical composition comprising the compound according
to claim 1 and a pharmaceutically acceptable carrier, excipient,
diluent, adjuvant, vehicle or a combination thereof.
20. The pharmaceutical composition according to claim 19 further
comprising a therapeutic agent selected from a chemotherapeutic
agent, an anti-proliferative agent, an agent for treating
atherosclerosis, an agent for treating lung fibrosis and
combinations thereof.
21. The pharmaceutical composition according to claim 20, wherein
the therapeutic agent is adriamycin, rapamycin, temsirolimus,
everolimus, ixabepilone, gemcitabine, cyclophosphamide,
dexamethasone, etoposide, fluorouracil, afatinib, alisertib,
amuvatinib, axitinib, bosutinib, brivanib, cabozantinib, cediranib,
crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib,
danusertib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib,
ibrutinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib,
linsitinib, masitinib, momelotinib, motesanib, neratinib,
niraparib, nilotinib, oprozomib, olaparib, pazopanib, pictilisib,
ponatinib, quizartinib, regorafenib, rigosertib, rucaparib,
ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib,
tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib,
trametinib, vandetanib, veliparib, vemurafenib, vismodegib,
volasertib, an interferon, carboplatin, topotecan, paclitaxel,
vinblastine, vincristine, temozolomide, tositumomab, trabectedin,
belimumab, bevacizumab, brentuximab, cetuximab, gemtuzumab,
ipilimumab, ofatumumab, panitumumab, ranibizumab, rituximab,
trastuzumab or a combination thereof.
22. A method of preventing, managing, treating or lessening the
severity of a proliferative disorder in a patient by administering
to the patient the compound according to claim 1.
23. The method according to claim 22, wherein the proliferative
disorder is metastatic cancer, colon cancer, gastric
adenocarcinoma, bladder cancer, breast cancer, kidney cancer, liver
cancer, lung cancer, skin cancer, thyroid cancer, a cancer of the
head and neck, prostate cancer, pancreatic cancer, a cancer of the
CNS, glioblastoma, a myeloproliferative disorder, atherosclerosis
or lung fibrosis.
24. A method of preventing, managing, treating or lessening the
severity of a proliferative disorder in a patient by administering
to the patient the pharmaceutical composition according to claim
19.
25. The method according to claim 24, wherein the proliferative
disorder is metastatic cancer, colon cancer, gastric
adenocarcinoma, bladder cancer, breast cancer, kidney cancer, liver
cancer, lung cancer, skin cancer, thyroid cancer, a cancer of the
head and neck, prostate cancer, pancreatic cancer, a cancer of the
CNS, glioblastoma, a myeloproliferative disorder, atherosclerosis
or lung fibrosis.
26. A method of inhibiting or modulating the activity of a protein
kinase in a biological sample comprising contacting a biological
sample with the compound according to claim 1.
27. The method of claim 26, wherein the protein kinase is a
receptor tyrosine kinase.
28. The method of claim 27, wherein the receptor tyrosine kinase is
VEGFR, c-Met, Ron, Axl or a combination thereof.
29. A method of inhibiting or modulating the activity of a protein
kinase in a biological sample comprising contacting a biological
sample with the pharmaceutical composition according to claim
19.
30. The method of claim 29, wherein the protein kinase is a
receptor tyrosine kinase.
31. The method of claim 30, wherein the receptor tyrosine kinase is
VEGFR, c-Met, Ron, Axl or a combination thereof.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefits of U.S. Provisional
Application No. 61/676,944, filed on Jul. 28, 2012, and U.S.
Provisional Application No. 61/679,416, filed on Aug. 3, 2012, all
of which are hereby incorporated by reference in their
entirety.
FIELD OF THE INVENTION
[0002] This invention relates to novel substituted pyrazolone
compounds, and salts thereof, which are useful in the treatment of
hyperproliferative diseases, such as cancers, in mammals. In
particular, the invention relates to compounds that inhibit the
protein tyrosine kinase activity, resulting in the inhibition of
inter- and/or intra-cellular signaling. This invention also relates
to a method of using such compounds in the treatment of
hyperproliferative diseases in mammals, especially humans, and to
pharmaceutical compositions containing such compounds.
BACKGROUND OF THE INVENTION
[0003] Protein kinases represent a large family of proteins that
play a central role in the regulation of a wide variety of cellular
processes. Through regulating an array of signaling pathways,
protein kinases control cell metabolism, cell cycle progression,
cell proliferation and cell death, differentiation and survival.
There are over 500 kinases in the human kinome, and over 150 of
these have been shown or are proposed to be involved in the onset
and/or progression of various human diseases including inflammatory
diseases, cardiovascular diseases, metabolic diseases,
neurodegenerative diseases and cancer.
[0004] A partial list of such kinases include abl, AATK, ALK, Aid,
Axl, bmx, bcr-abl, Blk, Brk, Btk, csk, c-kit, c-Met, c-src, c-fins,
CDK1, CDK2, CDK3, CDK4, CDKS, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1,
CSF1R, CSK, DDR1, DDR2, EPHA, EPHB, EGFR, ErbB2, ErbB3, ErbB4, Erk,
Fak, fes, FER, FGFR1, FGFR2, FGFR3, FGFR4, FGFRS, Fgr, flt-1, Fps,
Frk, Fyn, GSG2, GSK, Hck, ILK, INSRR, IRAK4, ITK, IGF-1R, INS-R,
Jak, KSR1, KDR, LMTK2, LMTK3, LTK, Lck, Lyn, MATK, MERTK, MLTK,
MST1R, MUSK, NPR1, NTRK, MEK, MER, PLK4, PTK, p38, PDGFR, PIK, PKC,
PYK2, RET, ROR1, ROR2, RYK, ros, Ron, SGK493, SRC, SRMS, STYK1,
SYK, TEC, TEK, TEX14, TNK1, TNK2, TNNI3K, TXK, TYK2, Tyro-3, tie,
tie2, TRK, Yes, and Zap70.
[0005] Protein tyrosine kinases are a subclass of protein kinase.
They also may be classified as growth factor receptor (e.g., Axl,
VEGFR, c-Met (HGFR), Ron, EGFR, PDGFR, and FGFR) or non-receptor
(e.g., c-src and bcr-abl) kinases. Receptor tyrosine kinases are
transmembrane proteins that possess an extracellular binding domain
for growth factors, a transmembrane domain, and an intracellular
portion that functions as a kinase to phosphorylate a specific
tyrosine residue in proteins. Abnormal expression or activity of
protein kinases has been directly implicated in the pathogenesis of
myriad human cancers.
[0006] Angiogenesis, the formation of new capillaries from
preexisting blood vessels, is a necessary process for organ
development during embryogenesis and is critical for the female
reproductive cycle, inflammation, and wound healing in the adult.
Certain diseases are known to be associated with deregulated
angiogenesis, for example ocular neovascularization, such as
retinopathies (including diabetic retinopathy), age-related macular
degeneration, psoriasis, hemangioblastoma, hemangioma,
arteriosclerosis, inflammatory disease, such as a rheumatoid or
rheumatic inflammatory disease, especially arthritis (including
rheumatoid arthritis), or other chronic inflammatory disorders,
such as chronic asthma, arterial or post-transplantational
atherosclerosis, endometriosis, and neoplastic diseases, for
example so-called solid tumors and liquid tumors (such as
leukemias). Solid tumors, in particular, are dependent on
angiogenesis to grow beyond a certain critical size by inducing new
capillaries sprouting from existing blood vessels to secure their
nutrition, oxygen supply, and waste removal. In addition,
angiogenesis also promotes metastasis of tumor cells to other
sites.
[0007] The new vessel growth and maturation are highly complex and
coordinated processes, requiring the stimulation by a number of
growth factors, but vascular endothelial growth factor (VEGF)
signaling often represents a critical rate-limiting step in
physiological angiogenesis and pathological angiogenesis. VEGF
binds to and activates the receptor tyrosine kinase, VEGFR. Three
VEGFR isoforms have been identified in humans: VEGFR-1 (Flt-1),
VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4). VEGFR-2 mediates the
majority of cellular responses to VEGF, in particular its mitogenic
and angiogenic effects. VEGFR-1 is thought to modulate VEGFR-2
signaling or to act as a dummy/decoy receptor to sequester VEGF
away from VEGFR-2. The expression of VEGFR-1 is also up-regulated
by hypoxia, in a similar mechanism to VEGF, via HIF-1; its
functions may vary depending on cell type and developmental stage.
(Stuttfeld E, Ballmer-Hofer K (September 2009), "Structure and
function of VEGF receptors," IUBMB Life 61 (9): 915-22.)
[0008] Since VEGFR-2 is the major mediator of vascular endothelial
cell (EC) mitogenesis and survival, as well as angiogenesis and
microvascular permeability, it is expected that direct inhibition
of the kinase activity of VEGFR-2 will result in the reduction of
angiogenesis and the suppression of tumor growth. Furthermore,
inhibition of VEGFR-2 targeting the genetically more stable host
endothelial cells, instead of labile tumor tissues, may decrease
the chance of resistance development. Several agents targeting
VEGFR signaling, administered either as single agents or in
combination with chemotherapy, have been shown to benefit patients
with advanced-stage malignancies. ("VEGF-targeted therapy:
mechanisms of anti-tumor activity," Nature Reviews Cancer, 2008, 8,
579; "Molecular basis for sunitinib efficacy and future clinical
development," Nature Reviews Drug Discovery, 2007, 6, 734; and
"Angiogenesis: an organizing principle for drug discovery?" Nature
Reviews Drug Discovery, 2007, 6, 273).
[0009] c-Met, also referred to as hepatocyte growth factor receptor
(HGFR), is expressed predominantly in epithelial cells but has also
been identified in endothelial cells, myoblasts, hematopoietic
cells and motor neurons. The natural ligand for c-Met is hepatocyte
growth factor (HGF), also known as scatter factor (SF). In both
embryos and adults, activated c-Met promotes a morphogenetic
program, known as invasive growth, which induces cell spreading,
the disruption of intercellular contacts, and the migration of
cells towards their surroundings. ("From Tpr-Met to Met,
tumorigenesis and tubes," Oncogene, 2007, 26, 1276; and "Met
Receptor Tyrosine Kinase as a Therapeutic Anticancer Target,"
Cancer Letter, 2009, 280, 1-14).
[0010] A wide variety of human malignancies exhibit sustained c-Met
stimulation, overexpression, or mutation, including carcinomas of
the breast, liver, lung, ovary, kidney, thyroid, colon, renal,
glioblastomas, and prostate, etc. c-Met is also implicated in
atherosclerosis and lung fibrosis. Invasive growth of certain
cancer cells is drastically enhanced by tumor-stromal interactions
involving the HGF/c-Met pathway. Thus, extensive evidence that
c-Met signaling is involved in the progression and spread of
several cancers and an enhanced understanding of its role in
disease have generated considerable interest in c-Met as major
targets in cancer drug development. ("Molecular cancer therapy: can
our expectation be MET," Euro. J. Cancer, 2008, 44, 641-651; and
"Targeting the c-Met Signaling Pathway in Cancer," Clin. Cancer
Res., 2006, 12, 3657). Agents targeting c-Met signaling pathway are
now under clinical investigation. ("Novel Therapeutic Inhibitors of
the c-Met Signaling Pathway in Cancer," Clinical Cancer Research,
2009, 15, 2207), and "Drug development of MET inhibitors: targeting
oncogene addiction and expedience," Nature Review Drug Discovery,
2008, 7, 504).
[0011] Axl belongs to the subfamily of receptor tyrosine kinases
(RTKs) that also includes Tyro3 and Mer (TAM). The TAM receptors
are characterized by a combination of two immunoglobin-like domains
and dual fibronectin type III repeats in the extracellular region
and a cytoplasmic kinase domain. The ligands for TAM receptors are
Gas6 (growth arrest-specific 6) and protein S, two vitamin
K-dependent proteins that exhibit 43% amino-acid sequence identity
and share similar domain structures ("The anticoagulation factor
protein S and its relative, Gas6, are ligands for the Tyro 3/Axl
family of receptor tyrosine kinases," Cell, 1995, 80, 661-670; and
"Axl receptor tyrosine kinase stimulated by the vitamin K-dependent
protein encoded by growth-arrest-specific gene 6," Nature, 1995,
373, 623-626).
[0012] Adequate evidence supports the role of the Gas6/Axl system
in driving cell growth and survival in normal and cancer cells
("TAM receptor tyrosine kinases: biologic functions, signaling, and
potential therapeutic targeting in human cancer," Adv Cancer Res,
2008, 100, 35-83). Axl overexpression and signaling has been
implicated in several human malignancies, such as colon, breast,
glioma, thyroid, gastric, melanoma, lung cancer, and in renal cell
carcinoma (RCC). A more detailed role of Axl biology has been
proven in glioma, where loss of Axl signaling diminished glioma
tumor growth, and in breast cancer, where Axl drive cell migration,
tube formation, neovascularization, and tumor growth. Axl has been
shown to play multiple roles in tumorigenesis and that therapeutic
antibodies against Axl may block Axl functions not only in
malignant tumor cells but also in the tumor stroma. The additive
effect of Axl inhibition with anti-VEGF suggests that blocking Axl
function could be an effective approach for enhancing
antiangiogenic therapy. ("Axl as a potential therapeutic target in
cancer: role of Axl in tumor growth, metastasis and angiogenesis,"
Oncogene, 2009, 28, 3442-3455; and "TAM Receptor Tyrosine Kinases:
Biologic Functions, Signaling, and Potential Therapeutic Targeting
in Human Cancer," Adv Cancer Res., 2008, 100, 35-83).
[0013] RON (MST1R, recepteur d'origine nantais), the other member
of the MET family, is a receptor tyrosine kinase for the ligand
macrophage-stimulating protein (MSP, also known as MST1, and
hepatocyte growth factor-like (HGFL)), which is associated with in
vitro and in vivo cell dissociation, motility and matrix
invasion--all of which are surrogate markers of an aggressive
cancer phenotype with metastatic potential. RON mediates oncogenic
phenotypes in lung, thyroid, pancreas, prostate, colon and breast
cancer cells and predicts a poor prognosis in human breast cancer.
Co-expression of RON with MET and the induction of RON expression
by HGF-MET signaling have both been described in hepatocellular
carcinoma. Furthermore, co-expression of MET and RON portends a
worse prognosis in ovary, breast and bladder cancers. Given RON and
MET signaling redundancy, it is possible that resistance to MET
inhibition is mediated by RON signaling ("RON (MST1R) is a novel
prognostic marker and therapeutic target for gastroesophageal
adenocarcinoma." Cancer Biol Ther. 2011 Jul. 1; 12(1): 9-46.).
[0014] The roles of MSP-RON signaling axis in cancer pathogenesis
has also been extensively studied in various model systems. Both in
vitro and in vivo evidence has revealed that MSP-RON signalling is
important for the invasive growth of different types of cancers.
Aberrant RON activation, which is induced by overexpression of
protein and the generation of oncogenic isoforms and is indicated
by the persistent activation of multi-intracellular signaling
cascades, occurs in various types of cancers. RON signaling is also
necessary for cancer cell growth and survival. These features
render RON as a drug target for cancer therapy ("MSP-RON signalling
in cancer: pathogenesis and therapeutic potential." Nature Reviews
Cancer, 2013, 13, 466-481).
[0015] It is widely known that cancer cells employ multiple
mechanisms to evade tightly regulated cellular processes such as
proliferation, apoptosis, and senescence. Thus, most tumors can
escape from the inhibition of any single kinase. System-wide
analyses of tumors identified receptor tyrosine kinase (RTK)
coactivation as an important mechanism by which cancer cells
achieve chemoresistance. One of the strategies to overcome RTK
coactivation may involve therapeutically targeting multiple RTKs
simultaneously in order to shut down oncogenic RTK signaling and
overcome compensatory mechanisms. ("Receptor Tyrosine Kinas
Coactivation Networks in Cancer," Cancer Research, 2010, 70, 3857).
Anti-tumor approaches in targeting VEGFR, c-Met, Ron and/or Axl
signaling may circumvent the ability of tumor cells to overcome
VEGFR, c-Met (HGFR), Ron and/or Axl inhibition alone and thus may
represent improved cancer therapeutics.
SUMMARY OF THE INVENTION
[0016] Provided herein are new compounds and methods for treating
cell proliferative diseases. The compounds disclosed herein are
inhibitors of protein tyrosine kinases. Preferably, the compounds
disclosed herein are multiple function inhibitors, capable of
inhibiting, for example, VEGFR, c-Met (HGFR), Ron and/or Axl.
Accordingly, provided herein are new inhibitors of protein tyrosine
kinase receptor signaling, such as VEGF receptor signaling, HGF
receptor signaling, Ron signaling and/or Axl signaling.
[0017] Specifically, it has been found that compounds disclosed
herein, and pharmaceutically acceptable compositions thereof, are
effective as inhibitors of receptor tyrosine kinases such as VEGFR,
c-Met, Ron and/or Axl.
[0018] In one aspect, provided herein is a compound having Formula
(I):
##STR00001##
or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a
solvate, a hydrate, a metabolite, a pharmaceutically acceptable
salt or a prodrug thereof, wherein each of Q, R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.5, R.sup.6, W, X, Y and Z is as defined
herein.
[0019] In some embodiments, the compound disclosed herein has
formula (II):
##STR00002##
wherein each of Q, X, Y and Z is as defined herein. In certain
embodiments, Q is H, NR.sup.aR.sup.b, OR.sup.a,
--N(R.sup.c)C(.dbd.O)R.sup.d or --N(R.sup.c)C(.dbd.O)OR.sup.a;
W is CR.sup.7 or N;
[0020] each of X, Y and Z is independently H, D,
(C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl comprising 1, 2, 3
or 4 heteroatoms independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl and
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3, 4 or 5 substituents
independently selected from D, F, Cl, Br, CN,
(C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, OR.sup.a,
NR.sup.aR.sup.b, --(C.sub.1-C.sub.4)alkylene-OR.sup.a and
--(C.sub.1-C.sub.4)alkylene-NR.sup.aR.sup.b; each of R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is
independently H, D, F, Cl, Br, CN, N.sub.3, OR.sup.a,
(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.2-C.sub.6)alkenyl or (C.sub.2-C.sub.6)alkynyl; each of
R.sup.a, R.sup.b and R.sup.c is independently H,
(C.sub.1-C.sub.6)aliphatic, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl comprising 1, 2, 3
or 4 heteroatoms independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), with the
proviso wherein R.sup.a and R.sup.b are bonded to the same nitrogen
atom, R.sup.a and R.sup.b, together with the nitrogen atom they are
attached to, optionally form a substituted or unsubstituted 3-8
membered heterocyclic ring, wherein each of the
(C.sub.1-C.sub.6)aliphatic, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10) aryl,
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) and 3-8
membered heterocyclic ring is optionally substituted with 1, 2, 3
or 4 substitutents independently selected from D, F, Cl, CN,
N.sub.3, OH, NH.sub.2, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.1-C.sub.6)alkoxy and (C.sub.1-C.sub.6)alkylamino; and
R.sup.d is H, (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl or
(C.sub.6-C.sub.10)aryl, with the proviso where each R.sup.1,
R.sup.2, R.sup.3, R.sup.5 (or R.sup.4), R.sup.6 and R.sup.7 is H,
R.sup.4 (or R.sup.5) is F, R.sup.d is not
(C.sub.3-C.sub.7)heterocyclyl, wherein each of the
(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl and
(C.sub.6-C.sub.10)aryl is optionally substituted with 1, 2, 3 or 4
substitutents independently selected from D, F, Cl, Br, CN,
OR.sup.a, NR.sup.aR.sup.b, (C.sub.1-C.sub.6)alkyl,
(C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl,
--(C.sub.1-C.sub.4)alkylene-OR.sup.a and
--(C.sub.1-C.sub.4)alkylene-NR.sup.aR.sup.b.
[0021] In another embodiment, Q is NR.sup.aR.sup.b,
--N(R.sup.c)C(.dbd.O)R.sup.d or --N(R.sup.c)C(.dbd.O)OR.sup.a.
[0022] In another embodiment, each of X, Y and Z is independently
H, D, (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, phenyl,
5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms
independently selected from O, S and N,
--(C.sub.1-C.sub.2)alkylene-phenyl or
--(C.sub.1-C.sub.2)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, phenyl,
5-10 membered heteroaryl, --(C.sub.1-C.sub.2)alkylene-phenyl and
--(C.sub.1-C.sub.2)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3, 4 or 5 substituents
independently selected from D, F, Cl, Br, CN,
(C.sub.2-C.sub.4)alkenyl, (C.sub.2-C.sub.4)alkynyl, OR.sup.a,
NR.sup.aR.sup.b, --(C.sub.1-C.sub.2)alkylene-OR.sup.a and
--(C.sub.1-C.sub.2)alkylene-NR.sup.aR.sup.b.
[0023] In another embodiment, each of R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently H, D, F or
Cl.
[0024] In another embodiment, each of R.sup.a, R.sup.b and R.sup.c
is independently H, (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)haloalkyl, (C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl or
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, with the
proviso where R.sup.a and R.sup.b are bonded to the same nitrogen
atom, R.sup.a and R.sup.b, together with the nitrogen atom they are
attached to, optionally form a substituted or unsubstituted 3-8
membered heterocyclic ring, wherein each of the
(C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)haloalkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl and 3-8
membered heterocyclic ring is optionally substituted with 1, 2, 3
or 4 substituents independently selected from D, F, Cl, CN,
N.sub.3, OH, NH.sub.2, (C.sub.1-C.sub.3)haloalkyl,
(C.sub.1-C.sub.3)alkoxy and (C.sub.1-C.sub.3)alkylamino
[0025] In another embodiment, R.sup.d is independently H, D,
(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl or
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, with the
proviso where each R.sup.1, R.sup.2, R.sup.3, R.sup.5 (or R.sup.4),
R.sup.6 and R.sup.7 is H, R.sup.4 (or R.sup.5) is F, R.sup.d is not
(C.sub.3-C.sub.6)heterocyclyl, wherein each of the
(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl and
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl is
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from D, F, CN, OR.sup.a, NR.sup.aR.sup.b,
(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.4)alkenyl,
(C.sub.2-C.sub.4)alkynyl, --(C.sub.1-C.sub.2)alkylene-OR.sup.a and
--(C.sub.1-C.sub.2)alkylene-NR.sup.aR.sup.b.
[0026] In another embodiment, Q is NH.sub.2 or
--N(R.sup.c)C(.dbd.O)R.sup.d.
[0027] In another embodiment, each of X, Y and Z is independently
H, D, methyl, ethyl, phenyl or phenyl group substituted with 1, 2,
3, 4 or 5 substituents independently selected from D, F and Cl.
[0028] In another embodiment, Q is:
##STR00003## ##STR00004##
[0029] In another aspect, provided herein is a pharmaceutical
composition comprising the compound disclosed herein that is an
inhibitor of receptor tyrosine kinase, or a stereoisomer, geometric
isomer, tautomer, solvate, metabolite, pharmaceutically acceptable
salt thereof, and a pharmaceutically acceptable carrier, excipient,
diluent, adjuvant, vehicle or a combination thereof. In some
embodiments, the pharmaceutical composition comprise the compound
disclosed herein that is an inhibitor of VEGF receptor signaling,
HGF receptor signaling, Ron signaling and/or Axl signaling, or a
stereoisomer, geometric isomer, tautomer, solvate, metabolite,
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier, excipient, diluent, adjuvant, vehicle or a
combination thereof.
[0030] In other embodiments, the composition further comprises a
therapeutic agent.
[0031] In other embodiments, the therapeutic agent is a
chemotherapeutic agent, an anti-proliferative agent, an agent for
treating atherosclerosis, an agent for treating lung fibrosis, or
combinations thereof.
[0032] In other embodiments, the therapeutic agent is chlorambucil,
melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine,
lomustine, streptozocin, cisplatin, carboplatin, oxaliplatin,
dacarbazine, temozolomide, procarbazine, methotrexate,
fluorouracil, cytarabine, gemcitabine, mercaptopurine, fludarabine,
vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel,
topotecan, irinotecan, etoposide, trabectedin, dactinomycin,
doxorubicin, epirubicin, daunorubicin, mitoxantrone, bleomycin,
mitomycin, ixabepilone, tamoxifen, flutamide, gonadorelin
analogues, megestrol, prednidone, dexamethasone,
methylprednisolone, thalidomide, interferon alfa, leucovorin,
sirolimus, temsirolimus, everolimus, afatinib, alisertib,
amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brivanib,
cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib,
dacomitinib, danusertib, dasatinib, dovitinib, erlotinib,
foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib,
iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib,
momelotinib, motesanib, neratinib, nilotinib, niraparib, oprozomib,
olaparib, pazopanib, pictilisib, ponatinib, quizartinib,
regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib,
saridegib, sorafenib, sunitinib, tasocitinib, telatinib,
tivantinib, tivozanib, tofacitinib, trametinib, vandetanib,
veliparib, vemurafenib, vismodegib, volasertib, alemtuzumab,
bevacizumab, brentuximab vedotin, catumaxomab, cetuximab,
denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab,
panitumumab, ramucirumab, rituximab, tositumomab, trastuzumab, or a
combination thereof.
[0033] In another aspect, provided herein is the compound disclosed
herein or the pharmaceutical composition disclosed herein for use
in preventing, managing, treating or lessening the severity of a
proliferative disorder in a patient.
[0034] In another aspect, provided herein is a method of
preventing, managing, treating or lessening the severity of a
proliferative disorder in a patient by administering to the patient
the compound disclosed herein.
[0035] In another aspect, provided herein is a method of
preventing, managing, treating or lessening the severity of a
proliferative disorder in a patient by administering to the patient
the pharmaceutical composition disclosed herein.
[0036] In some embodiments, the proliferative disorder is
metastatic cancer. In other embodiments, the proliferative disorder
is colon cancer, gastric adenocarcinoma, bladder cancer, breast
cancer, kidney cancer, liver cancer, lung cancer, skin cancer,
thyroid cancer, a cancer of the head and neck, prostate cancer,
pancreatic cancer, a cancer of the CNS, glioblastoma or a
myeloproliferative disorder, In further embodiments, the
proliferative disorder is atherosclerosis or lung fibrosis.
[0037] In another aspect, provided herein is the compound disclosed
herein or the pharmaceutical composition disclosed herein for use
in inhibiting or modulating the activity of a protein kinase in a
biological sample comprising contacting a biological sample with
the compound disclosed herein or the pharmaceutical composition
disclosed herein.
[0038] In another aspect, provided herein is a method of inhibiting
or modulating the activity of a protein kinase in a biological
sample comprising contacting a biological sample with the compound
disclosed herein.
[0039] In another aspect, provided herein is a method of inhibiting
or modulating the activity of a protein kinase in a biological
sample comprising contacting a biological sample with the
pharmaceutical composition disclosed herein.
[0040] In some embodiments, the protein kinase is a receptor
tyrosine kinase. In other embodiments, the receptor tyrosine kinase
is VEGFR, c-Met, Ron, Axl or a combination thereof.
[0041] In some embodiments, inhibition of the activity of a
receptor protein kinase, preferably VEGF receptor signaling, HGF
receptor signaling, Ron signaling or Axl receptor signaling, can be
in a cell or a multicellular organism. If in a multicellular
organism, the method according to this aspect of the invention
comprises administering to the organism the compound disclosed
herein, or the pharmaceutical composition disclosed herein. In some
embodiments, the organism is a mammal. In other embodiments is a
human. In yet another embodiment, the method further comprises
contacting the kinase with a therapeutic agent.
[0042] In another aspect, provided herein are methods of inhibiting
proliferative activity of a cell, the method comprising contacting
the cell with an effective proliferative inhibiting amount of a
compound according to the present invention or a composition
thereof. In some embodiments, the method further comprises
contacting the cell with a therapeutic agent.
[0043] In another aspect, provided herein are methods of treating a
cell proliferative disease in a patient, the method comprising
administering to the patient in need of such treatment an effective
therapeutic amount of a compound according to the present invention
or a composition thereof. In some embodiments, the method further
comprises administering a therapeutic agent.
[0044] In another aspect, provided herein are methods of inhibiting
tumor growth in a patient, the method comprising administering to
the patient in need thereof an effective therapeutic amount of a
compound according to the present invention or a composition
thereof. In some embodiments, the method further comprises
administering a therapeutic agent.
[0045] In another aspect, provided herein are methods of preparing,
methods of separating, and methods of purifying compounds of
Formula (I) or (II).
[0046] The foregoing merely summarizes certain aspects of the
invention and is not intended to be limiting in nature. These
aspects and other aspects and embodiments are described more fully
below.
DETAILED DESCRIPTION OF THE INVENTION
Definitions and General Terminology
[0047] Reference will now be made in detail to certain embodiments
of the invention, examples of which are illustrated in the
accompanying structures and formulas. The invention is intended to
cover all alternatives, modifications, and equivalents which may be
included within the scope of the present invention as defined by
the claims. One skilled in the art will recognize many methods and
materials similar or equivalent to those described herein, which
could be used in the practice of the present invention. The present
invention is in no way limited to the methods and materials
described herein. In the event that one or more of the incorporated
literature, patents, and similar materials differs from or
contradicts this application, including but not limited to defined
terms, term usage, described techniques, or the like, this
application controls.
[0048] As used herein, the following definitions shall apply unless
otherwise indicated. For purposes of this invention, the chemical
elements are identified in accordance with the Periodic Table of
the Elements, CAS version, and the Handbook of Chemistry and
Physics, 75.sup.th Ed. 1994. Additionally, general principles of
organic chemistry are described in "Organic Chemistry", Thomas
Sorrell, University Science Books, Sausalito: 1999, and "March's
Advanced Organic Chemistry," by Michael B. Smith and Jerry March,
John Wiley & Sons, New York: 2007, the entire contents of which
are hereby incorporated by reference.
[0049] As described herein, compounds disclosed herein may
optionally be substituted with one or more substituents, such as
are illustrated generally below, or as exemplified by particular
classes, subclasses, and species of the invention. It will be
appreciated that the phrase "optionally substituted" is used
interchangeably with the phrase "substituted or unsubstituted". In
general, the term "substituted" refers to the replacement of one or
more hydrogen radicals in a given structure with the radical of a
specified substituent. Unless otherwise indicated, an optionally
substituted group may have a substituent at each substitutable
position of the group. When more than one position in a given
structure can be substituted with more than one substituent
selected from a specified group, the substituent may be either the
same or different at each position.
[0050] The term "aliphatic" or "aliphatic group" refers to a
straight-chain (i.e., unbranched) or branched, substituted or
unsubstituted hydrocarbon chain that is completely saturated or
that contains one or more units of unsaturation. Unless otherwise
specified, aliphatic groups contain 1-20 carbon atoms. In some
embodiments, aliphatic groups contain 1-10 carbon atoms. In other
embodiments, aliphatic groups contain 1-8 carbon atoms. In still
other embodiments, aliphatic groups contain 1-6 carbon atoms, and
in yet other embodiments, aliphatic groups contain 1-3 carbon
atoms. Suitable aliphatic groups include, but are not limited to,
linear or branched, substituted or unsubstituted alkyl, alkenyl, or
alkynyl groups. For example, (C.sub.1-C.sub.6)aliphatic groups
include unbranched or branched, unsubstituted or suitably
substituted (C.sub.1-C.sub.6)alkyl, (C.sub.2-C.sub.6)alkenyl, or
(C.sub.2-C.sub.6)alkynyl groups. The aliphatic radicals are
optionally substituted independently with one or more substituents
described herein.
[0051] The term "alkyl" or "alkyl group" refers to a saturated
linear or branched-chain monovalent hydrocarbon radical of 1 to 20
carbon atoms, wherein the alkyl radical may be optionally
substituted independently with one or more substituents described
below. Unless otherwise specified, alkyl groups contain 1-20 carbon
atoms. In some embodiments, alkyl groups contain 1-10 carbon atoms.
In other embodiments, alkyl groups contain 1-8 carbon atoms. In
other embodiments, alkyl groups contain 1-6 carbon atoms. In still
other embodiments, alkyl groups contain 1-4 carbon atoms, and in
yet other embodiments, alkyl groups contain 1-3 carbon atoms.
[0052] Some non-limiting examples of alkyl groups include, but are
not limited to, methyl (Me, --CH.sub.3), ethyl (Et,
--CH.sub.2CH.sub.3), 1-propyl (n-Pr, n-propyl,
--CH.sub.2CH.sub.2CH.sub.3), 2-propyl (i-Pr, i-propyl,
--CH(CH.sub.3).sub.2), 1-butyl (n-Bu, n-butyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-methyl-1-propyl (i-Bu,
i-butyl, --CH.sub.2CH(CH.sub.3).sub.2), 2-butyl (s-Bu, s-butyl,
--CH(CH.sub.3)CH.sub.2CH.sub.3), 2-methyl-2-propyl (t-Bu, t-butyl,
--C(CH.sub.3).sub.3), 1-pentyl (n-pentyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-pentyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3), 3-pentyl
(--CH(CH.sub.2CH.sub.3).sub.2), 2-methyl-2-butyl
(--C(CH.sub.3).sub.2CH.sub.2CH.sub.3), 3-methyl-2-butyl
(--CH(CH.sub.3)CH(CH.sub.3).sub.2), 3-methyl-1-butyl
(--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2), 2-methyl-1-butyl
(--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3), 1-hexyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-hexyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 3-hexyl
(--CH(CH.sub.2CH.sub.3)(CH.sub.2CH.sub.2CH.sub.3)),
2-methyl-2-pentyl (--C(CH.sub.3).sub.2CH.sub.2CH.sub.2CH.sub.3),
3-methyl-2-pentyl (--CH(CH.sub.3)CH(CH.sub.3)CH.sub.2CH.sub.3),
4-methyl-2-pentyl (--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2),
3-methyl-3-pentyl (--C(CH.sub.3)(CH.sub.2CH.sub.3).sub.2),
2-methyl-3-pentyl (--CH(CH.sub.2CH.sub.3)CH(CH.sub.3).sub.2),
2,3-dimethyl-2-butyl (--C(CH.sub.3).sub.2CH(CH.sub.3).sub.2),
3,3-dimethyl-2-butyl (--CH(CH.sub.3)C(CH.sub.3).sub.3, 1-heptyl,
1-octyl, and the like.
[0053] The terms "alkyl" and the prefix "alk-" are inclusive of
both straight chain and branched saturated carbon chain.
[0054] The term "alkylene" refers to a saturated divalent
hydrocarbon group derived from a straight or branched chain
saturated hydrocarbon by the removal of two hydrogen atoms. Unless
otherwise specified, alkylene groups contain 1-10 carbon atoms. In
some embodiments, alkylene groups contain 1-6 carbon atoms. In
other embodiments, alkylene groups contain 1-4 carbon atoms. In
still other embodiments, alkylene groups contain 1-2 carbon atoms,
and is exemplified by methylene (--CH.sub.2--), ethylene
(--CH.sub.2CH.sub.2--), isopropylene (--CH(CH.sub.3)CH.sub.2--),
and the like.
[0055] The term "alkenyl" refers to linear or branched-chain
monovalent hydrocarbon radical of 2 to 12 carbon atoms with at
least one site of unsaturation, i.e., a carbon-carbon, sp2 double
bond, wherein the alkenyl radical may be optionally substituted
independently with one or more substituents described herein, and
includes radicals having "cis" and "trans" orientations, or
alternatively, "E" and "Z" orientations. Preferably, alkenyl group
contains 2 to 8 carbon atoms, and more preferably, 2 to 6 carbon
atoms. Examples include, but are not limited to, ethylenyl or vinyl
(--CH.dbd.CH.sub.2), allyl (--CH.sub.2CH.dbd.CH.sub.2), and the
like.
[0056] The term "alkynyl" refers to a linear or branched monovalent
hydrocarbon radical of 2 to 12 carbon atoms with at least one site
of unsaturation, i.e., a carbon-carbon, sp triple bond, wherein the
alkynyl radical may be optionally substituted independently with
one or more substituents described herein. Preferably, alkynyl
group contains 2 to 8 carbon atoms, and more preferably 2 to 6
carbon atoms. Examples include, but are not limited to, ethynyl
(--C.ident.CH), propynyl (propargyl, --CH.sub.2C.ident.CH),
--C.ident.C--CH.sub.3, and the like.
[0057] The term "alkoxy" refers to an alkyl group, as previously
defined, attached to the principal carbon atom through an oxygen
atom. Unless otherwise specified, alkoxy groups contain 1-20 carbon
atoms. In some embodiments, alkoxy groups contain 1-10 carbon
atoms. In other embodiments, alkoxy groups contain 1-8 carbon
atoms. In still other embodiments, alkoxy groups contain 1-6 carbon
atoms. In yet other embodiments, alkoxy groups contain 1-4 carbon
atoms. In further embodiments, alkoxy groups contain 1-3 carbon
atoms. The alkoxy radicals are optionally substituted independently
with one or more substituents described herein.
[0058] Some non-limiting examples of alkoxy groups include, but are
not limited to, methoxy (MeO, --OCH.sub.3), ethoxy (EtO,
--OCH.sub.2CH.sub.3), 1-propoxy (n-PrO, n-propoxy,
--OCH.sub.2CH.sub.2CH.sub.3), 2-propoxy (i-PrO, i-propoxy,
--OCH(CH.sub.3).sub.2), 1-butoxy (n-BuO, n-butoxy,
--OCH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-methyl-1-propoxy (i-BuO,
i-butoxy, --OCH.sub.2CH(CH.sub.3).sub.2), 2-butoxy (s-BuO,
s-butoxy, --OCH(CH.sub.3)CH.sub.2CH.sub.3), 2-methyl-2-propoxy
(t-BuO, t-butoxy, --OC(CH.sub.3).sub.3), 1-pentoxy (n-pentoxy,
--OCH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-pentoxy
(--OCH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3), 3-pentoxy
(--OCH(CH.sub.2CH.sub.3).sub.2), 2-methyl-2-butoxy
(--OC(CH.sub.3).sub.2CH.sub.2CH.sub.3), 3-methyl-2-butoxy
(--OCH(CH.sub.3)CH(CH.sub.3).sub.2), 3-methyl-1-butoxy
(--OCH.sub.2CH.sub.2CH(CH.sub.3).sub.2), 2-methyl-1-butoxy
(--OCH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3), and the like.
[0059] The terms "haloalkyl", "haloalkenyl" or "haloalkoxy" refers
to alkyl, alkenyl, or alkoxy, as the case may be, substituted with
one or more halogen atoms.
[0060] The term "carbocycle", "carbocyclyl", "carbocyclic ring" or
"cycloaliphatic" refers to a monovalent or multivalent
non-aromatic, saturated or partially unsaturated ring having 3 to
12 carbon atoms as a monocyclic, bicyclic, or tricyclic ring
system. Suitable cycloaliphatic groups include, but are not limited
to, cycloalkyl, cycloalkenyl, and cycloalkynyl. Further examples of
cycloaliphatic groups include cyclopropyl, cyclobutyl, cyclopentyl,
1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl,
cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl,
1-cyclohex-3-enyl, cyclohexadienyl, and the like.
[0061] The term "cycloalkyl" refers to a monovalent or multivalent
saturated ring having 3 to 12 carbon atoms as a monocyclic,
bicyclic, or tricyclic ring system. A bicyclic ring system includes
a spiro bicyclyl or a fused bicyclyl. In some embodiments, a
cycloalkyl contains 3 to 10 carbon atoms. In still other
embodiments, a cycloalkyl contains 3 to 8 carbon atoms, and in yet
other embodiments, a cycloalkyl contains 3 to 6 carbon atoms. The
cycloalkyl radicals are optionally substituted independently with
one or more substituents described herein.
[0062] The term "heterocycle", "heterocyclyl", or "heterocyclic" as
used interchangeably herein refers to a monocyclic, bicyclic, or
tricyclic ring system in which one or more ring members are
independently selected from heteroatoms and that is completely
saturated or that contains one or more units of unsaturation, but
which is not aromatic, that has a single point of attachment to the
rest of the molecule. A bicyclic ring system includes a spiro
bicyclyl or a fused bicyclyl, and one of the rings can be either a
monocarbocycle or a monoheterocycle. One or more ring atoms are
optionally substituted independently with one or more substituents
described herein. In some embodiments, the "heterocycle",
"heterocyclyl", or "heterocyclic" group is a monocycle having 3 to
7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected
from N, O, P, and S, wherein the S or P is optionally substituted
with one or more oxo to provide the group SO or SO.sub.2, PO or
PO.sub.2). In other embodiments, the "heterocycle", "heterocyclyl",
or "heterocyclic" group is a monocycle having 3 to 6 ring members
(2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, O, P,
and S, wherein the S or P is optionally substituted with one or
more oxo to provide the group SO or SO.sub.2, PO or PO.sub.2), or a
bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3
heteroatoms selected from N, O, P, and S, wherein the S or P is
optionally substituted with one or more oxo to provide the group SO
or SO.sub.2, PO or PO.sub.2).
[0063] The heterocyclyl may be a carbon radical or heteroatom
radical. Examples of heterocyclic rings include, but are not
limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl,
tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl,
tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino,
thioxanyl, piperazinyl, homo-piperazinyl, azetidinyl, oxetanyl,
thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl,
diazepinyl, thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl,
2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl,
dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl,
dihydrofuranyl, pyrazolidinylimidazolinyl, imidazolidinyl,
1,2,3,4-tetrahydroiso-quinolinyl. Examples of a heterocyclic group
wherein 2 ring carbon atoms are substituted with oxo (.dbd.O)
moieties are pyrimidindionyl and 1,1-dioxo-thiomorpholinyl.
[0064] The term "heteroatom" refers to one or more of oxygen,
sulfur, nitrogen, phosphorus, or silicon, including any oxidized
form of nitrogen, sulfur, or phosphorus; the quaternized form of
any basic nitrogen; or a substitutable nitrogen of a heterocyclic
ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in
pyrrolidinyl) or NR (as in N-substituted pyrrolidinyl).
[0065] The term "halogen" refers to F, Cl, Br, or I.
[0066] The term "H" refers to a single hydrogen atom. This radical
may be attached, for example, to an oxygen atom to form a hydroxyl
radical.
[0067] The term "D" or ".sup.2H" refers to a single deuterium atom.
One of this radical may be attached, for example, to a methyl group
to form a mono-deuterated methyl group (--CDH.sub.2), two of
deuterium atoms may attached to a methyl group to form a
di-deuterated methyl (--CD.sub.2H), and three of deuterium atoms
may attached to a methyl group to form a tri-deuterated methyl
group (--CD.sub.3).
[0068] The term "N.sub.3" refers to an azide moiety. This radical
may be attached, for example, to a methyl group to form
azidomethane (methyl azide, MeN.sub.3); or attached to a phenyl
group to form phenyl azide (PhN.sub.3).
[0069] The term "aryl" used alone or as part of a larger moiety as
in "aralkyl", "aralkoxy" or "aryloxyalkyl" refers to monocyclic,
bicyclic, and tricyclic carbocyclic ring systems having a total of
6 to 14 ring members, preferably, 6 to 12 ring members, and more
preferably 6 to 10 ring members, wherein at least one ring in the
system is aromatic, wherein each ring in the system contains 3 to 7
ring members and that has a single point of attachment to the rest
of the molecule. The term "aryl" may be used interchangeably with
the term "aryl ring." Examples of aryl rings would include phenyl,
naphthyl, and anthracene. The aryl radicals are optionally
substituted independently with one or more substituents described
herein.
[0070] The term "heteroaryl" used alone or as part of a larger
moiety as in "heteroaralkyl" or "heteroarylalkoxy" refers to
monocyclic, bicyclic, and tricyclic ring systems having a total of
5 to 14 ring members, preferably, 5 to 12 ring members, and more
preferably 5 to 10 ring members, wherein at least one ring in the
system is aromatic, at least one ring in the system contains one or
more heteroatoms, wherein each ring in the system contains 5 to 7
ring members and that has a single point of attachment to the rest
of the molecule. The term "heteroaryl" may be used interchangeably
with the term "heteroaryl ring" or the term "heteroaromatic". The
heteroaryl radicals are optionally substituted independently with
one or more substituents described herein.
[0071] Some non-limiting examples of heteroaryl rings include the
following monocycles: 2-furanyl, 3-furanyl, N-imidazolyl,
2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl,
4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl,
N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl,
4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl
(e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl,
tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and
5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g., 2-pyrazolyl),
isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl,
1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyrazinyl, 1,3,5-triazinyl,
and the following bicycles: benzimidazolyl, benzofuryl,
benzothiophenyl, indolyl (e.g., 2-indolyl), purinyl, quinolinyl
(e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), and isoquinolinyl
(e.g., 1-isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl).
[0072] The terms "carboxy" or "carboxyl", whether used alone or
with other terms, such as "carboxyalkyl", refers to --CO.sub.2H.
The term "carbonyl", whether used alone or with other terms, such
as "aminocarbonyl", denotes --(C.dbd.O)--.
[0073] The term "alkylamino" embraces "N-alkylamino" and
"N,N-dialkylamino" where amino groups are independently substituted
with one alkyl radical or with two alkyl radicals, respectively.
Some non-limiting examples of alkylamino radicals are "lower
alkylamino" radicals having one or two alkyl radicals of one to six
carbon atoms, attached to a nitrogen atom. Suitable alkylamino
radicals may be mono or dialkylamino such as N-methylamino,
N-ethylamino, N,N-dimethylamino, N,N-diethylamino and the like.
[0074] The term "arylamino" refers to amino groups, which have been
substituted with one or two aryl radicals, such as N-phenylamino.
The arylamino radicals may be further substituted on the aryl ring
portion of the radical.
[0075] The term "aminoalkyl" refers to linear or branched alkyl
radicals having one to about ten carbon atoms any one of which may
be substituted with one or more amino radicals. More preferred
aminoalkyl radicals are "lower aminoalkyl" radicals having one to
six carbon atoms and one or more amino radicals. Examples of such
radicals include aminomethyl, aminoethyl, aminopropyl, aminobutyl
and aminohexyl.
[0076] The term "unsaturated" refers to a moiety having one or more
units of unsaturation.
[0077] The term "comprising" is meant to be open ended, including
the indicated component but not excluding other elements.
[0078] Unless otherwise stated, structures depicted herein are also
meant to include all isomeric (e.g., enantiomeric, diastereomeric,
and geometric (or conformational)) forms of the structure; for
example, the R and S configurations for each asymmetric center, (Z)
and (E) double bond isomers, and (Z) and (E) conformational
isomers. Therefore, single stereochemical isomers as well as
enantiomeric, diastereomeric, and geometric (or conformational)
mixtures of the present compounds are within the scope of the
invention.
[0079] The term "tautomer" or "tautomeric form" refers to
structural isomers of different energies which are interconvertible
via a low energy barrier. For example, proton tautomers (also known
as prototropic tautomers) include interconversions via migration of
a proton, such as keto-enol and imine-enamine isomerizations.
Valence tautomers include interconversions by reorganization of
some of the bonding electrons.
[0080] Unless otherwise stated, all tautomeric forms of the
compounds disclosed herein are within the scope of the invention.
Additionally, unless otherwise stated, structures depicted herein
are also meant to include compounds that differ only in the
presence of one or more isotopically enriched atoms.
[0081] The term "prodrug" refers to a compound that is transformed
in vivo into a compound of formula (I) or (II). Such a
transformation can be affected, for example, by hydrolysis in blood
or enzymatic transformation of the prodrug form to the parent form
in blood or tissue. Prodrugs of the compounds disclosed herein may
be, for example, esters. Esters that may be utilized as prodrugs in
the present invention are phenyl esters, aliphatic
(C.sub.1-C.sub.24) esters, acyloxymethyl esters, carbonates,
carbamates, and amino acid esters. For example, a compound
disclosed herein that contains an OH group may be acylated at this
position in its prodrug form. Other prodrug forms include
phosphates, such as, for example those phosphates resulting from
the phosphonation of an OH group on the parent compound. A thorough
discussion of prodrugs is provided in T. Higuchi and V. Stella,
Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S.
Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in
Drug Design, American Pharmaceutical Association and Pergamon
Press, 1987, J. Rautio et al., Prodrugs: Design and Clinical
Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and
S. J. Hecker et al., Prodrugs of Phosphates and Phosphonates,
Journal of Medicinal Chemistry, 2008, 51, 2328-2345, each of which
is incorporated herein by reference.
[0082] A "metabolite" refers to a product produced through
metabolism in the body of a specified compound or salt thereof.
Metabolites of a compound may be identified using routine
techniques known in the art and their activities determined using
tests such as those described herein. Such products may result for
example from the oxidation, reduction, hydrolysis, amidation,
deamidation, esterification, deesterification, enzymatic cleavage,
and the like, of the administered compound. Accordingly, the
invention includes metabolites of compounds disclosed herein,
including compounds produced by a process comprising contacting a
compound disclosed herein with a mammal for a period of time
sufficient to yield a metabolic product thereof.
[0083] Stereochemical definitions and conventions used herein
generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of
Chemical Terms (1984) McGraw-Hill Book Company, New York; and
Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds",
John Wiley & Sons, Inc., New York, 1994. The compounds
disclosed herein may contain asymmetric or chiral centers, and
therefore exist in different stereoisomeric forms. It is intended
that all stereoisomeric forms of the compounds disclosed herein,
including but not limited to, diastereomers, enantiomers and
atropisomers, as well as mixtures thereof such as racemic mixtures,
form part of the present invention. Many organic compounds exist in
optically active forms, i.e., they have the ability to rotate the
plane of plane-polarized light. In describing an optically active
compound, the prefixes D and L, or R and S, are used to denote the
absolute configuration of the molecule about its chiral center(s).
The prefixes d and l or (+) and (-) are employed to designate the
sign of rotation of plane-polarized light by the compound, with (-)
or l meaning that the compound is levorotatory. A compound prefixed
with (+) or d is dextrorotatory. For a given chemical structure,
these stereoisomers are identical except that they are mirror
images of one another. A specific stereoisomer may also be referred
to as an enantiomer, and a mixture of such isomers is often called
an enantiomeric mixture. A 50:50 mixture of enantiomers is referred
to as a racemic mixture or a racemate, which may occur where there
has been no stereoselection or stereospecificity in a chemical
reaction or process. The terms "racemic mixture" and "racemate"
refer to an equimolar mixture of two enantiomeric species, devoid
of optical activity.
[0084] A "pharmaceutically acceptable salt" refers to organic or
inorganic salts of a compound disclosed herein. Pharmaceutically
acceptable salts are well known in the art. For example, S. M.
Berge et al., describe pharmaceutically acceptable salts in detail
in J. Pharmaceutical Sciences, 66: 1-19, 1977, which is
incorporated herein by reference. Examples of pharmaceutically
acceptable, nontoxic salts include, but are not limited to, salts
of an amino group formed with inorganic acids such as hydrochloric
acid, hydrobromic acid, phosphoric acid, sulfuric acid and
perchloric acid or with organic acids such as acetic acid, oxalic
acid, maleic acid, tartaric acid, citric acid, succinic acid or
malonic acid or by using other methods used in the art such as ion
exchange. Other pharmaceutically acceptable salts include adipate,
alginate, ascorbate, aspartate, benzenesulfonate, benzoate,
bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Salts derived from appropriate bases include alkali metal, alkaline
earth metal, ammonium and N.sup.+(C.sub.1-4 alkyl).sub.4 salts.
This invention also envisions the quaternization of any basic
nitrogen-containing groups of the compounds disclosed herein. Water
or oil-soluble or dispersable products may be obtained by such
quaternization. Representative alkali or alkaline earth metal salts
include sodium, lithium, potassium, calcium, magnesium, and the
like. Further pharmaceutically acceptable salts include, when
appropriate, nontoxic ammonium, quaternary ammonium, and amine
cations formed using counterions such as halide, hydroxide,
carboxylate, sulfate, phosphate, nitrate, C.sub.1-8 sulfonate and
aryl sulfonate.
[0085] A "solvate" refers to an association or complex of one or
more solvent molecules and a compound disclosed herein. Examples of
solvents that form solvates include, but are not limited to, water,
isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid,
and ethanolamine. The term "hydrate" refers to the complex where
the solvent molecule is water.
[0086] The term "protecting group" or "PG" refers to a substituent
that is commonly employed to block or protect a particular
functionality while reacting other functional groups on the
compound. For example, an "amino-protecting group" is a substituent
attached to an amino group that blocks or protects the amino
functionality in the compound. Suitable amino-protecting groups
include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC, Boc),
benzyloxycarbonyl (CBZ, Cbz) and 9-fluorenylmethylenoxycarbonyl
(Fmoc). Similarly, a "hydroxy-protecting group" refers to a
substituent of a hydroxy group that blocks or protects the hydroxy
functionality. Suitable protecting groups include acetyl and silyl.
A "carboxy-protecting group" refers to a substituent of the carboxy
group that blocks or protects the carboxy functionality. Common
carboxy-protecting groups include --CH.sub.2CH.sub.2SO.sub.2Ph,
cyanoethyl, 2-(trimethylsilyl)ethyl,
2-(trimethylsilyl)ethoxy-methyl-1,2-(p-toluenesulfonyl)ethyl,
2-(p-nitrophenylsulfenyl)-ethyl, 2-(diphenylphosphino)-ethyl,
nitroethyl and the like. For a general description of protecting
groups and their use, see T. W. Greene, Protective Groups in
Organic Synthesis, John Wiley & Sons, New York, 1991; and P. J.
Kocienski, Protecting Groups, Thieme, Stuttgart, 2005.
Description of Compounds of the Invention
[0087] The present invention provides substituted pyrazolone
compounds, salts, and pharmaceutical formulations thereof, which
are potentially useful in the treatment of diseases, conditions and
disorders modulated by receptor tyrosine kinases, especially VEGFR,
c-Met, Ron and/or Axl receptor. More specifically, the present
invention provides compounds of Formula (I):
##STR00005##
or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a
solvate, a hydrate, a metabolite, a pharmaceutically acceptable
salt or a prodrug thereof, wherein each of Q, R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.5, R.sup.6, W, X, Y and Z is as defined
herein.
[0088] In certain embodiments, Q in formula (I) is H,
NR.sup.aR.sup.b, OR.sup.a, --N(R.sup.c)C(.dbd.O)R.sup.d or
--N(R.sup.c)C(.dbd.O)OR.sup.a;
W in formula (I) is CR.sup.7 or N; each of X, Y and Z in formula
(I) is independently H, D, (C.sub.1-C.sub.6)alkyl,
(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl comprising 1, 2, 3
or 4 heteroatoms independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl and
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3, 4 or 5 substituents
independently selected from D, F, Cl, Br, CN,
(C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, OR.sup.a,
NR.sup.aR.sup.b, --(C.sub.1-C.sub.4)alkylene-OR.sup.a and
--(C.sub.1-C.sub.4)alkylene-NR.sup.aR.sup.b; each of R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 in formula
(I) is independently H, D, F, Cl, Br, CN, N.sub.3, OR.sup.a,
(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.2-C.sub.6)alkenyl or (C.sub.2-C.sub.6)alkynyl; each of
R.sup.a, R.sup.b and R.sup.c in formula (I) is independently H,
(C.sub.1-C.sub.6)aliphatic, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl comprising 1, 2, 3
or 4 heteroatoms independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), with the
proviso wherein R.sup.a and R.sup.b are bonded to the same nitrogen
atom, R.sup.a and R.sup.b, together with the nitrogen atom they are
attached to, optionally form a substituted or unsubstituted 3-8
membered heterocyclic ring, wherein each of the
(C.sub.1-C.sub.6)aliphatic, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
(C.sub.6-C.sub.10)aryl, 5-10 membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl,
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) and 3-8
membered heterocyclic ring is optionally substituted with 1, 2, 3
or 4 substitutents independently selected from D, F, Cl, CN,
N.sub.3, OH, NH.sub.2, (C.sub.1-C.sub.6)haloalkyl,
(C.sub.1-C.sub.6)alkoxy and (C.sub.1-C.sub.6)alkylamino; and
R.sup.d in formula (I) is H, (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl or
(C.sub.6-C.sub.10)aryl, with the proviso where each R.sup.1,
R.sup.2, R.sup.3, R.sup.5 (or R.sup.4), R.sup.6 and R.sup.7 is H,
R.sup.4 (or R.sup.5) is F, R.sup.d is not
(C.sub.3-C.sub.7)heterocyclyl, wherein each of the
(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl and
(C.sub.6-C.sub.10)aryl is optionally substituted with 1, 2, 3 or 4
substitutents independently selected from D, F, Cl, Br, CN,
OR.sup.a, NR.sup.aR.sup.b, (C.sub.1-C.sub.6)alkyl,
(C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl,
--(C.sub.1-C.sub.4)alkylene-OR.sup.a and
--(C.sub.1-C.sub.4)alkylene-NR.sup.aR.sup.b.
[0089] In another embodiment, Q in formula (I) is NR.sup.aR.sup.b,
--N(R.sup.c)C(.dbd.O)R.sup.d or --N(R.sup.c)C(.dbd.O)OR.sup.a.
[0090] In another embodiment, each of X, Y and Z in formula (I) is
independently H, D, (C.sub.1-C.sub.4)alkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, phenyl,
5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms
independently selected from O, S and N,
--(C.sub.1-C.sub.2)alkylene-phenyl or
--(C.sub.1-C.sub.2)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, phenyl,
5-10 membered heteroaryl, --(C.sub.1-C.sub.2)alkylene-phenyl and
--(C.sub.1-C.sub.2)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3, 4 or 5 substituents
independently selected from D, F, Cl, Br, CN,
(C.sub.2-C.sub.4)alkenyl, (C.sub.2-C.sub.4)alkynyl, OR.sup.a,
NR.sup.aR.sup.b, --(C.sub.1-C.sub.2)alkylene-OR.sup.a and
--(C.sub.1-C.sub.2)alkylene-NR.sup.aR.sup.b.
[0091] In another embodiment, each of R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6 and R.sup.7 in formula (I) is
independently H, D, F or Cl.
[0092] In another embodiment, each of R.sup.a, R.sup.b and R.sup.c
in formula (I) is independently H, (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)haloalkyl, (C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl or
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, with the
proviso where R.sup.a and R.sup.b are bonded to the same nitrogen
atom, R.sup.a and R.sup.b, together with the nitrogen atom they are
attached to, optionally form a substituted or unsubstituted 3-8
membered heterocyclic ring, wherein each of the
(C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)haloalkyl,
(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl and 3-8
membered heterocyclic ring is optionally substituted with 1, 2, 3
or 4 substituents independently selected from D, F, Cl, CN,
N.sub.3, OH, NH.sub.2, (C.sub.1-C.sub.3)haloalkyl,
(C.sub.1-C.sub.3)alkoxy and (C.sub.1-C.sub.3)alkylamino
[0093] In another embodiment, R.sup.d in formula (I) is
independently H, D, (C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl or
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, with the
proviso where each R.sup.1, R.sup.2, R.sup.3, R.sup.5 (or R.sup.4),
R.sup.6 and R.sup.7 is H, R.sup.4 (or R.sup.5) is F, R.sup.d is not
(C.sub.3-C.sub.6)heterocyclyl, wherein each of the
(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl and
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl is
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from D, F, CN, OR.sup.a, NR.sup.aR.sup.b,
(C.sub.1-C.sub.3)alkyl, (C.sub.2-C.sub.4)alkenyl,
(C.sub.2-C.sub.4)alkynyl, --(C.sub.1-C.sub.2)alkylene-OR.sup.a and
--(C.sub.1-C.sub.2)alkylene-NR.sup.aR.sup.b.
[0094] In another embodiment, Q in formula (I) is NH.sub.2 or
--N(R.sup.c)C(.dbd.O)R.sup.d.
[0095] In another embodiment, each of X, Y and Z in formula (I) is
independently H, D, methyl, ethyl, phenyl or phenyl group
substituted with 1, 2, 3, 4 or 5 substituents independently
selected from D, F and Cl.
[0096] In another embodiment, Q in formula (I) is:
##STR00006## ##STR00007##
[0097] In another embodiment, the invention provides compounds
having the formula (II):
##STR00008##
wherein each of Q, X, Y and Z is as defined herein.
[0098] In certain embodiment, Q in formula (II) is NR.sup.aR.sup.b,
--N(R.sup.c)C(.dbd.O)R.sup.d or --N(R.sup.c)C(.dbd.O)OR.sup.a;
each of X, Y and Z in formula (II) is independently H, D,
(C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl, (C.sub.6-C.sub.10)aryl, 5-10
membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms
independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl,
(C.sub.3-C.sub.7)heterocyclyl, (C.sub.6-C.sub.10)aryl, 5-10
membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.8)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.7)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl and
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3, 4 or 5 substituents
independently selected from D, F, Cl, Br, CN,
(C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, OR.sup.a,
NR.sup.aR.sup.b, --(C.sub.1-C.sub.4)alkylene-OR.sup.a and
--(C.sub.1-C.sub.4)alkylene-NR.sup.aR.sup.b; each of R.sup.a,
R.sup.b and R.sup.c in formula (II) is independently H,
(C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl, (C.sub.6-C.sub.10)aryl, 5-10
membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms
independently selected from O, S and N,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl or
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl), wherein
each of the (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl, (C.sub.6-C.sub.10)aryl, 5-10
membered heteroaryl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)cycloalkyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.4)alkylene-(C.sub.6-C.sub.10)aryl and
--(C.sub.1-C.sub.4)alkylene-(5-10 membered heteroaryl) is
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from D, F, Cl, CN, N.sub.3, OH, NH.sub.2,
(C.sub.1-C.sub.6)haloalkyl, (C.sub.1-C.sub.6)alkoxy and
(C.sub.1-C.sub.6)alkylamino; and R.sup.d is (C.sub.1-C.sub.6)alkyl,
wherein the (C.sub.1-C.sub.6)alkyl in formula (II) is optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from D, F, Cl, OH, NH.sub.2, (C.sub.1-C.sub.6)alkoxy and
(C.sub.1-C.sub.6)alkylamino
[0099] In another embodiment, Q in formula (II) is NR.sup.aR.sup.b
or --N(R.sup.c)C(.dbd.O)R.sup.d.
[0100] In another embodiment, each of X, Y and Z in formula (II) is
independently H, D, (C.sub.1-C.sub.4)alkyl or phenyl, wherein each
of the (C.sub.1-C.sub.4)alkyl and phenyl is optionally substituted
with 1, 2, 3, 4 or 5 substituents independently selected from D, F
and Cl.
[0101] In another embodiment, each of R.sup.a, R.sup.b and R.sup.c
in formula (II) is independently H, (C.sub.1-C.sub.4)alkyl,
(C.sub.3-C.sub.6)cycloalkyl, (C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl or
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl, wherein
each of the (C.sub.1-C.sub.4)alkyl, (C.sub.3-C.sub.6)cycloalkyl,
(C.sub.3-C.sub.6)heterocyclyl,
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)cycloalkyl and
--(C.sub.1-C.sub.2)alkylene-(C.sub.3-C.sub.6)heterocyclyl is
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from D, F, Cl, CN, N.sub.3, OH, NH.sub.2,
(C.sub.1-C.sub.6)haloalkyl, (C.sub.1-C.sub.6)alkoxy and
(C.sub.1-C.sub.6)alkylamino
[0102] In another embodiment, R.sup.d in formula (II) is Me, Et,
n-Pr or i-Pr.
[0103] In another embodiment, Q in formula (II) is NH.sub.2 or
--N(R.sup.c)C(.dbd.O)R.sup.d.
[0104] In another embodiment, each of X, Y and Z in formula (II) is
independently H, D, Me, CH.sub.2D, CHD.sub.2, CD.sub.3, ethyl,
propyl, isopropyl, phenyl or phenyl optionally substituted with 1,
2, 3, 4 or 5 substituents independently selected from D, F and
Cl.
[0105] In another embodiment, Q in formula (II) is:
##STR00009##
[0106] In some embodiments, non-limiting examples of compounds
disclosed herein, and their pharmaceutically acceptable salts and
solvates thereof, are shown in the following:
TABLE-US-00001 TABLE 1 ##STR00010## (1) ##STR00011## (2)
##STR00012## (3) ##STR00013## (4) ##STR00014## (5) ##STR00015## (6)
##STR00016## (7) ##STR00017## (8) ##STR00018## (9) ##STR00019##
(10) ##STR00020## (11) ##STR00021## (12) ##STR00022## (13)
##STR00023## (14) ##STR00024## (15) ##STR00025## (16) ##STR00026##
(17) ##STR00027## (18) ##STR00028## (19) ##STR00029## (20)
##STR00030## (21) ##STR00031## (22) ##STR00032## (23) ##STR00033##
(24) ##STR00034## (25) ##STR00035## (26) ##STR00036## (27)
##STR00037## (28) ##STR00038## (29) ##STR00039## (30) ##STR00040##
(31) ##STR00041## (32) ##STR00042## (33) ##STR00043## (34)
##STR00044## (35) ##STR00045## (36) ##STR00046## (37) ##STR00047##
(38) ##STR00048## (39) ##STR00049## (40) ##STR00050## (41)
##STR00051## (42) ##STR00052## (43) ##STR00053## (44) ##STR00054##
(45) ##STR00055## (46)
[0107] The present invention also comprises the use of a compound
disclosed herein, or pharmaceutically acceptable salt thereof, in
the manufacture of a medicament for the treatment either acutely or
chronically of a hyperproliferative disease state and/or an
angiogenesis mediated disease state, including those described
previously. The compounds disclosed herein are useful in the
manufacture of an anti-cancer medicament.
[0108] The compounds disclosed herein are also useful in the
manufacture of a medicament to attenuate or prevent disorders
through inhibition of protein kinases. The present invention
comprises a pharmaceutical composition comprising a therapeutically
effective amount of a compound of Formula (I) or (II) in
association with at least one pharmaceutically acceptable carrier,
adjuvant or diluent.
[0109] The present invention also comprises a method of treating
hyperproliferating and angiogenesis related disorders in a subject
having or susceptible to such disorder, the method comprising
treating the subject with a therapeutically effective amount of a
compound of Formula (I) or (II).
[0110] Unless otherwise stated, all stereoisomers, geometric
isomers, tautomers, solvates, hydrates, metabolites, salts, and
pharmaceutically acceptable prodrugs of the compounds disclosed
herein are within the scope of the invention.
[0111] In certain embodiments, the salt is a pharmaceutically
acceptable salt. The phrase "pharmaceutically acceptable" indicates
that the substance or composition must be compatible chemically
and/or toxicologically, with the other ingredients comprising a
formulation, and/or the mammal being treated therewith.
[0112] The compounds disclosed herein also include salts of such
compounds which are not necessarily pharmaceutically acceptable
salts, and which may be useful as intermediates for preparing
and/or purifying compounds of Formula (I) or (II) and/or for
separating enantiomers of compounds of Formula (I) or (II).
[0113] The desired salt may be prepared by any suitable method
available in the art, for example, treatment of the free base with
an inorganic acid, such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid and the like, or with
an organic acid, such as acetic acid, maleic acid, succinic acid,
mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic
acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as
glucuronic acid or galacturonic acid, an alpha hydroxy acid, such
as citric acid or tartaric acid, an amino acid, such as aspartic
acid or glutamic acid, an aromatic acid, such as benzoic acid or
cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or
ethanesulfonic acid, or the like.
Composition, Formulations and Administration of the Compounds
Disclosed Herein
[0114] In one aspect, featured herein are pharmaceutical
compositions that include a compound of formula (I) or (II), or a
compound listed in Table 1; and a pharmaceutically acceptable
carrier, adjuvant, or vehicle. The amount of compound in the
pharmaceutical compositions disclosed herein is such that is
effective to detectably inhibit a protein kinase in a biological
sample or in a patient.
[0115] It will also be appreciated that certain of the compounds
disclosed herein can exist in free form for treatment, or where
appropriate, as a pharmaceutically acceptable derivative thereof.
Some non-limiting examples of pharmaceutically acceptable
derivative include pharmaceutically acceptable prodrugs, salts,
esters, salts of such esters, or any other adduct or derivative
which upon administration to a patient in need is capable of
providing, directly or indirectly, a compound as otherwise
described herein, or a metabolite or residue thereof.
[0116] As described above, the pharmaceutical compositions or
pharmaceutically acceptable compositions disclosed herein
additionally comprise a pharmaceutically acceptable carrier,
adjuvant, or vehicle, which, as used herein, includes any and all
solvents, diluents, or other liquid vehicle, dispersion or
suspension aids, surface active agents, isotonic agents, thickening
or emulsifying agents, preservatives, solid binders, lubricants and
the like, as suited to the particular dosage form desired. In
Remington: The Science and Practice of Pharmacy, 21st edition,
2005, ed. D. B. Troy, Lippincott Williams & Wilkins,
Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds.
J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York,
the contents of each of which is incorporated by reference herein,
are disclosed various carriers used in formulating pharmaceutically
acceptable compositions and known techniques for the preparation
thereof. Except insofar as any conventional carrier medium is
incompatible with the compounds disclosed herein, such as by
producing any undesirable biological effect or otherwise
interacting in a deleterious manner with any other component(s) of
the pharmaceutically acceptable composition, its use is
contemplated to be within the scope of this invention.
[0117] Some non-limiting examples of materials which can serve as
pharmaceutically acceptable carriers include ion exchangers,
alumina, aluminum stearate, lecithin, serum proteins, such as human
serum albumin, buffer substances such as phosphates, glycine,
sorbic acid, or potassium sorbate, partial glyceride mixtures of
saturated vegetable fatty acids, water, salts or electrolytes, such
as protamine sulfate, disodium hydrogen phosphate, potassium
hydrogen phosphate, sodium chloride, zinc salts, colloidal silica,
magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers, wool fat, sugars such
as lactose, glucose and sucrose; starches such as corn starch and
potato starch; cellulose and its derivatives such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; excipients such as cocoa
butter and suppository waxes; oils such as peanut oil, cottonseed
oil, safflower oil, sesame oil, olive oil, corn oil and soybean
oil; glycols; such a propylene glycol or polyethylene glycol;
esters such as ethyl oleate and ethyl laurate; agar; buffering
agents such as magnesium hydroxide and aluminum hydroxide; alginic
acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl
alcohol, and phosphate buffer solutions, as well as other non-toxic
compatible lubricants such as sodium lauryl sulfate and magnesium
stearate, as well as coloring agents, releasing agents, coating
agents, sweetening, flavoring and perfuming agents, preservatives
and antioxidants can also be present in the composition, according
to the judgment of the formulator.
[0118] The compositions disclosed herein may be administered
orally, parenterally, by inhalation spray, topically, rectally,
nasally, buccally, vaginally or via an implanted reservoir. The
term "parenteral" as used herein includes subcutaneous,
intravenous, intramuscular, intra-articular, intra-synovial,
intrasternal, intrathecal, intraocular, intrahepatic, intralesional
and intracranial injection or infusion techniques. Preferably, the
compositions are administered orally, intraperitoneally or
intravenously. Sterile injectable forms of the compositions
disclosed herein may be aqueous or oleaginous suspension. These
suspensions may be formulated according to techniques known in the
art using suitable dispersing or wetting agents and suspending
agents. The sterile injectable preparation may also be a sterile
injectable solution or suspension in a non-toxic parenterally
acceptable diluent or solvent, for example as a solution in
1,3-butanediol. Among the acceptable vehicles and solvents that may
be employed are water, Ringer's solution and isotonic sodium
chloride solution. In addition, sterile, fixed oils are
conventionally employed as a solvent or suspending medium.
[0119] For this purpose, any bland fixed oil may be employed
including synthetic mono- or diglycerides. Fatty acids, such as
oleic acid and its glyceride derivatives are useful in the
preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant, such as carboxymethyl cellulose or similar dispersing
agents that are commonly used in the formulation of
pharmaceutically acceptable dosage forms including emulsions and
suspensions. Other commonly used surfactants, such as Tweens, Spans
and other emulsifying agents or bioavailability enhancers which are
commonly used in the manufacture of pharmaceutically acceptable
solid, liquid, or other dosage forms may also be used for the
purposes of formulation.
[0120] The pharmaceutically acceptable compositions disclosed
herein may be orally administered in any orally acceptable dosage
form including, but not limited to, capsules, tablets, aqueous
suspensions or solutions. In the case of tablets for oral use,
carriers commonly used include lactose and corn starch. Lubricating
agents, such as magnesium stearate, are also typically added. For
oral administration in a capsule form, useful diluents include
lactose and dried cornstarch. When aqueous suspensions are required
for oral use, the active ingredient is combined with emulsifying
and suspending agents. If desired, certain sweetening, flavoring or
coloring agents may also be added.
[0121] Alternatively, the pharmaceutically acceptable compositions
disclosed herein may be administered in the form of suppositories
for rectal administration. These can be prepared by mixing the
agent with a suitable non-irritating excipient that is solid at
room temperature but liquid at rectal temperature and therefore
will melt in the rectum to release the drug. Such materials include
cocoa butter, beeswax and polyethylene glycols.
[0122] The pharmaceutically acceptable compositions disclosed
herein may also be administered topically, especially when the
target of treatment includes areas or organs readily accessible by
topical application, including diseases of the eye, the skin, or
the lower intestinal tract. Suitable topical formulations are
readily prepared for each of these areas or organs.
[0123] Topical application for the lower intestinal tract can be
effected in a rectal suppository formulation (see above) or in a
suitable enema formulation. Topically-transdermal patches may also
be used. For topical applications, the pharmaceutically acceptable
compositions may be formulated in a suitable ointment containing
the active component suspended or dissolved in one or more
carriers. Carriers for topical administration of the compounds
disclosed herein include, but are not limited to, mineral oil,
liquid petrolatum, white petrolatum, propylene glycol,
polyoxyethylene, polyoxypropylene compound, emulsifying wax and
water. Alternatively, the pharmaceutically acceptable compositions
can be formulated in a suitable lotion or cream containing the
active components suspended or dissolved in one or more
pharmaceutically acceptable carriers. Suitable carriers include,
but are not limited to, mineral oil, sorbitan monostearate,
polysorbate 60, cetyl esters wax, cetearyl alcohol,
2-octyldodecanol, benzyl alcohol and water.
[0124] For ophthalmic use, the pharmaceutically acceptable
compositions may be formulated, e.g., as micronized suspensions in
isotonic, pH adjusted sterile saline or other aqueous solution, or,
preferably, as solutions in isotonic, pH adjusted sterile saline or
other aqueous solution, either with or without a preservative such
as benzylalkonium chloride. Alternatively, for ophthalmic uses, the
pharmaceutically acceptable compositions may be formulated in an
ointment such as petrolatum. The pharmaceutically acceptable
compositions disclosed herein may also be administered by nasal
aerosol or inhalation. Such compositions are prepared according to
techniques well-known in the art of pharmaceutical formulation and
may be prepared as solutions in saline, employing benzyl alcohol or
other suitable preservatives, absorption promoters to enhance
bioavailability, fluorocarbons, and/or other conventional
solubilizing or dispersing agents.
[0125] Liquid dosage forms for oral administration include, but are
not limited to, pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active compounds, the liquid dosage forms may
contain inert diluents commonly used in the art such as, for
example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending
agents, sweetening, flavoring, and perfuming agents.
[0126] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions may be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0127] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use. In order to
prolong the effect of a compound of the present invention, it is
often desirable to slow the absorption of the compound from
subcutaneous or intramuscular injection. This may be accomplished
by the use of a liquid suspension of crystalline or amorphous
material with poor water solubility. The rate of absorption of the
compound then depends upon its rate of dissolution that, in turn,
may depend upon crystal size and crystalline form. Alternatively,
dissolving or suspending the compound in an oil vehicle
accomplishes delayed absorption of a parenterally administered
compound form.
[0128] Injectable depot forms are made by forming microencapsule
matrices of the compound in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of compound to
polymer and the nature of the particular polymer employed, the rate
of compound release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the compound in liposomes or microemulsions that are
compatible with body tissues.
[0129] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds disclosed herein with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound.
[0130] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
[0131] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings and other
coatings well known in the pharmaceutical formulating art. They may
optionally contain opacifying agents and can also be of a
composition that they release the active ingredient(s) only, or
preferentially, in a certain part of the intestinal tract,
optionally, in a delayed manner. Examples of embedding compositions
that can be used include polymeric substances and waxes. Solid
compositions of a similar type may also be employed as fillers in
soft and hard-filled gelatin capsules using such excipients as
lactose or milk sugar as well as high molecular weight polyethylene
glycols and the like.
[0132] The active compounds can also be in micro-encapsulated form
with one or more excipients as noted above. The solid dosage forms
of tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active compound may be admixed with at least one inert diluent such
as sucrose, lactose or starch. Such dosage forms may also comprise,
as is normal practice, additional substances other than inert
diluents, e.g., tableting lubricants and other tableting aids such
a magnesium stearate and microcrystalline cellulose. In the case of
capsules, tablets and pills, the dosage forms may also comprise
buffering agents. They may optionally contain pacifying agents and
can also be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
substances and waxes.
[0133] Dosage forms for topical or transdermal administration of a
compound disclosed herein include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or
buffers as may be required. Ophthalmic formulation, eardrops, and
eye drops are also contemplated as being within the scope of this
invention. Additionally, the present invention contemplates the use
of transdermal patches, which have the added advantage of providing
controlled delivery of a compound to the body. Such dosage forms
can be made by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux
of the compound across the skin. The rate can be controlled by
either providing a rate controlling membrane or by dispersing the
compound in a polymer matrix or gel.
[0134] The compounds disclosed herein are preferably formulated in
dosage unit form for ease of administration and uniformity of
dosage. The expression "dosage unit form" as used herein refers to
a physically discrete unit of agent appropriate for the patient to
be treated. It will be understood, however, that the total daily
usage of the compounds and compositions disclosed herein will be
decided by the attending physician within the scope of sound
medical judgment. The specific effective dose level for any
particular patient or organism will depend upon a variety of
factors including the disorder being treated and the severity of
the disorder; the activity of the specific compound employed; the
specific composition employed; the age, body weight, general
health, sex and diet of the patient; the time of administration,
route of administration, and rate of excretion of the specific
compound employed; the duration of the treatment; drugs used in
combination or coincidental with the specific compound employed,
and like factors well known in the medical arts.
[0135] The amount of the compounds disclosed herein that may be
combined with the carrier materials to produce a composition in a
single dosage form will vary depending upon the host treated, the
particular mode of administration. Preferably, the compositions
should be formulated so that a dosage of between 0.01-200 mg/kg
body weight/day of the inhibitor can be administered to a patient
receiving these compositions.
[0136] The compounds disclosed herein can be administered as the
sole pharmaceutical agent or in combination with one or more other
additional therapeutic (pharmaceutical) agents where the
combination causes no unacceptable adverse effects. This may be of
particular relevance for the treatment of hyper-proliferative
diseases such as cancer. In this instance, the compound disclosed
herein can be combined with known cytotoxic agents, signal
transduction inhibitors, or with other anti-cancer agents, as well
as with admixtures and combinations thereof. As used herein,
additional therapeutic agents that are normally administered to
treat a particular disease, or condition, are known as "appropriate
for the disease, or condition, being treated". As used herein,
"additional therapeutic agents" is meant to include
chemotherapeutic agents and other anti-proliferative agents.
[0137] For example, chemotherapeutic agents or other
antiproliferative agents may be combined with the compounds
disclosed herein to treat proliferative disease or cancer. Examples
of chemotherapeutic agents or other antiproliferative agents
include HDAC inhibitors including, but are not limited to, SAHA,
MS-275, MGO 103, and those described in WO 2006/010264, WO
03/024448, WO 2004/069823, US 2006/0058298, US 2005/0288282, WO
00/71703, WO 01/38322, WO 01/70675, WO 03/006652, WO 2004/035525,
WO 2005/030705, WO 2005/092899, and demethylating agents including,
but not limited to, 5-aza-dC, Vidaza and Decitabine and those
described in U.S. Pat. No. 6,268,137, U.S. Pat. No. 5,578,716, U.S.
Pat. No. 5,919,772, U.S. Pat. No. 6,054,439, U.S. Pat. No.
6,184,211, U.S. Pat. No. 6,020,318, U.S. Pat. No. 6,066,625, U.S.
Pat. No. 6,506,735, U.S. Pat. No. 6,221,849, U.S. Pat. No.
6,953,783, U.S. Ser. No. 11/393,380.
[0138] In another embodiment of the present invention, for example,
chemotherapeutic agents or other anti-proliferative agents may be
combined with the compounds disclosed herein to treat proliferative
diseases and cancer. Examples of known chemotherapeutic agents
include, but are not limited to, for example, other therapies or
anticancer agents that may be used in combination with the
inventive anticancer agents of the present invention and include
surgery, radiotherapy (in but a few examples, gamma radiation,
neutron beam radiotherapy, electron beam radiotherapy, proton
therapy, brachytherapy, and systemic radioactive isotopes, to name
a few), endocrine therapy, taxanes (TAXOL.RTM., taxotere etc),
platinum derivatives, biologic response modifiers (interferons,
interleukins, and tumor necrosis factor (TNF), TRAIL receptor
targeting, agents, to name a few), hyperthermia and cryotherapy,
agents to attenuate any adverse effects (e.g., antiemetics), and
other approved chemotherapeutic drugs, including, but not limited
to, alkylating drugs (mechlorethamine, chlorambucil,
Cyclophosphamide, Melphalan, Ifosfamide), antimetabolites
(Methotrexate, Pemetrexed etc), purine antagonists and pyrimidine
antagonists (6-Mercaptopurine, 5-Fluorouracil, Cytarabile,
Gemcitabine), spindle poisons (Vinblastine, Vincristine,
Vinorelbine, Paclitaxel), podophyllotoxins (Etoposide, Irinotecan,
Topotecan), antibiotics (Doxorubicin, Bleomycin, Mitomycin),
nitrosoureas (Carmustine, Lomustine), inorganic ions (Cisplatin,
Carboplatin), Cell cycle inhibitors (KSP mitotic kinesin
inhibitors, CENP-E and CDK inhibitors), enzymes (Asparaginase), and
hormones (Tamoxifen, Leuprolide, Flutamide, and Megestrol),
GLEEVEC.RTM., adriamycin, dexamethasone, and cyclophosphamide.
Antiangiogenic agents (Avastin and others). Monoclonal antibodies
(Belimumab (BENLYSTA.RTM.), Brentuximab (ADCETRIS.RTM.), Cetuximab
(ERBITUX.RTM.), Gemtuzumab (MYLOTARG.RTM.), Ipilimumab
(YERVOY.RTM.), Ofatumumab (ARZERR.RTM.), Panitumumab
(VECTIBIX.RTM.), Ranibizumab (LUCENTIS.RTM.), Rituximab
(RITUXAN.RTM.), Tositumomab (BEXXAR.RTM.), Trastuzumab
(HERCEPTIN.RTM.)). Kinase inhibitors (Imatinib (GLEEVEC.RTM.),
Sunitinib (SUTENT.RTM.), Sorafenib (NEXAVAR.RTM.), Cetuximab
(ERBITUX.RTM.), Trastuzumab (HERCEPTIN.RTM.), Erlotinib
(TARCEVA.RTM.), Gefitinib (IRESSA.RTM.), Dasatinib (SPRYCEL.RTM.),
Nilotinib (TASIGNA.RTM.), Lapatinib (TYKERB.RTM.), Crizotinib
(XALKORI.RTM.), Ruxolitinib (JAKAFI.RTM.), Vemurafenib
(ZELBORAF.RTM.), Vandetanib (CAPRELSA.RTM.), Pazopanib
(VOTRIENT.RTM.), and others). Agents inhibiting or activating
cancer pathways such as the mTOR, HIF (hypoxia induced factor)
pathways (such as Everolimus and Temsirolimus) and others. For a
more comprehensive discussion of updated cancer therapies see,
http://www.nci.nih.gov/, a list of the FDA approved oncology drugs
at http://www.fda.gov/cder/cancer/druglist-rame.htm, and The Merck
Manual, Eighteenth Ed. 2006, the entire contents of which are
hereby incorporated by reference.
[0139] In other embodiments, the compounds disclosed herein can be
combined, with cytotoxic anti-cancer agents. Examples of such
agents can be found in the 13th Edition of the Merck Index (2001).
These agents include, by no way of limitation, asparaginase,
bleomycin, carboplatin, carmustine, chlorambucil, cisplatin,
colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin,
daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide,
5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide,
irinotecan, leucovorin, lomustine, mechlorethamine,
6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone,
prednisolone, prednisone, procarbazine, raloxifen, streptozocin,
tamoxifen, thioguanine, topotecan, vinblastine, vincristine, and
vindesine.
[0140] Other cytotoxic drugs suitable for use with the compounds
disclosed herein include, but are not limited to, those compounds
acknowledged to be used in the treatment of neoplastic diseases,
such as those for example in Goodman and Gilman's The
Pharmacological Basis of Therapeutics (Ninth Edition, 1996,
McGraw-Hill). These agents include, by no way of limitation,
aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine
cladribine, busulfan, diethylstilbestrol,
2',2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyladenine,
ethinyl estradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine
monophosphate, fludarabine phosphate, fluoxymesterone, flutamide,
hydroxyprogesterone caproate, idarubicin, interferon,
medroxyprogesterone acetate, megestrol acetate, melphalan,
mitotane, paclitaxel, pentostatin, N-phosphonoacetyl-L-aspartate
(PALA), plicamycin, semustine, teniposide, testosterone propionate,
thiotepa, trimethylmelamine, uridine, and vinorelbine.
[0141] Other cytotoxic anti-cancer agents suitable for use in
combination with the compounds disclosed herein also include newly
discovered cytotoxic principles such as oxaliplatin, gemcitabine,
capecitabine, epothilone and its natural or synthetic derivatives,
temozolomide (Quinn et al., J. Clin. Oncology 2003, 21(4),
646-651), tositumomab (BEXXAR.RTM.), trabedectin (Vidal et al.,
Proceedings of the American Society for Clinical Oncology, 2004,
23, abstract 3181), and the inhibitors of the kinesin spindle
protein Eg5 (Wood et al., Curr. Opin. Pharmacol. 2001, 1,
370-377).
[0142] In other embodiments, the compounds disclosed herein can be
combined with other signal transduction inhibitors. Examples of
such agents include, by no way of limitation, antibody therapies
such as trastuzumab (HERCEPTIN.RTM.), cetuximab (ERBITUX.RTM.),
ipilimumab (YERVOY.RTM.) and pertuzumab. Examples of such therapies
also include, by no way of limitation, small-molecule kinase
inhibitors such as Imatinib (GLEEVEC.RTM.), Sunitinib
(SUTENT.RTM.), Sorafenib (NEXAVAR.RTM.), Erlotinib (TARCEVA.RTM.),
Gefitinib (IRESSA.RTM.), Dasatinib (SPRYCEL.RTM.), Nilotinib
(TASIGNA.RTM.), Lapatinib (TYKERB.RTM.), Crizotinib (XALKORI.RTM.),
Ruxolitinib (JAKAFI.RTM.), Vemurafenib (ZELBORAF.RTM.), Vandetanib
(CAPRELSA.RTM.), Pazopanib (VOTRIENT.RTM.), afatinib, alisertib,
amuvatinib, axitinib, bosutinib, brivanib, canertinib,
cabozantinib, cediranib, crenolanib, dabrafenib, dacomitinib,
danusertib, dovitinib, foretinib, ganetespib, ibrutinib, iniparib,
lenvatinib, linifanib, linsitinib, masitinib, momelotinib,
motesanib, neratinib, niraparib, oprozomib, olaparib, pictilisib,
ponatinib, quizartinib, regorafenib, rigosertib, rucaparib,
saracatinib, saridegib, tandutinib, tasocitinib, telatinib,
tivantinib, tivozanib, tofacitinib, trametinib, vatalanib,
veliparib, vismodegib, volasertib, BMS-540215, BMS777607,
JNJ38877605, TKI258, GDC-0941 (Folkes, et al., J. Med. Chem., 2008,
51, 5522), BZE235, and others.
[0143] In other embodiments, the compounds disclosed herein can be
combined with inhibitors of histone deacetylase. Examples of such
agents include, by no way of limitation, suberoylanilide hydroxamic
acid (SAHA), LAQ-824 (Ottmann et al., Proceedings of the American
Society for Clinical Oncology, 2004, 23, abstract 3024), LBH-589
(Beck et al., Proceedings of the American Society for Clinical
Oncology, 2004, 23, abstract 3025), MS-275 (Ryan et al.,
Proceedings of the American Association of Cancer Research, 2004,
45, abstract 2452), FR-901228 (Piekarz et al., Proceedings of the
American Society for Clinical Oncology, 2004, 23, abstract 3028)
and MGCDO1 03 (U.S. Pat. No. 6,897,220).
[0144] In other embodiments, the compounds disclosed herein can be
combined with other anti-cancer agents such as proteasome
inhibitors, and m-TOR inhibitors. These include, by no way of
limitation, bortezomib, and CCI-779 (Wu et al., Proceedings of the
American Association of Cancer Research, 2004, 45, abstract 3849).
The compounds disclosed herein can be combined with other
anti-cancer agents such as topoisomerase inhibitors, including but
not limited to camptothecin.
[0145] Those additional agents may be administered separately from
the compound-containing composition, as part of a multiple dosage
regimen. Alternatively, those agents may be part of a single dosage
form, mixed together with the compound disclosed herein in a single
composition. If administered as part of a multiple dosage regimen,
the two active agents may be submitted simultaneously, sequentially
or within a period of time from one another which would result in
the desired activity of the agents.
[0146] The amount of both the compound and the additional
therapeutic agent (in those compositions which comprise an
additional therapeutic agent as described above) that may be
combined with the carrier materials to produce a single dosage form
will vary depending upon the host treated and the particular mode
of administration. Normally, the amount of additional therapeutic
agent present in the compositions disclosed herein will be no more
than the amount that would normally be administered in a
composition comprising that therapeutic agent as the only active
agent. Preferably the amount of additional therapeutic agent in the
presently disclosed compositions will range from about 50% to 100%
of the amount normally present in a composition comprising that
agent as the only therapeutically active agent. In those
compositions which comprise an additional therapeutic agent, that
additional therapeutic agent and the compound disclosed herein may
act synergistically.
Uses of the Compounds and Compositions Disclosed Herein
[0147] The invention features pharmaceutical compositions that
include a compound of formula (I) or (II), or a compound listed in
Table 1, and a pharmaceutically acceptable carrier, adjuvant, or
vehicle. The amount of compound in the compositions disclosed
herein is such that is effective to detectably inhibit a protein
kinase, such as VEGFR, c-Met, Ron or Axl inhibitory activity. The
compounds disclosed herein are useful in therapy as antineoplasia
agents or to minimize deleterious effects of VEGFR, c-Met, Ron
and/or Axl receptor signaling.
[0148] The compounds disclosed herein would be useful for, but not
limited to, the prevention or treatment of proliferative diseases,
condition, or disorder in a patient by administering to the patient
a compound or a composition disclosed herein in an effective
amount. Such diseases, conditions, or disorders include cancer,
particularly metastatic cancer, atherosclerosis, and lung
fibrosis.
[0149] The compounds disclosed herein would be useful for the
treatment of neoplasia including cancer and metastasis, including,
but not limited to: carcinoma such as cancer of the bladder,
breast, colon, kidney, liver, lung (including small cell lung
cancer), esophagus, gall-bladder, ovary, pancreas, stomach, cervix,
thyroid, prostate, and skin (including squamous cell carcinoma);
hematopoietic tumors of lymphoid lineage (including leukemia, acute
lymphocitic leukemia, acute lymphoblastic leukemia, B-cell
lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's
lymphoma, hairy cell lymphoma and Burkett's lymphoma);
hematopoietic tumors of myeloid lineage (including acute and
chronic myelogenous leukemias, myelodysplastic syndrome and
promyelocytic leukemia); tumors of mesenchymal origin (including
fibrosarcoma and rhabdomyosarcoma, and other sarcomas, e.g. soft
tissue and bone); tumors of the central and peripheral nervous
system (including astrocytoma, neuroblastoma, glioma and
schwannomas); and other tumors (including melanoma, seminoma,
teratocarcinoma, osteosarcoma, xenoderoma pigmentosum,
keratoctanthoma, thyroid follicular cancer and Kaposi's
sarcoma).
[0150] The compounds disclosed herein also would be useful for
treatment of ophthalmological conditions such as corneal graft
rejection, ocular neovascularization, retinal neovascularization
including neovascularization following injury or infection,
diabetic retinopathy, retrolental fibroplasia and neovascular
glaucoma; retinal ischemia; vitreous hemorrhage; ulcerative
diseases such as gastric ulcer; pathological, but non-malignant,
conditions such as hemangiomas, including infantile hemaginomas,
angiofibroma of the nasopharynx and avascular necrosis of bone; and
disorders of the female reproductive system such as endometriosis.
The compounds are also useful for the treatment of edema, and
conditions of vascular hyperpermeability.
[0151] The compounds disclosed herein are also useful in the
treatment of diabetic conditions such as diabetic retinopathy and
microangiopathy. The compounds disclosed herein are also useful in
the reduction of blood flow in a tumor in a subject. The compounds
disclosed herein are also useful in the reduction of metastasis of
a tumor in a subject.
[0152] Besides being useful for human treatment, the compounds
disclosed herein are also useful for veterinary treatment of
companion animals, exotic animals and farm animals, including
mammals, rodents, and the like. More preferred animals include
horses, dogs, and cats. As used herein, the compounds disclosed
herein include the pharmaceutically acceptable derivatives
thereof.
[0153] Where the plural form is used for compounds, salts, and the
like, this is taken to mean also a single compound, salt and the
like.
[0154] The treatment method that includes administering a compound
or composition disclosed herein can further include administering
to the patient an additional therapeutic agent (combination
therapy) selected from: a chemotherapeutic or anti-proliferative
agent, or an anti-inflammatory agent, wherein the additional
therapeutic agent is appropriate for the disease being treated and
the additional therapeutic agent is administered together with a
compound or composition disclosed herein as a single dosage form or
separately from the compound or composition as part of a multiple
dosage form. The additional therapeutic agent may be administered
at the same time as a compound disclosed herein or at a different
time. In the latter case, administration may be staggered by, for
example, 6 hours, 12 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks,
3 weeks, 1 month, or 2 months.
[0155] The invention also features a method of inhibiting the
growth of a cell that expresses VEGFR, c-Met, Ron or Axl that
includes contacting the cell with a compound or composition
disclosed herein, thereby causing inhibition of growth of the cell.
Examples of a cell whose growth can be inhibited include: a breast
cancer cell, a colorectal cancer cell, a lung cancer cell, a
papillary carcinoma cell, a prostate cancer cell, a lymphoma cell,
a colon cancer cell, a pancreatic cancer cell, an ovarian cancer
cell, a cervical cancer cell, a central nervous system cancer cell,
an osteogenic sarcoma cell, a renal carcinoma cell, a
hepatocellular carcinoma cell, a bladder cancer cell, a gastric
carcinoma cell, a head and neck squamous carcinoma cell, a melanoma
cell, or a leukemia cell.
[0156] The invention provides a method of inhibiting VEGFR, c-Met,
Ron or Axl kinase activity in a biological sample that includes
contacting the biological sample with a compound or composition
disclosed herein. The term "biological sample" as used herein,
means a sample outside a living organism and includes, without
limitation, cell cultures or extracts thereof; biopsied material
obtained from a mammal or extracts thereof; and blood, saliva,
urine, feces, semen, tears, or other body fluids or extracts
thereof. Inhibition of kinase activity, particularly VEGFR, c-Met,
Ron or Axl kinase activity, in a biological sample is useful for a
variety of purposes known to one of skill in the art. Examples of
such purposes include, but are not limited to, blood transfusion,
organ-transplantation, biological specimen storage, and biological
assays.
[0157] In certain embodiments of the present invention an
"effective amount" or "effective dose" of the compound or
pharmaceutically acceptable composition is that amount effective
for treating or lessening the severity of one or more of the
aforementioned disorders. The compounds and compositions, according
to the method of the present invention, may be administered using
any amount and any route of administration effective for treating
or lessening the severity of the disorder or disease. The exact
amount required will vary from subject to subject, depending on the
species, age, and general condition of the subject, the severity of
the infection, the particular agent, its mode of administration,
and the like. A compound or composition can also be administered
with one or more other therapeutic agents, as discussed above.
[0158] The compounds disclosed herein or pharmaceutical
compositions thereof may also be used for coating an implantable
medical device, such as prostheses, artificial valves, vascular
grafts, stents and catheters. Vascular stents, for example, have
been used to overcome restenosis (re-narrowing of the vessel wall
after injury). However, patients using stents or other implantable
devices risk clot formation or platelet activation. These unwanted
effects may be prevented or mitigated by pre-coating the device
with a pharmaceutically acceptable composition comprising a
compound disclosed herein.
[0159] Suitable coatings and the general preparation of coated
implantable devices are described in U.S. Pat. Nos. 6,099,562;
5,886,026; and 5,304,121, the contents of each of which are
incorporated by reference herein. The coatings are typically
biocompatible polymeric materials such as a hydrogel polymer,
polymethyldisiloxane, polycaprolactone, polyethylene glycol,
polylactic acid, ethylene vinyl acetate, and mixtures thereof. The
coatings may optionally be further covered by a suitable topcoat of
fluorosilicone, polysaccarides, polyethylene glycol, phospholipids
or combinations thereof to impart controlled release
characteristics into the composition. Implantable devices coated
with a compound disclosed herein are another embodiment of the
present invention. The compounds may also be coated on implantable
medical devices, such as beads, or co-formulated with a polymer or
other molecule, to provide a "drug depot" thus permitting the drug
to be released over a longer time period than administration of an
aqueous solution of the drug.
General Synthetic Procedures
[0160] In order to illustrate the invention, the following examples
are included. However, it is to be understood that these examples
do not limit the invention and are only meant to suggest a method
of practicing the invention.
[0161] Generally, the compounds in this invention may be prepared
by methods described herein, wherein the substituents are as
defined for formula (I) or (II), above, except where further noted.
The following non-limiting schemes and examples are presented to
further exemplify the invention. Persons skilled in the art will
recognize that the chemical reactions described herein may be
readily adapted to prepare a number of other compounds disclosed
herein, and alternative methods for preparing the compounds
disclosed herein are deemed to be within the scope of this
invention. For example, the synthesis of non-exemplified compounds
according to the invention may be successfully performed by
modifications apparent to those skilled in the art, e.g., by
appropriately protecting interfering groups, by utilizing other
suitable reagents known in the art other than those described,
and/or by making routine modifications of reaction conditions.
Alternatively, other reactions disclosed herein or known in the art
will be recognized as having applicability for preparing other
compounds disclosed herein.
[0162] In the examples described below, unless otherwise indicated
all temperatures are set forth in degrees Celsius. Reagents were
purchased from commercial suppliers such as Aldrich Chemical
Company, Arco Chemical Company and Alfa Chemical Company, Shanghai
Medpep Co., Ltd, Aladdin-Shanghai Jinchun Reagents, Ltd, and were
used without further purification unless otherwise indicated.
Common solvents were purchased from commercial suppliers such as
Shantou XiLong Chemical Factory, Guangdong Guanghua Reagent
Chemical Factory Co., Ltd., Guangzhou Reagent Chemical Factory,
Tainjin YuYu Fine Chemical Ltd., Qingdao Tenglong Reagent Chemical
Ltd., and Qingdao Ocean Chemical Factory.
[0163] Anhydrous THF, dioxane, toluene, and ether were obtained by
refluxing the solvent with sodium. Anhydrous CH.sub.2Cl.sub.2 and
CHCl.sub.3 were obtained by refluxing the solvent with CaH.sub.2.
EtOAc, PE, hexanes, DMA and DMF were treated with anhydrous
Na.sub.2SO.sub.4 prior use.
[0164] The reactions set forth below were done generally under a
positive pressure of nitrogen or argon or with a drying tube
(unless otherwise stated) in anhydrous solvents, and the reaction
flasks were typically fitted with rubber septa for the introduction
of substrates and reagents via syringe. Glassware was oven dried
and/or heat dried.
[0165] Column chromatography was conducted using a silica gel
column. Silica gel (300-400 mesh) was purchased from Qingdao Ocean
Chemical Factory. .sup.1H NMR spectra were recorded with a Bruker
400 MHz spectrometer at ambient temperature. .sup.1H NMR spectra
were obtained as CDCl.sub.3, DMSO-d.sub.6, CD.sub.3OD or
acetone-d.sub.6 solutions (reported in ppm), using TMS (0 ppm) or
chloroform (7.25 ppm) as the reference standard. When peak
multiplicities are reported, the following abbreviations are used:
s (singlet), d (doublet), t (triplet), m (multiplet), br
(broadened), dd (doublet of doublets), dt (doublet of triplets).
Coupling constants, when given, are reported in Hertz (Hz).
[0166] Low-resolution mass spectral (MS) data were generally
determined on an Agilent 1200 Series LCMS (Zorbax SB-C18,
2.1.times.30 mm, 4 micron, 10 minutes run, 0.6 mL/min flow rate, 5%
to 95% (0.1% formic acid in CH.sub.3CN) in (0.1% formic acid in
H.sub.2O)) with UV detection at 210/254 nm and a low resonance
electrospray mode (ESI).
[0167] Purities of compounds were assessed by Agilent 1100 Series
high performance liquid chromatography (HPLC) with UV detection at
210 nm and 254 nm. Column was normally operated at 40.degree.
C.
[0168] The following abbreviations are used throughout the
specification:
Ac.sub.2O acetic anhydride
ATP Adenosine Triphosphate
[0169] BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl BBr.sub.3
boron tribromide BSA bovine serum albumin BOC, Boc butyloxycarbonyl
Ca(SO.sub.3CF.sub.3).sub.2 calcium trifluoromethyl sulfonate
Cs.sub.2CO.sub.3 cesium carbonate CH.sub.2Cl.sub.2, DCM methylene
chloride CHCl.sub.3 chloroform CDCl.sub.3 chloroform deuterated Cu
copper CuI copper (I) iodide DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
D.sub.2 deuterium gas DIBAL diisobutylaluminum hydride DIAD
diisopropyl azodicarboxylate DIEA, DIPEA, iPr.sub.2Net
N,N-Diisopropylethylamine DEAD dimethyl azodicarboxylate DMF
dimethylformamide DMAP 4-dimethylaminopyridine DMSO
dimethylsulfoxide DPPA diphenylphosphoryl azide
DTT DL-Dithiothreitol
[0170] EDC, EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride EDTA ethylenediaminetetraacetic acid Et.sub.3N, TEA
triethylamine EtOAc, EA, ethyl acetate Et.sub.2O diethyl ether EtOH
ethanol FBS fetal bovine serum Fe iron g gram h hour HATU
2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate HBr hydrobromic acid HCl hydrochloric acid HOAc
acetic acid HOAT 1-Hydroxy-7-azabenzotriazole HOBt
1-hydroxybenzotriazole hydrate H.sub.2 hydrogen H.sub.2O water
H.sub.2O.sub.2 hydrogen peroxide H.sub.3PO.sub.4 orthophosphoric
acid H.sub.2SO.sub.4 sulphuric acid HNO.sub.3 nitric acid HCOOK
Potassium formate LiHMDS lithium bis(trimethylsilyl)-amide LDA
Lithium diisopropylamide MBP myelin basic protein MCPBA
meta-chloroperbenzoic acid MeCN, CH.sub.3CN acetonitrile MgSO.sub.4
magnesium sulfate MeOH, CH.sub.3OH methanol MeI methyl iodide MOPS
3-(N-Morpholino)propanesulfonic acid 2-MeTHF 2-methyl
tetrahydrofuran mL, ml milliliter N.sub.2 nitrogen
NMP N-methylpyrrolidinone
[0171] NaHCO.sub.3 sodium bicarbonate NaBH.sub.4 sodium borohydride
NaBH.sub.3CN sodium cyanoborohydride NaOtBu sodium tert-butoxide
NaOH sodium hydroxide NaClO.sub.2 sodium chlorite NaClO sodium
hypochlorite NaCl sodium chloride NaH.sub.2PO.sub.4 sodium
biphosphate NaH sodium hydride NaI sodium iodide Na.sub.2SO.sub.4
sodium sulfate NH.sub.3 ammonia NH.sub.4Cl ammonium chloride Pd/C
palladium on carbon Pd.sub.2(dba).sub.3 bis(dibenzylideneacetone)
palladium Pd(OAc).sub.2 palladium acetate Pd(OH).sub.2 palladium
hydroxide Pd(PPh.sub.3).sub.4 palladium tetrakis triphenylphosphine
Pd(dppf)Cl.sub.21,1-bis(diphenylphosphino)ferrocene palladium
chloride P(t-Bu).sub.3 tri(tert-butyl)phosphine PE petroleum ether
(60-90.degree. C.) PBS phosphate buffered saline POCl.sub.3
phosphorous oxychloride PhI(OAc).sub.2 iodobenzene diacetate
K.sub.2CO.sub.3 potassium carbonate KOH potassium hydroxide RT rt
r.t. room temperature Rt retention time SOCl.sub.2 thionyl chloride
t-BuOK Potassium tert-butanolate TBTU
O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate
TBS tris buffered saline THF tetrahydrofuran TFA trifluoroacetic
acid TEAC bis(tetra-ethylammonium)carbonate Tris trihydroxymethyl
aminomethane
[0172] Representative synthetic procedures for the preparation of
the compounds disclosed herein are outlined below in following
schemes. Unless otherwise indicated, each of X, Y, Z, W, R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 carry the
definitions set forth above in connection with formula (I) or
(II).
##STR00056##
[0173] The compounds disclosed herein can be prepared according to
the general synthetic methods illustrated in Scheme 1 and described
in details in the Examples. Referring to Scheme
1,6-aminopyridin-3-ol (1) is first condensed with substituted
pyrazolone (2) to provide compound (3). Coupling of picolinamide
(4) with compound (3) under basic condition (for example, t-BuOK or
NaH) at an elevated temperature in a polar solvent such as DMF
affords desired amide (5). Rearrangement of the amide in the
presence of an oxidant, such as PhI(OAc).sub.2 or NaClO leads to
aminopyridine (6). Acylation with acetyl group gives kinase
inhibitor (7).
##STR00057##
[0174] The compounds disclosed herein can also be prepared using
the alternative synthetic route as shown in Scheme 2. Referring to
Scheme 2, nitro derivative (8) is reduced into aniline (9) under
transfer hydrogenation conditions. This substituted aniline (9) is
then coupled with 4-chloropyridin-2-amine (10) in DMSO under
microwave condition to afford diaryl ether (11). Condensation of
diaryl ether (11) with substituted pyrazolone (2) leads to
aminopyridine (12), which can be further transformed into urea (13)
as the desired kinase inhibitor.
##STR00058##
[0175] The compounds disclosed herein can also be prepared using
the alternative synthetic route as shown in Scheme 3. Referring to
Scheme 3, aryl compound (with a free OH group) (14) is coupled with
substituted pyridine (15) under microwave condition to afford
diaryl ether (16). Condensation of compound (16) with substituted
pyrazolone (2) leads to the desired amide compound (17).
Rearrangement of the amide compound (17) in the presence of oxidant
PhI(OAc).sub.2 or NaClO leads to the desired kinase inhibitor
(18).
##STR00059##
[0176] The compounds disclosed herein can also be prepared using a
process as demonstrated in Scheme 4. Acylation of aminopyridine
(18) and acylation reagents (for example, using anhydride or acyl
chloride) gives the desired kinase inhibitor (19).
EXAMPLES
Example 1
N-(4-((2-aminopyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dih-
ydro-1H-pyrazole-4-carboxamide
##STR00060##
[0177] Step 1) 4-aminophenol
[0178] To a mixture of 4-nitrophenol (7 g, 50.3 mmol) and HCOOK
(1.8 g, 21.48 mmol) in THF (210 mL) and H.sub.2O (70 mL) was added
Pd/C (110 mg, 10% Pd content, 53%.about.55% water content). The
reaction was stirred at 50.degree. C. for 24 hours, and then
concentrated in vacuo. The residue was diluted with DCM (100 mL)
and filtered through a CELITE.RTM. pad. The filtrate was
concentrated in vacuo to give the title compound as a pale orange
solid (3.28 g, 60%).
[0179] MS (ESI, pos. ion) m/z: 110.1 [M+H].sup.+.
Step 2) 4-(4-aminophenoxy)pyridin-2-amine
[0180] To a mixture of 4-aminophenol (218 mg, 2 mmol) and
4-chloropyridin-2-amine (256 mg, 2 mmol) in DMSO (2.5 mL) was added
NaOCH.sub.3 (216 mg, 4 mmol). The reaction was microwaved at
180.degree. C. for 40 minutes, then cooled down to rt and quenched
with water (10 mL). The mixture was extracted with EtOAc (10
mL.times.3). The combined organic phases were dried over anhydrous
Na.sub.2SO.sub.4 and concentrated in vacuo. The residue was
purified by a silica gel column chromatography (DCM/CH.sub.3OH
(v/v)=30/1) to give the title compound as a brown solid (103 mg,
26%).
[0181] MS (ESI, pos. ion) m/z: 202.2 [M+H].sup.+;
[0182] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 3.65 (s,
2H), 4.37 (s, 1H), 5.89-5.90 (d, J=2.04 Hz, 1H), 6.25-6.27 (dd,
J=2.08 Hz, 5.88 Hz, 1H), 6.68-6.71 (m, 2H), 6.86-6.89 (m, 2H),
7.88-7.89 (d, J=5.88 Hz, 1H).
Step 3)
N-(4-((2-aminopyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-
-2,3-dihydro-1H-pyrazole-4-carboxamide
[0183] To a mixture of 4-(4-aminophenoxy)pyridin-2-amine (101 mg,
0.5 mmol) and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxyli- c
acid (118 mg, 0.51 mmol) in DCM (5 mL) was added EDCI (115 mg, 0.6
mmol) and HOAT (13.6 mg, 0.1 mmol). The reaction was stirred at
45.degree. C. for 3 hours, and then quenched with water (20 mL).
The organic phase was separated and concentrated in vacuo. The
residue was purified by a silica gel column chromatography
(DCM/CH.sub.3OH (v/v)=20/1) to give the title compound as a light
grey solid (110 mg, 49.2%).
[0184] MS (ESI, pos. ion) m/z: 416.4 [M+H].sup.+;
[0185] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.71 (s,
3H), 3.36 (s, 3H), 5.80-5.81 (d, J=2.16 Hz, 1H), 5.92 (s, 2H),
6.12-6.14 (dd, J=2.24 Hz, 5.8 Hz, 1H), 7.08-7.10 (m, 2H), 7.42-7.45
(m, 2H), 7.51-7.53 (m, 1H), 7.57-7.61 (m, 2H), 7.65-7.67 (m, 2H),
7.77-7.79 (d, J=5.8 Hz, 1H).
Example 2
N-(4-((2-amino-3-chloropyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-pheny-
l-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00061##
[0186] Step 1)
N-(4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-
-carboxamide
[0187] To a mixture of 4-aminophenol (1.09 g, 10 mmol) and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (2.37 g, 10.2 mmol) in DCM (30 mL) was added EDCI (2.3 g, 12
mmol) and HOAT (0.27 g, 2 mmol). The mixture was stirred at
46.degree. C. for 4 hours, then cooled to rt and diluted with EtOAc
(10 mL) and water (10 mL). The mixture was stirred at rt for 1
hour, then filtered to give the title compound as a white solid
(1.7 g, 52.5%).
[0188] MS (ESI, pos. ion) m/z: 324.1 [M+H].sup.+;
[0189] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.68 (s,
3H), 3.32 (s, 3H), 6.72 (d, J=8.8 Hz, 2H), 7.36-7.42 (m, 4H), 7.49
(t, J=7.4 Hz, 1H), 7.57 (t, J=7.6 Hz, 2H), 9.21 (s, 1H), 10.46 (s,
1H).
Step 2) 3,4-dichloropicolinamide
[0190] To a mixture of 2,2,6,6-tetramethylpiperidine (6.2 mL, 37.2
mmol) in diethylether (50 mL) was added n-BuLi in hexane (2.5 M, 23
mL, 57.5 mmol) at 0.degree. C. via syringe over 15 minutes. The
mixture was stirred at 0.degree. C. for 0.5 hour, then cooled to
-78.degree. C. A solution of 3,4-dichloropyridine (5.00 g, 33.8
mmol) in diethylether (20 mL) was added to the mixture via a
syringe over 15 minutes. The reaction was stirred at -78.degree. C.
for 2 hours, then isocyanatotrimethylsilane (94% pure, 6.7 mL, 50.7
mmol) was added. The mixture was warmed up to rt and continued to
stir for 2 hours, quenched with acetic acid (6.76 g, 112.6 mmol) in
35 mL of water. The mixture was continued to stir overnight. The
title product was precipitated overnight as a white solid, which
was collected through filtration. More products were recovered from
the filtrate. Thus, the filtrate was extracted with ethyl acetate
(50 mL.times.3) and the combined organic phases were washed with
brine (50 mL), and dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo. The solid was combined and washed with 35 mL
of Et.sub.2O to give the title compound as a pale yellow solid
(2.20 g, 34.0%).
[0191] MS (ESI, pos. ion) m/z: 191.1 [M+H].sup.+;
[0192] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 8.48 (d,
J=5.2 Hz, 1H), 8.09 (br s, 1H), 7.82 (s, 1H), 7.81 (d, J=5.2 Hz,
1H).
Step 3)
3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-
-4-carboxamido)phenoxy)picolinamide
[0193] To a mixture of
N-(4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-
-carboxamide (356 mg, 1 .mu.mol) in DMSO (4 mL) in a microwave vial
was added NaH (88 mg, 2.2 mmol, 60% dispersed in mineral oil) at
rt. The reaction was stirred at rt for 30 minutes, then
3,4-dichloropicolinamide (191 mg, 1.0 mmol) was added. The mixture
was microwaved at 160.degree. C. for 2 hours, then cooled to rt,
and diluted with water (10 mL). The resulted mixture was extracted
with ethyl acetate (30 mL.times.3). The combined organic phases
were washed with brine (30 mL.times.3), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo. The residue was
purified by a silica gel column chromatography (DCM/MeOH
(v/v)=50/1) to give the title compound as a pale yellow solid (140
mg, 29%).
[0194] MS (ESI, pos. ion) m/z: 478.1 [M+H].sup.+;
[0195] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.71 (s,
3H), 3.35 (s, 3H), 6.82 (d, J=5.4 Hz, 1H), 7.19 (d, J=9.0 Hz, 2H),
7.44 (d, J=7.5 Hz, 2H), 7.53 (m, 1H), 7.59 (m, 2H), 7.74 (m, 3H),
8.02 (s, 1H), 8.33 (d, J=5.4 Hz, 1H), 10.84 (s, 1H).
Step 4)
N-(4-((2-amino-3-chloropyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-
-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0196] To a mixture of
3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)phenoxy)picolinamide (140 mg, 0.29 mmol) in a solution of
ethyl acetate (2.5 mL), acetonitrile (2.5 mL) and water (1.3 mL)
was added iodobenzene diacetate (113 mg, 0.35 mmol) at 0.degree. C.
The reaction was stirred at 0.degree. C. for 30 minutes, then
warmed up to rt and continued to stir for 4 hours. The mixture was
diluted with DCM (30 mL), washed with brine (20 mL.times.3), and
concentrated in vacuo. The residue was purified by a silica gel
column chromatography (DCM/MeOH (v/v)=50/1) to give the title
compound as a light yellow solid (37 mg, 26.8%).
[0197] MS (ESI, pos. ion) m/z: 450.1 [M+H].sup.+;
[0198] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.70 (s,
3H), 3.37 (s, 3H), 5.95 (d, J=5.6 Hz, 1H), 6.36 (s, 2H), 7.10 (d,
J=8.5 Hz, 2H), 7.44 (d, J=7.6 Hz, 2H), 7.51 (m, 1H), 7.59 (m, 2H),
7.66 (d, J=8.5 Hz, 2H), 7.75 (d, J=5.6 Hz, 1H), 10.79 (s, 1H).
Example 3
N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-ox-
o-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00062##
[0199] Step 1) 4-(4-amino-2-fluorophenoxy)-3-chloropicolinamide
[0200] To a solution of 4-amino-2-fluorophenol (254 mg, 2.0 mmol)
in DMF (5 mL) was added t-BuOK (359 mg, 3.2 mmol). The mixture was
stirred at rt for 30 minutes, then 3,4-dichloropicolinamide (420
mg, 2.2 mmol) was added, and the mixture was microwaved at
120.degree. C. for 2 hours. The mixture was cooled to rt, quenched
with 25 mL of water. The resulted solution was extracted with EtOAc
(30 mL.times.3) and the combined organic phases were washed with
brine (30 mL.times.3), dried over Na.sub.2SO.sub.4 and concentrated
in vacuo. The residue was purified by a silica gel column
chromatography (EtOAc/PE (v/v)=2/1) to give the title compound as a
pale yellow solid (306 mg, 54.4%).
[0201] MS (ESI, pos. ion) m/z: 282.1 [M+H].sup.+;
[0202] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 8.30 (d,
J=5.6 Hz, 1H), 8.03 (s, 1H), 7.73 (s, 1H), 7.03 (t, J=9.0 Hz, 1H),
6.72 (dd, J=0.8 Hz, 5.6 Hz, 1H), 6.53 (dd, J=2.4 Hz, 13.2 Hz, 1H),
6.44 (dd, J=1.8 Hz, 8.7 Hz, 1H), 5.55 (s, 2H).
Step 2)
3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-
-4-carboxamido)-2-fluorophenoxy)picolinamide
[0203] To a suspension of
4-(4-amino-2-fluorophenoxy)-3-chloropicolinamide (306 mg, 1.40
mmol) and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (390 mg, 1.68 mmol) in DCM (6 mL) was added EDCI (322 mg, 1.68
mmol) and HOAT (38 mg, 0.28 mmol). The mixture was stirred at
45.degree. C. for 14.5 hours, then cooled to rt and quenched with 5
mL of water. The mixture was extracted with EtOAc (10 mL.times.3)
and the combined organic phases were washed with brine (10
mL.times.3), dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
The residue was purified by a silica gel column chromatography
(PE/EtOAc (v/v)=1/4) to give the title compound as a pale yellow
solid (647 mg, 93.2%).
[0204] MS (ESI, pos. ion) m/z: 496.1 [M+H].sup.+;
[0205] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 10.98 (s,
1H), 8.33 (d, J=5.6 Hz, 1H), 8.06 (br, s, 1H), 7.99 (dd, J=2.2 Hz,
13.2 Hz, 1H), 7.75 (br s, 1H), 7.60 (t, J=7.2 Hz, 2H), 7.52 (m,
1H), 7.45 (d, J=5.6 Hz, 2H), 7.35 (m, 2H), 6.84 (d, J=5.5 Hz, 1H),
3.37 (s, 3H), 2.71 (s, 3H).
Step 3)
N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimet-
hyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0206] To a suspension of
3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)-2-fluorophenoxy)picolinamide (437 mg, 0.88 mmol) in EtOAc
(5 mL), CH.sub.3CN (5 mL) and H.sub.2O (2.5 mL) was added
iodobenzene diacetate (341 mg, 1.06 mmol) at 0.degree. C. The
reaction was stirred at 0.degree. C. for 30 minutes, then warmed up
to rt and continued to stir for 3 hours. The mixture was
concentrated in vacuo, and the residue was purified by a silica gel
column chromatography (PE/EtOAc (v/v)=1/3) to give the title
compound as a yellow solid (290 mg, 70.6%).
[0207] MS (ESI, pos. ion) m/z: 468.2 [M+H].sup.+;
[0208] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 10.93 (s,
1H), 7.92 (d, J=12.6 Hz, 1H), 7.74 (d, J=5.7 Hz, 1H), 7.59 (t,
J=7.4 Hz, 2H), 7.52 (m, 1H), 7.43 (d, J=7.6 Hz, 2H), 7.28 (d, J=4.3
Hz, 2H), 6.40 (s, 2H), 5.92 (d, J=5.6 Hz, 1H), 5.86 (d, J=1.9 Hz,
1H), 3.36 (s, 3H), 2.70 (s, 3H).
Example 4
N-(4-((2-acetamido-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl--
3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00063##
[0209] Step 1)
N-(4-((2-(N-acetylacetamido)-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,-
5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0210] A mixture of
N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-o-
xo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (0.22 g, 0.47
mmol), acetic anhydride (1.3 mL, 13.75 mmol) and Et.sub.3N (0.51 g,
5.04 mmol) was stirred at 60.degree. C. for 24 hours, then quenched
with 50 mL of saturated Na.sub.2CO.sub.3 solution and extracted
with EtOAc (50 mL.times.3). The combined organic phases were washed
with brine (50 mL.times.3), dried over anhydrous Na.sub.2SO.sub.4,
and concentrated in vacuo. The residue was used directly for the
next step without further purification.
[0211] MS (ESI, pos. ion) m/z: 552.1 [M+H].sup.+.
Step 2)
N-(4-((2-acetamido-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,5-d-
imethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0212] To a solution of
N-(4-((2-(N-acetylacetamido)-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-1,-
5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
(259 mg, 0.47 mmol) in CH.sub.3OH (20 mL) was added a solution of
Na.sub.2CO.sub.3 (59.8 mg, 0.56 mmol) in H.sub.2O (1 mL). After
stirring at rt for 15 minutes, the mixture was concentrated in
vacuo and the residue was purified by a silica gel column
chromatography (CH.sub.3OH/EtOAc (v/v)=1/50) to give the title
compound as a beige solid (160 mg, 66.7%).
[0213] MS (ESI, pos. ion) m/z: 510.1 [M+H].sup.+;
[0214] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 10.97 (s,
1H), 10.27 (s, 1H), 8.20 (d, J=5.6 Hz, 1H), 7.98 (dd, J=2.3 Hz,
13.2 Hz, 1H), 7.60 (m, 2H), 7.54 (m, 1H), 7.44 (d, J=7.3 Hz, 2H),
7.38 (m, 1H), 7.33 (dd, J=2.0 Hz, 9.0 Hz, 1H), 6.67 (d, J=5.4 Hz,
1H), 3.40 (s, 3H), 2.71 (s, 3H), 2.08 (s, 3H).
Example 5
N-(4-((2-aminopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-oxo-2-p-
henyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00064##
[0215] Step 1) 1-(benzyloxy)-2,3-difluoro-4-nitrobenzene
[0216] To a solution of 2,4,5-trifluoronitrobenzene (5.00 g, 28.2
mmol) and benzyl alcohol (3.07 g, 28.4 mmol) in DMF (10 mL) was
added K.sub.2CO.sub.3 (5.87 g, 42.5 mmol). The reaction was stirred
at rt for 72 hours, then diluted with water (35 mL) and continued
to stir at 4.degree. C. overnight. The precipitates were collected
through filtration, washed with water (20 mL), and purified by a
silica gel column chromatography (EtOAc/PE (v/v)=1/20) to give the
title compound as a pale yellow solid (2.15 g, 28.7%).
[0217] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 7.90 (m,
1H), 7.43 (s, 2H), 7.42 (s, 2H), 7.39 (m, 1H), 6.86 (m, 1H), 5.27
(s, 2H).
Step 2) 4-amino-2,3-difluorophenol
[0218] To a suspension of 1-(benzyloxy)-2,3-difluoro-4-nitrobenzene
(1.93 g, 0.73 mmol) in CH.sub.3OH (45 mL) and THF (9 mL) was added
Pd/C (333 mg, 6% Pd content, 53% 55% water content). The mixture
was stirred at 32.degree. C. for 13 hours under H.sub.2 atmosphere.
The mixture was filtered through a CELITE.RTM. pad, which was
washed with 50 mL of EtOAc. The filtrate was concentrated in vacuo
and the residue was washed with 30 mL of CH.sub.2Cl.sub.2 to give
the title compound as a dark brown solid (0.89 g, 84%).
[0219] MS (ESI, pos. ion) m/z: 146.2 [M+H].sup.+;
[0220] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 6.49 (m,
1H), 6.38 (m, 1H), 4.71 (s, 2H).
Step 3) 4-(4-amino-2,3-difluorophenoxy)picolinamide
[0221] To a solution of 4-amino-2,3-difluorophenol (208 mg, 1.43
mmol) in DMF (4 mL) was added t-BuOK (257 mg, 2.29 mmol). The
reaction was stirred at rt for 30 minutes, then
4-chloropicolinamide (249 mg, 1.59 mmol) was added. The mixture was
microwaved at 120.degree. C. for 3 hours, then cooled to rt and
diluted with 25 mL of water. The resulted mixture was extracted
with EtOAc (30 mL.times.3), and the combined organic phases were
washed with brine (30 mL.times.3), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo. The residue was
purified by a silica gel column chromatography (PE/EtOAc (v/v)=1/2)
to give the title compound as an orange solid (110 mg, 41.5%).
[0222] MS (ESI, pos. ion) m/z: 266.0 [M+H].sup.+, 283.2
[M+NH.sub.4].sup.+;
[0223] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 8.42 (d,
J=5.6 Hz, 1H), 7.84 (br s, 1H), 7.65 (d, J=2.5 Hz, 1H), 7.03 (m,
1H), 6.77 (m, 1H), 6.56 (m, 1H), 5.56 (br s, 1H), 3.08 (s, 2H).
Step 4)
4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbox-
amido)-2,3-difluorophenoxy)picolinamide
[0224] To a suspension of
4-(4-amino-2,3-difluorophenoxy)picolinamide (180 mg, 0.68 mmol) and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (161 mg, 0.69 mmol) in DCM (4 mL) was added EDCI (157 mg, 0.82
mmol) and HOAT (19 mg, 0.14 mmol). The mixture was stirred at
45.degree. C. for 12 hours, then more
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (87 mg, 0.37 mmol) was added and the reaction was continued to
stir at 45.degree. C. for 5 hours. The mixture was cooled to rt,
quenched with 5 mL of water, and extracted with EtOAc (10
mL.times.3). The combined organic phases were washed with brine (10
mL.times.3), dried over Na.sub.2SO.sub.4, and concentrated in
vacuo. The residue was purified by a silica gel column
chromatography (EtOAc 100%) to give the title compound as an orange
solid (108 mg, 33.2%).
[0225] MS (ESI, pos. ion) m/z: 480.1 [M+H].sup.+.
[0226] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.20 (s,
1H), 8.55 (d, J=5.7 Hz, 1H), 8.34 (m, 1H), 8.16 (br s, 1H), 7.76
(br s, 1H), 7.64 (m, 3H), 7.59 (d, J=7.8 Hz, 1H), 7.46 (m, 3H),
7.28 (m, 1H), 3.38 (s, 3H), 2.71 (s, 3H).
Step 5)
N-(4-((2-aminopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-
-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0227] To a suspension of
4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)--
2,3-difluorophenoxy)picolinamide (108 mg, 0.22 mmol) in EtOAc (2.5
mL), CH.sub.3CN (2.5 mL) and H.sub.2O (1.5 mL) was added
iodobenzene diacetate (96 mg, 0.30 mmol) at 0.degree. C. The
reaction was stirred at 0.degree. C. for 30 minutes, then warmed up
to rt and continued to stir for 4 hours. The mixture was
concentrated in vacuo, and the residue was purified by a silica gel
column chromatography (EtOAc/CH.sub.3OH (v/v)=10/1) to give the
title compound as a pale yellow solid (32 mg, 32.3%).
[0228] MS (ESI, pos. ion) m/z: 452.2 [M+H].sup.+;
[0229] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.12 (s,
1H), 8.27 (m, 1H), 7.81 (d, J=5.8 Hz, 1H), 7.60 (m, 2H), 7.54 (m,
1H), 7.44 (d, J=7.4 Hz, 2H), 7.16 (m, 1H), 6.19 (m, 1H), 5.98 (s,
2H), 5.86 (d, J=1.9 Hz, 1H), 3.34 (s, 3H), 2.70 (s, 3H).
Example 6
N-(4-((2-acetamidopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-oxo-
-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00065##
[0231] To a suspension of
N-(4-((2-aminopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-oxo-2--
phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (135 mg, 0.3 mmol) in
acetic anhydride (6 mL) was added Et.sub.3N (0.4 mL, 2.9 mmol). The
reaction mixture was stirred at 35.degree. C. for 4 hours, then
filtered, and the filter cake washed with PE (5 mL), EtOAc (5 mL)
and CH.sub.3OH (2 mL) respectively to give the title compound as a
beige solid (102 mg, 68.9%).
[0232] MS (ESI, pos. ion) m/z: 494.1 [M+H].sup.+;
[0233] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.16 (s,
1H), 10.60 (s, 1H), 8.31 (m, 1H), 8.20 (d, J=5.8 Hz, 1H), 7.70 (d,
J=2.0 Hz, 1H), 7.61 (m, 2H), 7.52 (m, 1H), 7.45 (m, 2H), 7.22 (m,
1H), 6.73 (dd, J=2.4 Hz, 5.7 Hz, 1H), 3.38 (s, 3H), 2.71 (s, 3H),
2.04 (s, 3H).
Example 7
N-(4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido-
)-2,3-difluorophenoxy)pyridin-2-yl)morpholine-4-carboxamide
##STR00066##
[0235] To a suspension of
N-(4-((2-aminopyridin-4-yl)oxy)-2,3-difluorophenyl)-1,5-dimethyl-3-oxo-2--
phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (224 mg, 0.50 mmol) in
THF (3 mL) was added Et.sub.3N (0.138 mL, 0.99 mmol), followed by
adding phenyl carbonochloridate (0.125 mL, 1.00 mmol) dropwise. The
reaction mixture was stirred at rt for 2 hours, then morpholine
(0.4 mL, 5.00 mmol) was added. The mixture was stirred at rt for 36
hours, then quenched with saturated NH.sub.4Cl aqueous solution (20
mL) and CH.sub.2Cl.sub.2 (20 mL). The resulted mixture was stirred
at rt for 10 minutes and extracted with CH.sub.2Cl.sub.2 (20
mL.times.3). The combined organic phases were washed with brine (20
mL.times.3), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo. The residue was purified by a silica gel
column chromatography (EtOAc/PE (v/v)=20/1) to give the title
compound as an orange solid (148 mg, 52.5%).
[0236] MS (ESI, pos. ion) m/z: 565.2 [M+H].sup.+;
[0237] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.16 (s,
1H), 9.32 (s, 1H), 8.30 (m, 1H), 8.14 (d, J=5.8 Hz, 1H), 7.60 (m,
2H), 7.53 (m, 1H), 7.44 (m, 3H), 7.20 (m, 1H), 6.66 (dd, J=2.4 Hz,
5.7 Hz, 1H), 3.55 (dd, J=4.4 Hz, 5.1 Hz, 4H), 3.41 (dd, J=4.1 Hz,
4.8 Hz, 4H), 3.38 (s, 3H), 2.71 (s, 3H).
Example 8
N-(4-((2-aminopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo-2-p-
henyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00067##
[0238] Step 1) 1-(benzyloxy)-2,5-difluoro-4-nitrobenzene
[0239] To a solution of 2,4,5-trifluoronitrobenzene (5.4 g, 30.5
mmol) and benzyl alcohol (3.2 mL, 30.5 mmol) in DMF (20 mL) was
added K.sub.2CO.sub.3 (6.33 g, 46.1 mmol). The reaction was stirred
at room temperature for 72 hours. Water (60 mL) was added at
0.degree. C. and the resulted mixture was continued to stir at
4.degree. C. for 24 hours. The solid was collected by filtration,
washed with 30 mL of water, and dried in vacuo at 45.degree. C. to
provide the title compound as a pale yellow solid (6.0 g, 74%).
[0240] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 5.22 (s,
2H), 6.85-6.89 (m, 1H), 7.40-7.43 (m, 5H), 7.89-7.94 (m, 1H).
Step 2) 4-amino-2,5-difluorophenol
[0241] To a suspension of 1-(benzyloxy)-2,5-difluoro-4-nitrobenzene
(1.06 g, 4 mmol) in CH.sub.3OH (25 mL) and THF (5 mL) was added
Pd/C (50% Pd content, 185 mg). The reaction was stirred at
32.degree. C. under H.sub.2 atmosphere for 10 hours. The mixture
was filtered through a CELITE.RTM. pad and the filtrate was
concentrated in vacuo. The residue was washed with DCM (15 mL) to
give the title compound as a dark brown solid (500 mg, 86%).
[0242] MS (ESI, pos. ion) m/z: 146.2 [M+H].sup.+.
[0243] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 4.68 (s,
2H), 6.53-6.65 (m, 2H), 9.06 (br, 1H).
Step 3) 4-(4-amino-2,5-difluorophenoxy)picolinamide
[0244] To a mixture of 4-amino-2,5-difluorophenol (100 mg, 0.64
mmol), and 4-chloropicolinamide (110 mg, 0.71 mmol) in DMF (2 mL)
was added NaH (80 mg, 1.3 mmol, 60% dispersed in mineral oil). The
reaction mixture was microwaved at 120.degree. C. for 1.5 hours,
then cooled to rt, diluted with water (20 mL), and extracted with
EtOAc (30 mL.times.3). The combined organic phases were washed with
brine (80 mL), dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The residue was purified by flash column chromatography with
(EtOAc/PE (v/v)=4/1) to afford the title compound as a brown solid
(52 mg, 26%).
[0245] MS (ESI, pos. ion) m/z: 266.2 [M+H].sup.+.
Step 4)
4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbox-
amido)-2,5-difluorophenoxy)picolinamide
[0246] To a solution of 4-(4-amino-2,5-difluorophenoxy)picolinamide
(200 mg, 0.76 mmol), and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (165 mg, 0.75 mmol) in DCM (10 mL) was added EDCI (175 mg,
0.93 mmol), and HOAT (26 mg, 0.15 mmol). The reaction was stirred
at 45.degree. C. for 16 hours, cooled to rt and diluted with EtOAc
(20 mL). The solid was collected through filtration, dried at
45.degree. C. in vacuo overnight to give the title compound as a
white solid (230 mg, 63.7%).
[0247] MS (ESI, pos. ion) m/z: 480.1 [M+H].sup.+;
[0248] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.24 (s,
1H), 8.53-8.57 (m, 2H), 8.15 (s, 1H), 7.75 (s, 1H), 7.53-7.59 (m,
4H), 7.44-7.45 (m, 3H), 7.24-7.25 (d, J=5.2 Hz, 1H), 3.43 (s, 3H),
2.70 (s, 3H).
Step 5)
N-(4-((2-aminopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-
-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0249] To a solution of
4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)--
2,5-difluorophenoxy)picolinamide (80 mg, 0.17 mmol) in EtOAc (2
mL), CH.sub.3CN (2 mL), and H.sub.2O (1 mL) was added
PhI(OAc).sub.2 (70 mg, 1.2 mmol). The reaction was stirred at
0.degree. C. for 30 minutes, then warmed up to rt and continued to
stir for 8 hours. The mixture was filtered through a CELITE.RTM.
pad, which was washed with EtOAc (30 mL). The filtrate was
concentrated in vacuo and the residue was purified by a silica gel
column chromatography (DCM/CH.sub.3OH (v/v)=20/1) to afford the
tile compound as a white solid (51 mg, 68%).
[0250] MS (ESI, pos. ion) m/z: 452.1 [M+H].sup.+;
[0251] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.18 (s,
1H), 8.45-8.50 (dd, J=7.4 Hz, 12.8 Hz, 1H), 7.79-7.81 (d, J=5.76
Hz, 1H), 7.57-7.61 (m, 2H), 7.43-7.54 (m, 4H), 6.16-6.18 (m, 1H),
5.96 (s, 2H), 5.83-5.83 (d, J=2.16 Hz, 1H), 3.37 (s, 3H), 2.70 (s,
3H).
Example 9
N-(4-((2-acetamidopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo-
-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00068##
[0253] To a solution of
N-(4-((2-aminopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo-2--
phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (220 mg, 0.48 mmol) in
(Ac).sub.2O (8 mL) was added Et.sub.3N (0.5 mL, 1.32 mmol). The
reaction mixture was stirred at rt for 8 hours and concentrated in
vacuo. The residue was purified by a silica gel column
chromatography (DCM/CH.sub.3OH (v/v)=10/1) to give the title
compound as a white solid (175 mg, 73%).
[0254] MS (ESI, pos. ion) m/z: 494.0 [M+H].sup.+;
[0255] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.21 (s,
1H), 10.58 (s, 1H), 8.49-8.54 (dd, J=7.3 Hz, 12.8 Hz, 1H),
8.18-8.20 (d, J=5.7 Hz, 1H), 7.67-7.68 (m, 1H), 7.51-7.61 (m, 4H),
7.43-7.45 (m, 2H), 6.70-6.72 (dd, J=2.4 Hz, 5.7 Hz, 1H), 3.32 (s,
3H), 2.70 (s, 3H), 2.04 (s, 3H).
Example 10
N-(4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido-
)-2,5-difluorophenoxy)pyridin-2-yl)morpholine-4-carboxamide
##STR00069##
[0257] To a suspension of
N-(4-((2-aminopyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl-3-oxo-2--
phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (250 mg, 0.56 mmol)
and Et.sub.3N (0.25 mL, 1.68 mmol) in THF (10.0 mL) was added
phenyl carbonochloridate (0.25 mL, 1.68 mmol). The mixture was
stirred at rt for 2 hours, then morpholine (0.35 mL, 3.46 mmol) was
added. The reaction mixture was stirred rt for 24 hours and
partitioned between aq NH.sub.4Cl (40 mL) and DCM (40 mL). The
organic phase was separated and the aqueous phase was extracted
with DCM (40 mL.times.3). The combined organic phases was dried
over anhydrous Na.sub.2SO.sub.4 and concentrated in vacuo. The
residue was purified by a silica gel column chromatography
(EtOAc/PE (v/v)=4/1) to give the title compound as a white solid
(70 mg, 21%).
[0258] MS (ESI, pos. ion) m/z: 565.0 [M+H].sup.+;
[0259] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.20 (s,
1H), 9.28 (s, 1H), 8.47-8.52 (dd, J=7.3 Hz, 12.8 Hz, 1H), 8.12-8.14
(d, J=5.7 Hz, 1H), 7.57-7.61 (m, 2H), 7.50-7.54 (m, 2H), 7.39-7.45
(m, 3H), 6.63-6.65 (dd, J=2.5 Hz, 5.6 Hz, 1H), 3.53-3.56 (m, 4H),
3.40-3.41 (m, 4H), 3.35 (s, 3H), 2.70 (s, 3H).
Example 11
N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-dimethyl--
3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00070##
[0260] Step 1)
3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)-2,5-difluorophenoxy)picolinamide
[0261] To a solution of
N-(2,5-difluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro--
1H-pyrazole-4-carboxamide (395 mg, 1.1 mmol) in DMF (5.0 mL) was
added t-BuOK (202 mg, 1.8 mmol) and the mixture was stirred at rt
for 30 minutes. Then 3,4-dichloropicolinamide (190 mg, 1.0 mmol)
was added and the mixture was microwaved at 120.degree. C. for 2
hours, then cooled to rt, quenched with water (30 mL) and extracted
with EtOAc (50 mL.times.3). The combined organic phases were washed
with brine (50 mL.times.3), dried over anhydrous Na.sub.2SO.sub.4,
and concentrated in vacuo. The residue was purified by a silica gel
column chromatography (MeOH/DCM (v/v)=1/30) to give the title
compound as a pale yellow solid (310 mg, 60%).
[0262] MS (ESI, pos. ion) m/z: 514.2 [M+H].sup.+;
[0263] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.70 (s,
3H), 3.38 (s, 3H), 6.96 (d, J=5.5 Hz, 1H), 7.45 (d, J=7.0 Hz, 2H),
7.51-7.55 (m, 1H), 7.58-7.66 (m, 3H), 7.75 (s, 1H), 8.05 (s, 1H),
8.34 (d, J=5.5 Hz, 1H), 8.53-8.58 (m, 1H), 11.25 (s, 1H).
Step 2)
N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-2,5-difluorophenyl)-1,5-d-
imethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0264] To a suspension of
3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)-2,5-difluorophenoxy)picolinamide (310 mg, 0.60 mmol) in
EtOAc (6.0 mL), CH.sub.3CN (6.0 mL) and H.sub.2O (3.0 mL) at
0.degree. C. was added iodobenzene diacetate (234 mg, 0.72 mmol).
After stirring at 0.degree. C. for 30 minutes, the mixture was
allowed warm up to rt and stirred for 4 hours. The mixture was
concentrated in vacuo and the residue was purified by a silica gel
column chromatography (MeOH/DCM (v/v)=1/70) to give the title
compound as a pale yellow solid (200 mg, 69%).
[0265] MS (ESI, pos. ion) m/z: 486.1 [M+H].sup.+;
[0266] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.70 (s,
3H), 3.38 (s, 3H), 6.01 (d, J=5.6
[0267] Hz, 1H), 6.42 (s, 2H), 7.43 (d, J=7.2 Hz, 2H), 7.50-7.55 (m,
2H), 7.60 (t, J=7.4 Hz, 2H), 7.75 (d, J=5.6 Hz, 1H), 8.48-8.53 (m,
1H), 11.19 (s, 1H).
Example 12
N-(4-((2-aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-pheny-
l-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00071##
[0268] Step 1) 4-(4-amino-3-chlorophenoxy)picolinamide
[0269] To a mixture of 4-amino-2-chlorophenol hydrochloride (446
mg, 2.4 mmol) in DMSO (4 mL) was added NaH (280 mg, 7.0 mmol, 60%
dispersed in mineral oil). The reaction was stirred at rt for 30
minutes, followed by the addition of 4-chloropicolinamide (345 mg,
2.2 mmol). The reaction was microwaved at 160.degree. C. for 2
hours, then cooled to rt, and diluted with water (20 mL). The
resulted mixture was extracted with ethyl acetate (20 mL.times.3)
and the combined organic phases were washed with brine (20 mL),
dried over anhydrous Na.sub.2SO.sub.4, and concentrated in vacuo.
The residue was purified by a silica gel column chromatography
(EtOAc/PE (v/v)=1/1) to give the title compound as an orange solid
(170 mg, 29%).
[0270] MS (ESI, pos. ion) m/z: 264.1 [M+H].sup.+;
[0271] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 5.45 (s,
2H), 6.89 (d, J=8.7 Hz, 1H), 6.92 (m, 1H), 7.11 (m, 1H), 7.16 (d,
J=2.6 Hz, 1H), 7.34 (d, J=2.6 Hz, 1H), 7.68 (s, 1H), 8.10 (s, 1H),
8.47 (d, J=5.6 Hz, 1H).
Step 2)
4-(3-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-
-4-carboxamido)phenoxy)picolinamide
[0272] To a suspension of 4-(4-amino-3-chlorophenoxy)picolinamide
(191 mg, 0.72 mmol) and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (168 mg, 0.72 mmol) in DCM (10 mL) was added EDCI (166 mg,
0.86 mmol) and HOAT (20 mg, 0.14 mmol). The reaction was stirred at
46.degree. C. for 6 hours, followed by the addition of
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (32 mg, 0.14 mmol) and EDCI (27 mg, 0.14 mmol). The mixture
was continued to stir at 46.degree. C. for 13 hours, then cooled to
rt and diluted with water (10 mL). The resulted mixture was
extracted with ethyl acetate (10 mL.times.3), and the combined
organic phases were washed with brine (10 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo. The residue was
purified by a silica gel column chromatography (DCM/MeOH
(v/v)=50/1) to give the title compound as a pale yellow solid (160
mg, 46.5%).
[0273] MS (ESI, pos. ion) m/z: 478.2 [M+H].sup.+;
[0274] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.71 (s,
3H), 3.37 (s, 3H), 7.19 (m, 1H), 7.23 (m, 1H), 7.43 (m, 3H), 7.50
(m, 2H), 7.60 (m, 2H), 7.72 (s, 1H), 8.13 (s, 1H), 8.52 (d, J=5.6
Hz, 1H), 8.63 (d, J=9.1 Hz, 1H), 11.19 (s, 1H).
Step 3)
N-(4-((2-aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-
-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0275] To a mixture of
4-(3-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)phenoxy)picolinamide (160 mg, 0.33 mmol) in EtOAc (3 mL),
CH.sub.3CN (2.5 mL) and H.sub.2O (1.3 mL) was added iodobenzene
diacetate (130 mg, 0.40 mmol) at 0.degree. C. The reaction was
stirred at 0.degree. C. for 30 minutes, then warmed up to rt and
continued to stir for 3 hours. The mixture was concentrated in
vacuo and the residue was purified by a silica gel column
chromatography (DCM/MeOH (v/v)=25/1) to give the title compound as
a beige solid (100 mg, 67%).
[0276] MS (ESI, pos. ion) m/z: 450.2 [M+H].sup.+;
[0277] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.71 (s,
3H), 3.43 (s, 3H), 5.83 (d, J=2.1 Hz, 1H), 5.95 (s, 2H), 6.16 (m,
1H), 7.14 (m, 1H), 7.45 (d, J=7.3 Hz, 2H), 7.52 (t, J=7.3 Hz, 1H),
7.60 (t, J=7.3 Hz, 2H), 7.80 (d, J=5.8 Hz, 2H), 8.56 (d, J=9.1 Hz,
1H), 11.12 (s, 1H).
Example 13
N-(4-((2-acetamidopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-p-
henyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00072##
[0279] To a suspension of
N-(4-((2-aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-phen-
yl-2,3-dihydro-1H-pyrazole-4-carboxamide (125 mg, 0.28 mmol) in
acetic anhydride (6.0 mL) was added triethylamine (0.4 mL). The
reaction mixture was stirred at 35.degree. C. for 13 hours, then
filtered, and the filter cake was washed with petroleum ether (6
mL), MeOH (3 mL), and ethyl acetate (6 mL) respectively to give the
title compound as a light blue solid (87 mg, 63%).
[0280] MS (ESI, pos. ion) m/z: 492.1 [M+H].sup.+;
[0281] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.04 (s,
3H), 2.72 (s, 3H), 3.37 (s, 3H), 6.68 (m, 1H), 7.18 (m, 1H), 7.44
(m, 3H), 7.52 (t, J=7.4 Hz, 1H) 7.60 (t, J=7.5 Hz, 2H), 7.67 (d,
J=2.0 Hz, 1H), 8.18 (d, J=5.7 Hz, 1H), 8.60 (d, J=9.1 Hz, 1H),
10.55 (s, 1H), 11.16 (s, 1H).
Example 14
N-(4-(3-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-ca-
rboxamido)phenoxy)pyridin-2-yl)morpholine-4-carboxamide
##STR00073##
[0283] To a suspension of
N-(4-((2-aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-phen-
yl-2,3-dihydro-1H-pyrazole-4-carboxamide (125 mg, 0.28 mmol) and
Et.sub.3N (0.12 mL, 0.84 mmol) in THF (4.0 mL) was added phenyl
carbonochloridate (0.10 mL, 0.84 mmol). The mixture was stirred at
rt for 2 hours, then morpholine (0.15 mL, 1.68 mmol) was added. The
resulted mixture was stirred rt for 22 hours, then partitioned
between aqueous NH.sub.4Cl solution (20 mL) and DCM (20 mL). The
organic phase was separated and the aqueoud phase was extracted
with DCM (20 mL.times.3). The combined organic phases were dried
over anhydrous Na.sub.2SO.sub.4, and concentrated in vacuo. The
residue was purified by a silica gel column chromatography
(EtOAc/PE (v/v)=20/1), followed by washing with methanol (4 mL) to
give the title compound as a beige solid (60 mg, 38%).
[0284] MS (ESI, pos. ion) m/z: 563.2 [M+H].sup.+;
[0285] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 2.80 (s,
3H), 3.35 (s, 3H), 3.50 (t, J=4.8 Hz, 4H), 3.73 (t, J=4.8 Hz, 4H),
6.50 (m, 1H), 7.02 (m, 1H), 7.14 (d, J=2.7 Hz, 1H), 7.29 (s, 1H),
7.39 (d, J=7.2 Hz, 2H), 7.46 (m, 1H), 7.55 (m, 2H), 7.65 (s, 1H),
8.02 (d, J=5.9 Hz, 1H), 8.60 (d, J=9.0 Hz, 1H), 11.03 (s, 1H).
Example 15
N-(4-((2-aminopyridin-4-yl)oxy)-2-deuteriumphenyl)-1,5-dimethyl-3-oxo-2-ph-
enyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00074##
[0287] To a suspension of
N-(4-((2-aminopyridin-4-yl)oxy)-2-chlorophenyl)-1,5-dimethyl-3-oxo-2-phen-
yl-2,3-dihydro-1H-pyrazole-4-carboxamide (200 mg, 0.44 mmol) and
triethylamine (0.10 mL, 0.66 mmol) in methanol (8.0 mL) was added
Pd/C (40 mg, 20%). The reaction mixture was stirred under D.sub.2
atmosphere at 62.degree. C. for 12 hours. Filtered and the filtrate
was concentrated in vacuo. The residue was purified by a silica gel
column chromatography (MeOH/DCM (v/v)=1/30) and TLC (MeOH/DCM
(v/v)=1/20) to give the title compound as a pale yellow solid (40
mg, 21%).
[0288] MS (ESI, pos. ion) m/z: 417.3 [M+H].sup.+;
[0289] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 2.80 (s,
3H), 3.36 (s, 3H), 4.75 (s, 2H), 5.93 (d, J=1.8 Hz, 1H), 6.31 (m,
1H), 7.04 (d, J=8.8 Hz, 2H), 7.37 (d, J=7.4 Hz, 2H), 7.47 (m, 1H),
7.56 (m, 2H), 7.68 (d, J=8.8 Hz, 2H), 10.73 (s, 1H).
Example 16
N-(5-((2-aminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2-
,3-dihydro-1H-pyrazole-4-carboxamide
##STR00075##
[0290] Step 1) 4-((6-aminopyridin-3-yl)oxy)picolinamide
[0291] To a mixture of 6-aminopyridin-3-ol (220 mg, 2 mmol) and
t-BuOK (225 mg, 2.16 mmol) in DMF (2.5 mL) was added
4-chloropicolinamide (315 mg, 2 mmol). The reaction was heated to
80.degree. C. for 5 hours, then cooled to rt and diluted with EtOAc
(50 mL) and H.sub.2O (50 mL). The organic phase was concentrated in
vacuo and the residue was purified by a silica gel column
chromatography (DCM/CH.sub.3OH (v/v)=30/1) to give the title
compound as a brown solid (230 mg, 50%).
[0292] MS (ESI, pos. ion) m/z: 231.1 [M+H].sup.+;
[0293] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 6.09 (s,
2H), 6.53-6.56 (d, J=8.88 Hz, 1H), 7.12-7.14 (dd, J=2.64 Hz, 5.6
Hz, 1H), 7.31-7.34 (dd, J=2.92 Hz, 8.88 Hz, 1H), 7.35-7.36 (d,
J=2.48 Hz, 1H), 7.70 (s, 1H), 7.83-7.84 (d, J=2.8 Hz, 1H), 8.11 (s,
1H), 8.46-8.49 (d, J=5.6 Hz, 1H).
Step 2)
4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbo-
xamido) pyridin-3-yl)oxy)picolinamide
[0294] To a suspension of 4-((6-aminopyridin-3-yl)oxy)picolinamide
(230 mg, 1 mmol) and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (237 mg, 1.02 mmol) in DCM (5 mL) was added EDCI (230 mg, 1.2
mmol) and HOAT (27 mg, 0.2 mmol). The reaction was stirred at
45.degree. C. for 28 hours, then cooled to rt and diluted with
water (10 mL) and DCM (20 mL). The organic phase was concentrated
in vacuo and the residue was purified by a silica gel column
chromatography (DCM/CH.sub.3OH (v/v)=40/1) to give the title
compound as a light grey solid (111 mg, 25%).
[0295] MS (ESI, pos. ion) m/z: 445.1 [M+H].sup.+;
[0296] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.72 (s,
3H), 3.33 (s, 3H), 7.20-7.22 (dd, J=2.64 Hz, 5.64 Hz, 1H),
7.43-7.46 (m, 3H), 7.52-7.54 (m, 1H), 7.58-7.62 (m, 2H), 7.72 (s,
1H), 7.75-7.78 (dd, J=2.88 Hz, 8.96 Hz, 1H), 8.13 (s, 1H),
8.27-8.28 (d, J=2.68 Hz, 1H), 8.34-8.36 (d, J=9.08 Hz, 1H),
8.52-8.54 (d, J=5.6 Hz, 1H), 11.26 (s, 1H).
Step 3)
N-(5-((2-aminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2--
phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0297] To a solution of
4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)-
pyridin-3-yl)oxy)picolinamide (111 mg, 0.25 mmol) in EtOAc (2 mL),
CH.sub.3CN (2 mL) and H.sub.2O (1 mL) was added PhI(OAc).sub.2 (97
mg, 0.3 mmol). The reaction was stirred at 0.degree. C. for 30
minutes, then warmed up to rt and continued to stir for 12 hours.
The mixture was concentrated in vacuo and the residue was purified
by a silica gel column chromatography (DCM/CH.sub.3OH (v/v)=40/1)
to give the title compound as a light beige solid (85 mg,
81.7%).
[0298] MS (ESI, pos. ion) m/z: 417.2 [M+H].sup.+;
[0299] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.71 (s,
3H), 3.38 (s, 3H), 5.83 (s, 1H), 5.98 (s, 2H), 6.17 (s, 1H),
7.08-7.10 (m, 2H), 7.42-7.81 (m, 6H), 7.80-7.81 (d, J=5.8 Hz, 1H),
8.17 (s, 1H), 8.29-8.31 (d, J=8.56 Hz, 1H), 11.19 (s, 1H).
Example 17
N-(5-((2-acetamidopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phen-
yl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00076##
[0301] To a solution of
N-(5-((2-aminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl--
2,3-dihydro-1H-pyrazole-4-carboxamide (300 mg, 0.72 mmol) in acetic
anhydride (4 mL) was added Et.sub.3N (400 mg, 4 mmol), the reaction
mixture was stirred at 30.degree. C. for 12 hours and concentrated
in vacuo. The residue was purified by a silica gel column
chromatography (DCM/CH.sub.3OH (v/v)=40/1) to give the title
compound as a light yellow solid (197 mg, 60.1%).
[0302] MS (ESI, pos. ion) m/z: 459.0 [M+H].sup.+;
[0303] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.23 (s,
1H), 10.57 (s, 1H), 8.34-8.31 (d, J=9.1 Hz, 1H), 8.22-8.21 (d,
J=2.8 Hz, 1H), 8.20-8.19 (d, J=5.7 Hz, 1H), 7.72-7.69 (dd, J=9.0
Hz, 2.8 Hz, 1H), 7.67-7.67 (d, J=1.6 Hz, 1H), 7.62-7.59 (m, 2H),
7.54-7.51 (m, 1H), 7.46 (s, 1H), 7.44 (s, 1H), 3.37 (s, 3H), 2.72
(s, 3H), 2.05 (s, 3H).
Example 18
N-(4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamid-
o)pyridin-3-yl)oxy)pyridin-2-yl)morpholine-4-carboxamide
##STR00077##
[0305] To a suspension of
N-(5-((2-aminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl--
2,3-dihydro-1H-pyrazole-4-carboxamide (171 mg, 0.41 mmol) and
Et.sub.3N (0.17 mL, 1.23 mmol) in THF (8.0 mL) was added phenyl
carbonochloridate (0.15 mL, 1.23 mmol). The mixture was stirred at
rt for 2 hours, then morpholine (0.21 mL, 2.46 mmol) was added. The
reaction mixture was stirred rt for 24 hours and partitioned
between aq NH.sub.4Cl (40 mL) and DCM (40 mL). The organic phase
was separated and the aqueous phase was extracted with DCM (40
mL.times.3). The combined organic phases were dried over anhydrous
Na.sub.2SO.sub.4 and concentrated in vacuo. The residue was
purified by a silica gel column chromatography (MeOH/EtOAc
(v/v)=1/50) and TLC (MeOH/EtOAc (v/v)=1/30) to give the title
compound as a pale yellow solid (40 mg, 18%).
[0306] MS (ESI, pos. ion) m/z: 530.2 [M+H].sup.+;
[0307] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 2.79 (s,
3H), 3.36 (s, 3H), 3.50 (t, J=4.8 Hz, 4H), 3.72 (t, J=4.8 Hz, 4H),
6.49-6.51 (m, 1H), 7.36-7.38 (m, 3H), 7.42-7.46 (m, 2H), 7.52-7.56
(m, 2H), 7.66 (s, 1H), 8.03 (d, J=5.6 Hz, 1H), 8.14 (d, J=2.7 Hz,
1H), 8.34 (d, J=9.0 Hz, 1H), 11.19 (s, 1H).
Example 19
N-(5-((2-amino-3-chloropyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-
-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00078##
[0308] Step 1)
N-(5-hydroxypyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyra-
zole-4-carboxamide
[0309] To a suspension of 6-aminopyridin-3-ol (330 mg, 3 mmol) and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (710 mg, 306 mmol) in DMF (10 mL) was added EDCI (690 mg, 3.6
mmol) and HOAT (80 mg, 0.6 mmol). The reaction was stirred at
60.degree. C. for 4 hours, then cooled to rt and diluted with water
(100 mL) and EtOAc (2 mL). The mixture was cooled to 0.degree. C.
and stirred overnight. The resulted solid was collected through
filtration to give title compound as a light brown solid (680 mg,
70%).
[0310] MS (ESI, pos. ion) m/z: 325.1 [M+H].sup.+;
[0311] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.50 (s,
3H), 3.33 (s, 3H), 7.18-7.20 (dd, J=2.3 Hz, 8.8 Hz, 1H), 7.40-7.42
(d, J=7.5 Hz, 2H), 7.48-7.52 (m, 1H), 7.56-7.60 (m, 2H), 7.81-7.82
(d, J=2.2 Hz, 1H), 7.95 (s, 1H), 8.04-8.06 (d, J=8.8 Hz, 1H), 9.61
(s, 1H), 10.85 (s, 1H).
Step 2)
3-chloro-4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-
e-4-carboxamido)pyridin-3-yl)oxy)picolinamide
[0312] To a mixture of 6-aminopyridin-3-ol (324 mg, 1 mmol) and
t-BuOK (135 mg, 1.2 mmol) in DMF (2 mL) was added
3,4-dichloropicolinamide (191 mg, 1 mmol). The reaction was heated
to 80.degree. C. for 15 hours, then cooled to rt and diluted with
EtOAc (1 mL) and H.sub.2O (20 mL). The mixture was stirred
overnight and the resulted solid was collected through filtration
to give the title compound as a brown solid (290 mg, 60.5%).
[0313] MS (ESI, pos. ion) m/z: 479.2 [M+H].sup.+;
[0314] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 2.72 (s,
3H), 3.35 (s, 3H), 6.91-6.92 (d, J=5.5 Hz, 1H), 6.09 (s, 2H),
7.43-7.45 (m, 2H), 7.50-7.54 (m, 1H), 7.58-7.62 (m, 2H), 7.73-7.76
(m, 2H), 8.03 (s, 1H), 8.26-8.27 (d, J=2.7 Hz, 1H), 8.33-8.36 (m,
2H), 11.26 (s, 1H).
Step 3)
N-(5-((2-amino-3-chloropyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-
-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0315] To a solution of
3-chloro-4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-car-
boxamido)pyridin-3-yl)oxy)picolinamide (290 mg, 0.6 mmol) in EtOAc
(4 mL), CH.sub.3CN (4 mL), and H.sub.2O (2 mL) was added
PhI(OAc).sub.2 (234 mg, 0.72 mmol). The reaction was stirred at
0.degree. C. for 30 minutes, then warmed up to rt and continued to
stir for 12 hours. The mixture was filtered through a CELITE.RTM.
pad, which was washed with DCM (30 mL). The filtrate was washed
with water (20 mL), then concentrated in vacuo. The residue was
purified by a silica gel column chromatography (DCM/CH.sub.3OH
(v/v)=50/1) to give the title compound as a light beige solid (120
mg, 44.7%).
[0316] MS (ESI, pos. ion) m/z: 451.1 [M+H].sup.+;
[0317] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.71 (s,
3H), 3.36 (s, 3H), 5.99-6.01 (d, J=5.6 Hz, 1H), 6.42 (s, 2H),
7.42-7.44 (m, 2H), 7.51-7.53 (m, 1H), 7.57-7.61 (m, 2H), 7.63-7.66
(dd, J=2.9 Hz, 9.0 Hz, 1H), 7.76-7.77 (d, J=5.6 Hz, 1H), 8.18-8.19
(d, J=2.8 Hz, 1H), 8.28-8.30 (d, J=9.1 Hz, 1H), 11.21 (s, 1H).
Example 20
N-(5-((2-acetamido-3-chloropyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-o-
xo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00079##
[0319] To a solution of
N-(5-((2-amino-3-chloropyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo--
2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (60 mg, 0.13 mmol),
and Et.sub.3N (26.3 mg, 0.26 mmol) in CH.sub.2Cl.sub.2 (1 mL) and
THF (2 mL) was added acetyl chloride (20 mg, 0.26 mmol). The
reaction was stirred at rt for 3 hours, then treated with saturated
Na.sub.2CO.sub.3 aqueous solution (2 mL). The resulted mixture was
continued to stir at rt for 5 minutes, then concentrated in vacuo.
The residue was purified by a silica gel column chromatography
(DCM/CH.sub.3OH (v/v)=50/1) to give the title compound as a light
beige solid (15 mg, 22.7%).
[0320] MS (ESI, pos. ion) m/z: 493.1 [M+H].sup.+;
[0321] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.08 (s,
3H), 2.71 (s, 3H), 3.35 (s, 3H), 6.72-6.74 (d, J=5.6 Hz, 1H),
7.43-7.45 (m, 2H), 7.50-7.54 (m, 1H), 7.58-7.62 (m, 2H), 7.63-7.66
(dd, J=2.9 Hz, 9.0 Hz, 1H), 8.19-8.20 (d, J=5.6 Hz, 1H), 8.26-8.27
(d, J=2.8 Hz, 1H), 8.33-8.35 (d, J=9.1 Hz, 1H), 10.24 (s, 1H),
11.25 (s, 1H).
Example 21
N-(4-((2-acetamido-3-chloropyridin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-p-
henyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00080##
[0323] To a suspension of
3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)phenoxy)picolinamide (124 mg, 0.28 mmol) in acetic
anhydride (8.0 mL) was added triethylamine (0.4 mL). The reaction
was stirred at 40.degree. C. for 26 hours. The mixture was washed
with a saturated Na.sub.2CO.sub.3 aqueous solution (60 mL.times.3),
and extracted with dichloromethane (60 mL.times.3). The combined
organic phases were dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo. The residue was purified by a silica gel
column chromatography (DCM/MeOH (v/v)=40/1) to give the title
compound as a light pink solid (80 mg, 59%).
[0324] MS (ESI, pos. ion) m/z: 492.2 [M+H].sup.+;
[0325] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.07 (s,
3H), 2.70 (s, 3H), 3.37 (s, 3H), 6.64 (d, J=5.6 Hz, 1H), 7.20 (d,
J=9.0 Hz, 2H), 7.44 (d, J=7.2 Hz, 2H), 7.51 (m, 1H), 7.59 (m, 2H),
7.72 (d, J=9.0 Hz, 2H), 8.18 (d, J=5.6 Hz, 1H), 10.21 (s, 1H),
10.83 (s, 1H).
Example 22
N-(4-((2-aminopyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-pheny-
l-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00081##
[0326] Step 1)
N-(3-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-p-
yrazole-4-carboxamide
[0327] To a suspension of 4-amino-2-fluorophenol (2.54 g, 20 mmol)
and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (4.74 g, 20.4 mmol) in DCM (60 mL) were added EDCI (4.6 g, 24
mmol) and HOAT (0.54 g, 4 mmol). The reaction was stirred at
45.degree. C. for 12 hours, then cool to rt, quenched with H.sub.2O
(10 mL), and stirred for another 4 hours. The solid was obtained by
filtration and washed with DCM (20 mL.times.3), then dried at
60.degree. C. in vacuo for 12 hours to give the title compound as a
pale yellow solid (6.37 g, 93.4%).
[0328] MS (ESI, pos. ion) m/z: 342.1 [M+H].sup.+;
[0329] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 10.59 (s,
1H), 9.58 (s, 1H), 7.64 (dd, J=2.4 Hz, 13.5 Hz, 1H), 7.60 (m, 2H),
7.50 (m, 1H), 7.42 (m, 2H), 6.97 (m, 1H), 6.88 (dd, J=9.6 Hz, 8.8
Hz, 1H), 3.34 (s, 3H), 2.70 (s, 3H).
Step 2)
4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbox-
amido)-2-fluorophenoxy)picolinamide
[0330] To a suspension of
N-(3-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-p-
yrazole-4-carboxamide (2.2 g, 6.4 mmol) and 4-chloropicolinamide (1
g, 6.39 mmol) in DMSO (12 mL) was added NaH (615 mg, 12.3 mmol, 50%
dispersed in mineral oil). The reaction was stirred at 160.degree.
C. for 20 hours, then cooled to rt, and diluted with H.sub.2O (70
mL). The mixture was extracted with EtOAc (100 mL.times.3). The
combined organic phases were washed with brine (100 mL), dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The residue was
purified by a silica gel column chromatography (PE/EtOAc (v/v)=1/4)
to give the title compound as a white solid (0.85 g, 29%).
[0331] MS (ESI, pos. ion) m/z: 462.1 [M+H].sup.+;
[0332] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 10.87 (s,
1H), 8.40-8.41 (d, J=5.6 Hz, 1H), 7.88-7.92 (dd, J=2.4 Hz, 12.6 Hz,
1H), 7.82-7.83 (d, J=3.9 Hz, 1H), 7.71-7.71 (d, J=2.5 Hz, 1H),
7.54-7.58 (m, 2H), 7.46-7.49 (m, 1H), 7.35-7.37 (d, J=8.6 Hz, 2H),
7.07-7.11 (m, 1H), 6.96-6.98 (dd, J=2.5 Hz, 5.6 Hz, 1H), 5.56 (s,
1H), 3.37 (s, 3H), 2.79 (s, 3H).
Step 3)
N-(4-((2-aminopyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-
-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0333] A solution of
4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)--
2-fluorophenoxy)picolinamide (0.4 g, 0.86 mmol) and PhI(OAc).sub.2
(419 mg, 1.5 mmol) in a mixture of EtOAc (8 mL), MeCN (8 mL) and
H.sub.2O (4 mL) was cooled to 0.degree. C. and stirred for 30
minutes. The reaction was then allowed to warm to rt, and stirred
for another 8 hours. The mixture was diluted with NaHCO.sub.3 (aq.,
60 mL) and extracted with EtOAc (100 mL.times.3). The combined
organic phases were washed with brine, dried over Na.sub.2SO.sub.4
and concentrated in vacuo. The residue was purified by a silica gel
column chromatography (DCM/MeOH (v/v)=10/1) to give the title
compound as a white solid (0.21 g, 56%).
[0334] MS (ESI, pos. ion) m/z: 434.2 [M+H].sup.+;
[0335] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 10.83 (s,
1H), 7.91-7.92 (d, J=5.9 Hz, 1H), 7.83-7.86 (dd, J=2.4 Hz, 10.1 Hz,
1H), 7.56-7.58 (m, 2H), 7.46-7.52 (d, J=5.9 Hz, 2H), 7.35-7.37 (d,
J=8.6 Hz, 2H), 7.04-7.09 (m, 1H), 6.29-6.31 (m, 1H), 5.92-5.93 (d,
J=2.1 Hz, 1H), 4.45 (s, 2H), 3.37 (s, 3H), 2.79 (s, 3H).
Example 23
N-(4-((2-acetamidopyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-p-
henyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00082##
[0337] To a solution of
N-(4-((2-aminopyridin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phen-
yl-2,3-dihydro-1H-pyrazole-4-carboxamide (90 mg, 0.21 mmol) in
acetic anhydride (6 mL) was added Et.sub.3N (0.3 mL). The reaction
was stirred at rt for 8 hours, then concentrated in vacuo. The
residue was purified by a silica gel column chromatography
(DCM/MeOH (v/v)=10/1) to give the title compound as a white solid
(53 mg, 49%).
[0338] MS (ESI, pos. ion) m/z: 476.1 [M+H].sup.+;
[0339] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 10.83 (s,
1H), 8.15 (s, 1H), 8.05-8.07 (d, J=5.8 Hz, 1H), 7.84-7.89 (m, 2H),
7.54-7.58 (m, 2H), 7.47-7.49 (d, J=7.3 Hz, 1H), 7.35-7.37 (d, J=7.4
Hz, 2H), 7.25 (s, 1H), 7.06-7.11 (m, 1H), 6.53-6.54 (dd, J=2.2 Hz,
5.7 Hz, 1H), 3.36 (s, 3H), 2.79 (s, 3H), 2.16 (s, 3H).
Example 24
N-(4-((2-aminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl-3-ox-
o-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00083##
[0340] Step 1) 1-chloro-4,5-difluoro-2-nitrobenzene
[0341] To a flask was added 4-chloro-1,2-difluorobenzene (8.97 g,
60.4 mmol), followed by adding 98% con. H.sub.2SO.sub.4 (16.1 mL,
302 mmol) and 65% con. HNO.sub.3 (5.0 mL, 66.4 mmol) at 0.degree.
C. The mixture was stirred at rt for 5 hours, then poured into ice
water (500 mL). The resulted mixture was extracted with ethyl
acetate (200 mL.times.3). The combined organic phase were washed
with saturated aqueous NaHCO.sub.3 solution (200 mL.times.2) and
brine (200 mL), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo to give the title compound as yellow liquid
(11.31 g, 96.7%).
[0342] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 7.41-7.45
(m, 1H), 7.86-7.90 (m, 1H).
Step 2) potassium 5-chloro-2-fluoro-4-nitrophenolate
[0343] A mixture of 1-chloro-4,5-difluoro-2-nitrobenzene (5.12 g,
26.5 mmol) and 15% aqueous KOH (19.9 g) solution was stirred at
reflux for 3 hours, then cooled to rt, and filtered to give the
title compound as a yellow crystalloid (5.67 g, 93.3%).
[0344] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 6.20 (d,
J=13.2 Hz, 1H), 7.70 (d, J=8.6 Hz, 1H).
Step 3) 4-amino-5-chloro-2-fluorophenol
[0345] To a solution of potassium
5-chloro-2-fluoro-4-nitrophenolate (1.0 g, 4.35 mmol) in 95% EtOH
(22 mL) and H.sub.2O (8 mL) was added Fe (0.97 g, 17.4 mmol) and
NH.sub.4Cl (1.86 g, 34.8 mmol). The mixture was stirred at rt for
10 hours, then diluted with methanol (100 mL) and ethyl acetate
(100 mL). Filtered and the filtrate was concentrated in vacuo. The
residue was dissolved in water (50 mL) and ethyl acetate (50 mL).
The organic phase was separated and the water phase was extracted
with ethyl acetate (50 mL.times.2). The combined organic layers
were washed with brine (50 mL.times.3), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give the title
compound as a pale solid (0.6 g, 85.3%).
[0346] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 4.90 (s,
2H), 6.60 (d, J=12.9 Hz, 1H), 6.79 (d, J=8.8 Hz, 1H), 9.11 (s,
1H).
Step 4)
N-(2-chloro-5-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl--
2,3-dihydro-1H-pyrazole-4-carboxamide
[0347] To a suspension of 4-amino-5-chloro-2-fluorophenol (0.97 g,
6 mmol) and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (1.42 g, 6.12 mmol) in DMF (20 mL) was added EDCI (0.38 mg,
7.2 mmol) and HOAT (0.16 g, 1.2 mmol). The mixture was allowed to
warm up to 80.degree. C. and stirred for 24 hours. Then H.sub.2O
(200 mL) and EtOAc (2 mL) was added. The resulted mixture was
stirred at 0.degree. C. for 2 hours, then filtered to give the
title compound as a light brown solid (1.2 g, 53.2%).
[0348] MS (ESI, pos. ion) m/z: 376.1 [M+H].sup.+;
[0349] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 2.68 (s,
3H), 3.34 (s, 3H), 7.02-7.04 (d, J=8.8 Hz, 1H), 7.41-7.43 (m, 2H),
7.48-7.52 (m, 1H), 7.56-7.60 (m, 2H), 829-8.33 (d, J=13.8 Hz, 1H),
10.08 (s, 1H), 10.95 (s, 1H).
Step 5)
4-(5-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-
-4-carboxamido)-2-fluorophenoxy)picolinamide
[0350] To a suspension of
N-(2-chloro-5-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dih-
ydro-1H-pyrazole-4-carboxamide (751.6 mg, 2 mmol) and t-BuOK (224.4
mg, 2 mmol) in DMF (4 mL) and was added 4-chloropicolinamide (313.2
mg, 2 mmol). The reaction was warmed up to 120.degree. C. and
stirred for 15 hours. After the mixture cooling to rt, H.sub.2O (40
mL) was added and the resulted mixture was stirred at rt overnight.
Filtered and the filter cake was purified by a silica gel column
chromatography (DCM/CH.sub.3OH (v/v)=50/1) to give the title
compound as a light yellow solid (290 mg, 60.5%).
[0351] MS (ESI, pos. ion) m/z: 496.2 [M+H].sup.+;
[0352] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.37 (s,
1H), 8.69-8.66 (d, J=13.4 Hz, 1H), 8.55-8.54 (d, J=5.6 Hz, 1H),
8.15 (s, 1H), 7.78-7.75 (m, 2H), 7.62-7.58 (m, 2H), 7.55-7.51 (m,
1H), 7.46-7.43 (m, 3H), 7.26-7.24 (dd, J=5.6 Hz, 2.6 Hz, 1H), 3.38
(s, 3H), 2.72 (s, 3H).
Step 6)
N-(4-((2-aminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimet-
hyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0353] To a suspension of
4-(5-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)-2-fluorophenoxy)picolinamide (297.6 mg, 0.6 mmol) in EtOAc
(4 mL), CH.sub.3CN (4 mL) and H.sub.2O (2 mL) was added
PhI(OAc).sub.2 (97 mg, 0.3 mmol) at 0.degree. C., the mixture was
stirred at 0.degree. C. for 30 minutes, then warmed up to rt and
stirred for 12 hours. The mixture was concentrated in vacuo and the
residue was purified by a silica gel column chromatography
(DCM/CH.sub.3OH (v/v)=20/1) to give the title compound as a light
beige solid (220 mg, 78.3%).
[0354] MS (ESI, pos. ion) m/z: 468.0 [M+H].sup.+;
[0355] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.32 (s,
1H), 8.63-8.60 (d, J=13.4 Hz, 1H), 7.82-7.81 (d, J=5.9 Hz, 1H),
7.64-7.62 (m, 3H), 7.55-7.54 (m, 1H), 7.46-7.44 (m, 2H), 6.22-6.20
(dd, J=5.8 Hz, 2.2 Hz, 1H), 6.05 (s, 2H), 5.85-5.84 (d, J=2.0 Hz,
1H), 3.33 (s, 3H), 2.71 (s, 3H).
Example 25
N-(4-((2-acetamidopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl--
3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00084##
[0357] To a solution of
N-(4-((2-aminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl-3-o-
xo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (200 mg, 0.43
mmol) in acetic anhydride (4 mL) was added Et.sub.3N (400 mg, 2.6
mmol). The mixture was stirred at 30.degree. C. for 12 hours and
concentrated in vacuo. The residue was purified by a silica gel
column chromatography (DCM/CH.sub.3OH (v/v)=40/1) to give the title
compound as a light yellow solid (110 mg, 50.5%).
[0358] MS (ESI, pos. ion) m/z: 510.2 [M+H].sup.+;
[0359] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 12.15 (s,
1H), 11.38 (s, 1H), 9.45-9.42 (d, J=13.4 Hz, 1H), 9.00-8.98 (d,
J=5.7 Hz, 1H), 8.50-8.48 (m, 2H), 8.42-8.38 (m, 2H), 8.34-8.31 (m,
1H), 8.26-8.24 (m, 2H), 7.52-7.50 (dd, J=5.7 Hz, 1.3 Hz, 1H), 4.14
(s, 3H), 3.51 (s, 3H), 2.84 (s, 3H).
Example 26
N-(4-(5-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-ca-
rboxamido)-2-fluorophenoxy)pyridin-2-yl)morpholine-4-carboxamide
##STR00085##
[0361] To a suspension of
N-(4-((2-aminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl-3-o-
xo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (234 mg, 0.5
mmol) and Et.sub.3N (0.1 mg, 1 mmol) in THF (5 mL) was added phenyl
chloroformate (0.16 mg, 1 mmol). The mixture was stirred at rt for
2 hours, then morpholine (0.44 mL, 5 mmol) was added. The reaction
mixture was stirred rt for 24 hours, then partitioned between aq
NH.sub.4Cl (30 mL) and DCM (30 mL). The organic phase was separated
and the aqueous phase extracted with DCM (30 mL.times.3). The
combined organic phases were dried over anhydrous Na.sub.2SO.sub.4
and concentrated in vacuo. The residue was purified by a silica gel
column chromatography (DCM/CH.sub.3OH (v/v)=50/1) to give the title
compound as a white solid (145 mg, 49.9%).
[0362] MS (ESI, pos. ion) m/z: 581.2 [M+H].sup.+;
[0363] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 11.35 (s,
1H), 9.30 (s, 1H), 8.65-8.61 (d, J=13.4 Hz, 1H), 8.14-8.13 (d,
J=5.7 Hz, 1H), 7.69-7.67 (d, J=8.1 Hz, 1H), 7.62-7.58 (m, 2H),
7.54-7.51 (m, 1H), 7.45-7.40 (m, 3H), 6.65-6.63 (dd, J=5.7 Hz, 2.2
Hz, 1H), 3.55-3.53 (m, 4H), 3.43-3.36 (m, 7H), 2.71 (s, 3H).
Example 27
N-(4-((2-aminopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-2-pheny-
l-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00086##
[0364] Step 1)
N-(3-chloro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-p-
yrazole-4-carboxamide
[0365] To a suspension of 4-amino-2-chlorophenol (4.0 g, 28.00
mmol) and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (7.4 g, 30.11 mmol) in DCM (70 mL) were added EDCI (6.65 g,
30.11 mmol) and HOAT (0.76 g, 5.68 mmol). The mixture was stirred
at 45.degree. C. for 20 hours, then cooled to rt and filtered. The
filter cake was washed with DCM (20 mL.times.3), and dried at
50.degree. C. in a vacuum oven overnight to give the title product
as a gray solid (7.1 g, 72.1%).
[0366] MS (ESI, pos. ion) m/z: 358.1 [M+H].sup.+;
[0367] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 10.56 (s,
1H), 9.92 (s, 1H), 7.59 (m, 2H), 7.50 (m, 1H), 7.42 (m, 2H), 7.83
(dd, J=2.6 Hz, 8.7 Hz, 1H), 6.90 (d, J=8.7 Hz, 1H), 6.88 (dd, J=9.6
Hz, 8.8 Hz, 1H), 3.33 (s, 3H), 2.68 (s, 3H).
Step 2)
4-(2-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-
-4-carboxamido)phenoxy)picolinamide
[0368] To a suspension of
N-(3-chloro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-p-
yrazole-4-carboxamide (1.074 g, 3.0 mmol) in DMF (12 mL) was added
t-BuOK (539 mg, 4.8 mmol). The mixture was stirred at rt for 30
minutes, then 4-chloropicolinamide (517 mg, 3.3 mmol) was added.
The mixture was stirred at 120.degree. C. for 36 hours, then cooled
to rt, quenched with 50 mL of water and extracted with EtOAc (50
mL.times.3). The combined organic phases were washed with brine (50
mL.times.3), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo. The residue was purified by a silica gel
column chromatography (EtOAc/PE (v/v)=3/1) to give the title
compound as a white solid (580 mg, 40.4%).
[0369] MS (ESI, pos. ion) m/z: 478.0 [M+H].sup.+;
[0370] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 10.95 (s,
1H), 8.53 (d, J=5.6 Hz, 1H), 8.16 (d, J=2.4 Hz, 1H), 8.13 (br s,
1H), 7.72 (br s, 1H), 7.60 (m, 2H), 7.51 (m, 2H), 7.44 (d, J=7.3
Hz, 2H), 7.38 (d, J=8.8 Hz, 1H), 7.32 (d, J=2.6 Hz, 1H), 7.17 (dd,
J=2.6 Hz, 5.6 Hz, 1H), 3.16 (d, J=5.2 Hz, 3H), 2.70 (s, 3H).
Step 3)
N-(4-((2-aminopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-
-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0371] To a suspension of
4-(2-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)phenoxy)picolinamide (540 mg, 1.13 mmol) in EtOAc (6 mL),
CH.sub.3CN (6 mL) and H.sub.2O (3 mL) was added iodobenzene
diacetate (438 mg, 1.36 mmol) at 0.degree. C. The mixture was
stirred at 0.degree. C. for 30 minutes, then warmed up to rt and
stirred for 4.5 hours. The mixture was concentrated in vacuo and
the residue was purified by a silica gel column chromatography
(EtOAc/PE (v/v)=6/1) to give the title compound as a beige solid
(265 mg, 52.2%).
[0372] MS (ESI, pos. ion) m/z: 450.2 [M+H].sup.+;
[0373] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 10.89 (s,
1H), 8.10 (d, J=2.4 Hz, 1H), 7.79 (d, J=5.8 Hz, 1H), 7.59 (m, 2H),
7.52 (m, 1H), 7.43 (d, J=5.7 Hz, 3H), 7.25 (d, J=8.8 Hz, 1H), 6.13
(dd, J=2.3 Hz, 5.8 Hz, 1H), 5.93 (s, 2H), 5.72 (d, J=2.2 Hz, 1H),
3.36 (s, 3H), 2.70 (s, 3H).
Example 28
N-(4-((2-acetamidopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-2-p-
henyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00087##
[0375] To a solution of
N-(4-((2-aminopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-2-phen-
yl-2,3-dihydro-1H-pyrazole-4-carboxamide (120 mg, 0.27 mmol) in
(Ac).sub.2O (5 mL) was added Et.sub.3N (0.4 mL, 1.12 mmol). The
reaction mixture was stirred at rt for 8 hours and concentrated in
vacuo. The residue was purified by a silica gel column
chromatography (DCM/CH.sub.3OH (v/v)=40/1) to give the title
compound as a white solid (65 mg, 49%).
[0376] MS (ESI, pos. ion) m/z: 492.0 [M+H].sup.+;
[0377] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 10.92 (s,
1H), 10.53 (s, 1H), 8.16-8.17 (d, J=5.7 Hz, 1H), 8.12-8.13 (d,
J=2.4 Hz, 1H), 7.49-7.61 (m, 4H), 7.42-7.47 (m, 3H), 7.29-7.32 (d,
J=8.7 Hz, 1H), 6.60-6.62 (dd, J=2.4 Hz, 5.7 Hz, 1H), 3.36 (s, 3H),
2.70 (s, 3H), 2.03 (s, 3H).
Example 29
N-(4-(2-chloro-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-ca-
rboxamido)phenoxy)pyridin-2-yl)morpholine-4-carboxamide
##STR00088##
[0379] To a suspension of
N-(4-((2-aminopyridin-4-yl)oxy)-3-chlorophenyl)-1,5-dimethyl-3-oxo-2-phen-
yl-2,3-dihydro-1H-pyrazole-4-carboxamide (135 mg, 0.3 mmol) in THF
(3 mL) was added Et.sub.3N (0.080 mL, 0.6 mmol), followed by adding
phenyl carbonochloridate (0.075 mL, 0.6 mmol) dropwise. The
reaction mixture was stirred at rt for 2 hours, then morpholine
(0.250 mL, 3.0 mmol) was added. The reaction mixture was stirred at
rt for 22 hours, quenched with saturated NH.sub.4Cl aqueous (20 mL)
and CH.sub.2Cl.sub.2 (20 mL). The resulted mixture was stirred at
rt for 10 minutes, and extracted with CH.sub.2Cl.sub.2 (20
mL.times.3). The combined organic phases were washed with brine (20
mL.times.3), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo. The residue was purified by a silica gel
column chromatography (EtOAc/PE (v/v)=6/1) to give the title
compound as a beige solid (43 mg, 25.4%).
[0380] MS (ESI, pos. ion) m/z: 563.2 [M+H].sup.+;
[0381] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. (ppm) 10.92 (s,
1H), 9.25 (s, 1H), 8.12 (s, 1H), 8.11 (d, J=3.9 Hz, 1H), 7.59 (m,
2H), 7.52 (m, 1H), 7.44 (m, 3H), 7.31 (m, 2H), 6.56 (dd, J=2.3 Hz,
5.7 Hz, 1H), 3.54 (t, J=4.4 Hz, 5.0 Hz, 4H), 3.37 (br s, 7H), 2.70
(s, 3H).
Example 30
N-(4-((2-aminopyridin-4-yl)oxy)-2-fluorophenyl)-1,5-dimethyl-3-oxo-2-pheny-
l-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00089##
[0382] Step 1) 4-amino-3-fluorophenol
[0383] A suspension of 3-fluoro-4-nitrophenol (2.0 g, 12.73 mmol),
10% Pd/C (0.4 g) and HCOOK (8.75 g, 101.85 mmol) in THF/H.sub.2O
(70 mL/20 mL) was stirred at 50.degree. C. for 5 hours, then cooled
to rt, and filtered through CELITE.RTM.. The filtrate was diluted
with water (30 mL) and extracted with THF (50 mL). The organic
layer was dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
The residue was diluted with water (50 mL) and extracted with DCM
(50 mL). The organic layer was dried over anhydrous
Na.sub.2SO.sub.4 and concentrated in vacuo to give the title
compound as a brown solid (1.17 g, 72.3%).
[0384] MS (ESI, pos, ion) m/z: 128.1 [M+H].sup.+.
Step 2)
N-(2-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihyd-
ro-1H-pyrazole-4-carboxamide
[0385] To a suspension of 4-amino-3-fluorophenol (1.0 g, 7.87 mmol)
and
1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
acid (2.19 g, 9.44 mmol) in CH.sub.2Cl.sub.2 (20 mL) were added
EDCI (3.02 g, 15.7 mmol) and HOAT (0.21 g, 1.57 mmol). The reaction
mixture was refluxed for 20 hours, and then cooled to rt. Water (10
mL) was added and the mixture stirred at rt overnight, then
filtered and the filter cake was washed with water (5 mL), followed
by purifying by a silica gel column chromatography
(CH.sub.2Cl.sub.2/MeOH (v/v)=70/1) to give the title compound as a
beige white solid (1.25 g, 46.6%).
[0386] MS (ESI, pos, ion) m/z: 342.1 [M+H].sup.+.
Step 3)
4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbox-
amido)-3-fluorophenoxy)picolinamide
[0387] To a mixture of
N-(2-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-p-
yrazole-4-carboxamide (300 mg, 0.879 mmol) and t-BuOK (118 mg, 1.05
mmol) was added DMF (2.5 mL). The resulted mixture was stirred at
rt for 30 minutes, then 4-chloropicolinamide (165 mg, 1.05 mmol)
was added. The mixture was heated at 120.degree. C. for 5 hours,
then cooled to rt, and H.sub.2O (50 mL) and EtOAc (2 mL) was added.
The resulted mixture was stirred at rt overnight. Filtered and the
precipitation was washed with water (5 mL) to give the title
compound as a dark brown solid (370 mg, 91.2%).
[0388] MS (ESI, pos, ion) m/z: 462.2 [M+H].sup.+, Rt=3.012 min.
Step 4)
N-(4-((2-aminopyridin-4-yl)oxy)-2-fluorophenyl)-1,5-dimethyl-3-oxo-
-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0389] A solution of
4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)--
3-fluorophenoxy)picolinamide (370 mg (a little wet), 0.746 mmol) in
EtOAc (4.5 mL), CH.sub.3CN (4.5 mL) and H.sub.2O (2.5 mL) was
cooled and stirred at 0.degree. C. for 30 minutes and then
PhI(OAc).sub.2 (288 mg, 0.895 mmol) was added. The resulted mixture
was stirred at 0.degree. C. for another 30 minutes, then warmed up
to rt and stirred for 7 hours. The mixture was filtered and the
filter cake was washed with EtOAc (5 mL). The filtrate was
concentrated in vacuo and the residue was purified by a silica
column gel chromatography (CH.sub.2Cl.sub.2/MeOH (v/v)=250/9),
followed by purifying again by silica gel column chromatography
(CH.sub.2Cl.sub.2/MeOH (v/v)=50/1) to give the title compound as a
beige white solid (46 mg, 17.3%).
[0390] MS (ESI, pos, ion) m/z: 434.2 [M+H].sup.+;
[0391] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 10.90 (s,
1H), 8.46 (t, J=8.7 Hz, 1H), 7.91 (d, J=5.9 Hz, 1H), 7.54 (t, J=7.6
Hz, 2H), 7.45 (t, J=7.4 Hz, 1H), 7.36 (d, J=7.3 Hz, 2H), 6.86 (d,
J=9.0 Hz, 2H), 6.30 (dd, J=5.9 Hz, 2.1 Hz, 1H), 5.96 (d, J=2.0 Hz,
1H), 4.58 (s, 2H), 3.36 (s, 3H), 2.79 (s, 3H).
Example 31
N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-2-fluorophenyl)-1,5-dimethyl-3-ox-
o-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
##STR00090##
[0392] Step 1)
3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)-3-fluorophenoxy)picolinamide
[0393] A mixture of
N-(2-fluoro-4-hydroxyphenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-p-
yrazole-4-carboxamide (300 mg, 0.879 mmol) and t-BuOK (118 mg, 1.05
mmol) in DMF (3 mL) was stirred at rt for 30 minutes, then
3,4-dichloropicolinamide (201 mg, 1.05 mmol) was added. The
reaction mixture was heated to 120.degree. C. and stirred for 12
hours. EtOAc (1 mL) and H.sub.2O (20 mL) were added, and the
resulted mixture was stirred at rt overnight. Filtered to give the
title compound as a brown solid (379 mg, 87.0%).
[0394] MS (ESI, pos, ion) m/z: 496.0 [M+H].sup.+.
Step 2)
N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-2-fluorophenyl)-1,5-dimet-
hyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide
[0395] A suspension of
3-chloro-4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carb-
oxamido)-3-fluorophenoxy)picolinamide (379 mg, 0.764 mmol) in EtOAc
(4.5 mL), CH.sub.3CN (4.5 mL) and H.sub.2O (2.5 mL) was cooled and
stirred at 0.degree. C. for 30 minutes, then PhI(OAc).sub.2 (295
mg, 0.917 mmol) was added and the mixture was stirred for another
30 minutes at 0.degree. C., then allowed to warmed up to rt and
stirred for another 10 hours. Filtered and the filter cake was
washed with EtOAc (5 mL). The filtrate was concentrated in vacuo
and the residue was purified by a silica gel column chromatography
(CH.sub.2Cl.sub.2/MeOH (v/v)=50/1) to give the title compound as a
yellow solid (150 mg, 47.0%).
[0396] MS (ESI, pos, ion) m/z: 468.2 [M+H].sup.+;
[0397] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. (ppm) 10.97 (s,
1H), 8.53 (t, J=9.0 Hz, 1H), 7.81 (d, J=5.9 Hz, 1H), 7.56 (t, J=7.6
Hz, 2H), 7.48 (t, J=7.4 Hz, 1H), 7.39 (d, J=7.4 Hz, 2H), 6.95-6.90
(m, 1H), 6.90-6.86 (m, 1H), 6.17 (d, J=5.9 Hz, 1H), 5.21 (s, 2H),
3.38 (s, 3H), 2.81 (s, 3H).
Biological Testing
[0398] The LC/MS/MS system used in the analysis consists of an
Agilent 1200 Series vacuum degasser, binary pump, well-plate
autosampler, thermostatted column compartment, the Agilent G6430
TripleQuadrupole Mass Spectrometer with an electrosprayionization
(ESI) source. Quantitative analysis was carried out using MRM mode.
The parameters for MRM transitions are in the Table A.
TABLE-US-00002 TABLE A MRM 490.2.fwdarw.383.1 Fragmentor 230 V CE
55 V Drying Gas Temp 350.degree. C. Nebulize 40 psi Drying Gas Flow
10 L/min
[0399] An Agilent XDB-C18, 2.1.times.30 mm, 3.5 .mu.M column was
used for the analysis. 5 .mu.L of the samples were injected.
Analysis condition: The mobile phase was 0.1% formic acid in water
(A) and 0.1% formic acidin methanol (B). The flow rate was 0.4
mL/min. And the gradient of Mobile phase was in the Table B.
TABLE-US-00003 TABLE B Time Gradient of Mobile Phase B 0.5 min 5%
1.0 min 95% 2.2 min 95% 2.3 min 5% 5.0 min stop
[0400] Alternatively, an Agilent 6330 series LC/MS/MS spectrometer
equipped with G1312A binary pumps, a G1367A autosampler and a
G1314C UV detector were used in the analysis. An ESI source was
used on the LC/MS/MS spectrometer. The analysis was done in
positive ion mode as appropriate and the MRM transition for each
analyte was optimized using standard solution. A Capcell MP-C18
100.times.4.6 mm I.D., 5 .mu.M column (Phenomenex, Torrance,
Calif., USA) was used during the analysis. The mobile phase was 5
mM ammonia acetate, 0.1% MeOH in water (A): 5 mM ammonia acetate,
0.1% MeOH in acetonitrile (B) (70:30, v/v). The flow rate was 0.6
mL/min. Column was maintained at ambient temperature. 20 .mu.L of
the samples were injected.
Example A
Compound Stability in Human and Rat Liver Microsomes
[0401] Human or rat liver microsomes incubations were conducted in
duplicate in polypropylene tubes. The typical incubation mixtures
consisted of human liver microsomes (0.5 mg protein/mL), compounds
of interest (5 .mu.M) and NADPH (1.0 mM) in a total volume of 200
.mu.L potassium phosphate buffer (PBS, 100 mM, pH 7.4). Compounds
were dissolved in DMSO and diluted with PBS such that the final
concentration of DMSO was 0.05%. The enzymatic reactions were
commenced with the addition of protein after a 3-min preincubation
and incubated in a water bath open to the air at 37.degree. C.
Reactions were terminated at various time points (0, 5, 10, 15, 30,
60 min) by adding equal volume of ice-cold acetonitrile. The
samples were stored at -80.degree. C. until LC/MS/MS assays.
[0402] The concentrations of compounds in the incubation mixtures
of human liver microsomes were determined by a LC/MS/MS method. The
ranges of the linearity in the concentration range were determined
for each tested compounds.
[0403] A parallel incubation was performed using denatured
microsomes as the negative control, and reactions were terminated
at various time points (0, 15, 60 min) after incubation at
37.degree. C.
[0404] Dextromethorphan (70 .mu.M) was selected as the positive
control, and reactions were terminated at various time points (0,
5, 10, 15, 30, 60 min) after incubation at 37.degree. C. Both
positive and negative control samples were included in each assay
to ensure the integrity of the microsomal incubation system.
Data Analysis
[0405] The concentrations of compounds in human liver microsome
incubations were plotted as a percentage of the relevant zero time
point control for each reaction. The in vivo CL.sub.int were
extrapolated (ref: Naritomi Y, Terashita S, Kimura S, Suzuki A,
Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from
in vivo animal experiments and in vitro metabolic studies with
liver microsomes from animals and humans. Drug Metabolism and
Disposition 2001, 29: 1316-1324.)
TABLE-US-00004 TABLE 2 Human and rat liver microsomes stability
Human Rat T.sub.1/2 CL.sub.int T.sub.1/2 CL.sub.int Example # (min)
(mL/min/kg) (min) (mL/min/kg) Ex. 3 741.5 2.34 61.23 40.56 Ex. 30
125.3 13.87 96.33 25.78 Ex. 31 146.7 11.85 36.66 67.75
[0406] The compounds disclosed herein exhibited desirable half-life
(T.sub.112) when the compounds were incubated in human and rat
liver microsomes.
Example B
Evaluation of Pharmacokinetics after Intravenous and Oral
Administration of the Compounds Disclosed Herein in Mice, Rats,
Dogs and Monkeys
[0407] The compounds disclosed herein are assessed in
pharmacokinetic studies in mice, rats, dogs or monkeys. The
compounds are administered as a water solution, 2% HPMC+1%
TWEEN.RTM.80 in water solution, 5% DMSO+5% solutol in saline, 4% MC
suspension or capsule. For the intravenous administration, the
animals are generally given at 1 or 2 mg/kg dose. For the oral
(p.o.) dosing, mice and rats are generally given 5 or 10 mg/kg
dose, and dogs and monkeys are generally given 10 mg/kg dose. The
blood samples (0.3 mL) are drawn at 0.25, 0.5, 1.0, 2.0, 3.0, 4.0,
6.0, 8.0, 12 and 24 h time points or 0.083, 0.25, 0.5, 1.0, 2.0,
4.0, 6.0, 8.0 and 24 h time points and centrifuged at 3,000 or 4000
rpm for 2 to 10 min. The plasma solutions are collected, stored at
-20.degree. C. or -70.degree. C. until analyzed by LC/MS/MS as
described above.
TABLE-US-00005 TABLE 3 Pharmacokinetic profiles in rats iv dosing
dose T.sub.1/2 AUC.sub.last Cl/F Vss F Example # mg/kg h ng h/ml
L/h/kg L/kg % Ex. 1 1 1.13 706 1.42 0.68 31.2 Ex. 2 1 4.10 685 1.39
1.75 98.5 Ex. 3 1 2.69 922 1.02 1.61 177.1 Ex. 5 2 0.31 1081 1.87
0.53 19.1 Ex. 8 2 0.82 3348 0.61 0.51 85.1 Ex. 9 1 4.76 23331 0.04
0.24 61.2 Ex. 10 1 4.60 9644 0.11 0.53 83.2 Ex. 11 2 2.90 3343 0.57
1.17 88.0 Ex. 12 2 1.56 2117 0.94 0.69 125.0 Ex. 17 2 7.29 69862
0.03 0.22 59.7 Ex. 18 1 1.23 4294 0.24 0.36 77.2 Ex. 22 2 0.72 2506
0.80 0.56 78.1 Ex. 23 2 4.40 56572 0.03 0.18 69.7 Ex. 30 2 11.79
1490 1.32 2.64 54.4 Ex. 31 2 3.29 3908 0.53 0.40 70.3
[0408] Selected compounds disclosed herein exhibited optimized
pharmacokinetic properties with desirable clearance (Cl), half-life
(T.sub.112) and excellent oral bioavailability when the compounds
were administered intravenously or orally.
[0409] The efficacy of the compounds disclosed herein as inhibitors
of receptor tyrosine kinases, such as c-Met, VEGFR, Ron, and Axl
related activity and as anti-tumor agents in xenograft animal
models can be evaluated as follows. The assay results can
demonstrate that certain compounds disclosed herein potently
inhibit c-Met, VEGF-R2, Ron, and Axl phosphorylation, and
demonstrate potent, dose dependent anti-tumor activity in certain
xenograft models.
Kinase Assays
[0410] Kinase assays can be performed by measurement of
incorporation of .gamma.-.sup.33P ATP into immobilized myelin basic
protein (MBP). High binding white 384 well plates (Greiner) are
coated with MBP (Sigma #M-1891) by incubation of 60 .mu.l/well of
20 .mu.g/ml MBP in Tris-buffered saline (TBS; 50 mM Tris pH 8.0,
138 mM NaCl, 2.7 mM KCl) for 24 hours at 4.degree. C. Plates are
washed 3.times. with 100 .mu.L TBS. Kinase reactions are carried
out in a total volume of 34 .mu.L in kinase buffer (5 mM Hepes pH
7.6, 15 mM NaCl, 0.01% bovine gamma globulin (Sigma #1-5506), 10 mM
MgCl.sub.2, 1 mM DTT, 0.02% TritonX-100). Compound dilutions are
performed in DMSO and added to assay wells to a final DMSO
concentration of 1%. Each data point is measured in duplicate, and
at least two duplicate assays are performed for each individual
compound determination. Enzyme is added to final concentrations of
10 nM or 20 nM, for example. A mixture of unlabeled ATP and
.gamma.-.sup.33P ATP is added to start the reaction
(2.times.10.sup.6 cpm of .gamma.-.sup.33P ATP per well (3000
Ci/mmole) and 10 .mu.M unlabeled ATP, typically. The reactions are
carried out for 1 hour at room temperature with shaking. Plates are
washed 7.times. with TBS, followed by the addition of 50 .mu.L/well
scintillation fluid (Wallac). Plates are read using a Wallac Trilux
counter. This is only one format of such assays; various other
formats are possible, as known to one skilled in the art.
[0411] The above assay procedure can be used to determine the
IC.sub.50 for inhibition and/or the inhibition constant, K.sub.i.
The IC.sub.50 is defined as the concentration of compound required
to reduce the enzyme activity by 50% under the condition of the
assay. The IC.sub.50 value is estimated by preparing a 10 point
curve using al/2 log dilution series (for example, a typical curve
may be prepared using the following compound concentrations; 100
.mu.M, 30 .mu.M, 10 .mu.M, 3 .mu.M, 1 .mu.M, 0.3 .mu.M, 0.1 .mu.M,
0.03 .mu.M, 0.01 .mu.M and 0 .mu.M).
c-Met (h) Assay
[0412] Met (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250
.mu.M KKKSPGEYVNIEFG, 10 mM MgAcetate and [.gamma.-.sup.33P-ATP]
(specific activity approx. 500 cpm/pmol, concentration as
required). The reaction is initiated by the addition of the MgATP
mix. After incubation for 40 minutes at room temperature, the
reaction is stopped by the addition of 3% phosphoric acid solution.
10 .mu.L of the reaction is then spotted onto a P30 filtermat and
washed three times for 5 minutes in 75 mM phosphoric acid and once
in methanol prior to drying and scintillation counting.
KDR (h) (VEGF-R2 (h)) Assay
[0413] KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA,
0.33 mg/mL myelin basic protein, 10 mM MgAcetate and
[.gamma.-.sup.33P-ATP] (specific activity approx. 500 cpm/pmol,
concentration as required). The reaction is initiated by the
addition of the MgATP mix. After incubation for 40 minutes at room
temperature, the reaction is stopped by the addition of 3%
phosphoric acid solution. 10 .mu.L of the reaction is then spotted
onto a P30 filtermat and washed three times for 5 minutes in 75 mM
phosphoric acid and once in methanol prior to drying and
scintillation counting.
Axl (h) Assay
[0414] Axl (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250
.mu.M KKSRGDYMTMQIG, 10 mM MgAcetate and [.gamma.-.sup.33P-ATP]
(specific activity approx. 500 cpm/pmol, concentration as
required). The reaction is initiated by the addition of the MgATP
mix. After incubation for 40 minutes at room temperature, the
reaction is stopped by the addition of 3% phosphoric acid solution.
10 .mu.L of the reaction is then spotted onto a P30 filtermat and
washed three times for 5 minutes in 75 mM phosphoric acid and once
in methanol prior to drying and scintillation counting.
[0415] The kinase assays described herein can be performed at
Millipore UK Ltd, Dundee Technology Park, Dundee DD2 1SW, UK c-Met
(h) Assay.
[0416] Alternatively, the kinase activities of the compounds can be
measured using KINOMEscan.TM., which is based on a competition
binding assay that quantitatively measures the ability of a
compound to compete with an immobilized, active-site directed
ligand. The assay was performed by combining three components:
DNA-tagged kinase; immobilized ligand; and a test compound. The
ability of the test compound to compete with the immobilized ligand
was measured via quantitative PCR of the DNA tag.
[0417] For most assays, kinase-tagged T7 phage strains were
prepared in an E. coli host derived from the BL21 strain. E. coli
were grown to log-phase and infected with T7 phage and incubated
with shaking at 32.degree. C. until lysis. The lysates were
centrifuged and filtered to remove cell debris. The remaining
kinases were produced in HEK-293 cells and subsequently tagged with
DNA for qPCR detection. Streptavidin-coated magnetic beads were
treated with biotinylated small molecule ligands for 30 minutes at
room temperature to generate affinity resins for kinase assays. The
liganded beads were blocked with excess biotin and washed with
blocking buffer (SEABLOCK.TM. (Pierce), 1% BSA, 0.05% TWEEN.RTM.20,
1 mM DTT) to remove unbound ligand and to reduce nonspecific
binding. Binding reactions were assembled by combining kinases,
liganded affinity beads, and test compounds in 1.times. binding
buffer (20% SEABLOCK.TM., 0.17.times.PBS, 0.05% TWEEN.RTM.20, 6 mM
DTT). All reactions were performed in polystyrene 96-well plates in
a final volume of 0.135 mL. The assay plates were incubated at room
temperature with shaking for 1 hour and the affinity beads were
washed with wash buffer (1.times.PBS, 0.05% TWEEN.RTM.20). The
beads were then re-suspended in elution buffer (1.times.PBS, 0.05%
TWEEN.RTM.20, 0.5 .mu.M non-biotinylated affinity ligand) and
incubated at room temperature with shaking for 30 minutes. The
kinase concentration in the eluates was measured by qPCR.
[0418] The kinase assays described herein were performed using
KINOMEscan.TM. Profiling Service at DiscoveRx Corporation, 42501
Albrae St. Fremont, Calif. 94538, USA, and the selected results are
listed in Table 4.
TABLE-US-00006 TABLE 4 Binding constants (Kds) of selected examples
Kd (nM) Example # KDR (h) c-Met (h) Ex. 1 >3000 (IC.sub.50) 611
(IC.sub.50) Ex. 2 43 13 Ex. 3 23 4.4 Ex. 4 540 24 Ex. 5 3300 37 Ex.
8 1500 4.8 Ex. 9 160 1.8 Ex. 11 340 1.4 Ex. 12 19000 56 Ex. 13 570
18 Ex. 15 3800 180 Ex. 16 1800 200 Ex. 17 25 20 Ex. 18 39 2.9 Ex.
19 26 16 Ex. 20 1600 620 Ex. 21 1100 120 Ex. 22 >3000
(IC.sub.50) 84 (IC.sub.50) Ex. 23 13 5.1
Cellular Phosphorylation Assays
[0419] Generally, cells are preincubated with test compounds to
allow thorough target binding. The autophosphorylation level was
determined Sandwich-ELISA technique. IC.sub.50 values are
determined by testing 8 compound concentrations in semi-logarithmic
steps (each concentration in duplicates). The cellular
phosphorylation assays described herein can be performed at
ProQinase GmbH, Breisacher Stra.beta.e 117 D-79106, Freiburg,
Germany.
c-Met Phosphorylation Assay:
[0420] The human gastric adenocarcinoma cell line MKN45 is known to
overexpress c-Met. c-Met overexpression results in a constitutive,
ligand-independent autophosphorylation of the kinase. By adding
SU11274 phospho-MET levels are largely decreased and thus the
dynamic behavior to determine inhibitory potentials of compounds
was achieved. Phospho-MET signal is subsequently quantified by
Sandwich-ELISA technique. The assay is validated based on known
inhibitors of MET kinase activity.
VEGF-R2 Phosphorylation Assay:
[0421] Immortalized human umbilical vein endothelial cells (HUE)
are known to overexpress human VEGF-R2. Stimulation of these cells
with its physiological ligand VEGF-A results in a robust receptor
autophosphorylation. Compounds are preincubated before cell
stimulation to allow thorough target binding. Stimulation
conditions are optimized to determine dose-related inhibition of
the phospho-VEGF-R2 signal, which is subsequently quantified by
Sandwich-ELISA technique. The assay is validated based on known
inhibitors of VEGF-R2 kinase activity.
Axl Phosphorylation Assay:
[0422] Cellular AXL phosphorylation assay was generated on a mouse
embryonal fibroblast (MEF) background. Cells were transfected to
express a full-length AXL protein. After clonal selection a
transformed cell line with a high level of autophosphorylated AXL
was obtained. By adding Staurosporine phospho-AXL levels are
largely decreased and thus the dynamic behavior to determine
inhibitory potentials of compounds was achieved. PhosphoAXL levels
are quantified by Sandwich-ELISA technique.
Tumor Xenograft Models
[0423] The efficacy of compounds disclosed herein was evaluated in
a standard murine model of tumorigenesis. Human tumor cells (U87MG
glioblastoma cells from ATCC) were expended in culture, harvested,
and injected subcutaneously onto the rear flank of 6-7 week old
female athymic nude mice (BALB/cA nu/nu, Hunan SLAC Laboratory
Animal, Co.) (n=6-10 for vehicle group and for each dosing group).
When tumors reached a volume of 100-250 mm.sup.3, animals were
randomly divided into vehicle control (for example, 5% DMSO+70%
Captisol.RTM. (30%), 7% HCl (pH1), 18% Captisol.RTM. (30%); or 7%
DMSO, 7% HCl (pH1), 70% Captisol.RTM. (30%), 16% Captisol.RTM.
(30%), or the like) and compound groups. Subsequent administration
of compound by oral gavage begins anywhere from day 0 to day 15
post tumor cell challenge and generally continues with once a day
for the duration of the experiment.
Tumor Growth Inhibition (TGI) Analysis
[0424] Progression of tumor growth is assessed by tumor volumes and
recorded as a function of time. The long (L) and short (W) axes of
the subcutaneous tumors were measured with calipers twice weekly,
and the tumor volume (TV) calculated as (L.times.W.sup.2)/2). TGI
was calculated from the difference between the median tumor volumes
of vehicle-treated and drug-treated mice, expressed as a percentage
of the median tumor volume of the vehicle-treated control group, by
the following relation:
% TGI = ( Median Tumor Volume control - Median Tumor Volume drug -
treated Median Tumor Volume control ) .times. 100 ##EQU00001##
Initial statistical analysis is done by repeated measures analysis
of variance (RMANOVA), followed by Scheffe psot hoc testing for
multiple comparisons. Vehicle alone (5% DMSO+70% Captisol.RTM.
(30%), 7% HCl (pH1), 18% Captisol.RTM. (30%); or 7% DMSO, 7% HCl
(pH1), 70% Captisol.RTM. (30%), 16% Captisol.RTM. (30%), or the
like) is the negative control.
TABLE-US-00007 TABLE 5 Selected results from tumor xenograft model
studies TGI % (on last U87MG Xenograft models day of dosing) 6
mg/kg 10 mg/kg 20 mg/kg 40 mg/kg 60 mg/kg Ex. 2 (14 days) 29 -- 69
-- 82 Ex. 3 (16 days) -- 53 68 85 -- Ex. 8 (14 days) 13 -- 25 -- 43
Ex. 17 (12 days) 26 -- 56 -- 85 Ex. 18 (14 days) 28 -- 49 -- 57 Ex.
19 (12 days) 22 -- 49 -- 103
[0425] Finally, it should be noted that there are alternative ways
of implementing the present invention. Accordingly, the present
embodiments are to be considered as illustrative and not
restrictive and the invention is not be limited to the details
given herein, but may be modified within the scope and equivalents
of the appended claims. All publications and patents cited herein
are incorporated by reference.
* * * * *
References